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CHAPTER I 
 
INTRODUCTION 
 
 This dissertation focuses on the discovery and analysis of the mTOR-p73 
signaling axis and human cancer.  In this chapter, the current knowledge of mammalian 
transcription factors and gene regulatory networks in the context of recent genomic 
advances will be presented, as well as the role of p73 signaling during development and 
tumorigenesis.  Relevant anti-cancer strategies will be reviewed, including a discussion 
of  mTOR inhibitors.  The major focus of this dissertation research was to understand p73 
biology through its essential function as a transcription factor, the gene expression that it 
regulates.   The data generated and presented in subsequent chapters has implications 
both for transcription factor signaling at large, as well as anti-cancer strategies that use 
predefined cancer subgroups. 
 
Mammalian Transcription Factors 
 
Post-genomic revelations about transcription factors  
There are over 2,000 transcription factors in the human genome (1,2).  These 
factors, by definition, bind to specific sequences of DNA to control recruitment of RNA 
polymerase and thus gene expression.  Structurally, they contain both a DNA-binding 
domain and an activation domain.  These domains can be functionally uncoupled; many 
hybrid proteins engineered to contain the DNA-binding domain of one transcription 
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factor and the activation domain of another can activate the same genes as the first.  
Transcription factors can be classified by the structure of their DNA-binding domain; 
annotation of the human genome reveals that ~10% of all genes encode a basic-helix-
loop-helix, basic-leucine zipper, winged helix, zinc finger, or other structure predicted to 
bind DNA (1,2). 
DNA-binding is sequence specific, and usually occurs at regulatory sites in 
promoters, introns, and enhancers (see below).  These sites are used by transcription 
factors to modulate transcript levels, but are not essential for gene expression per se.  
A preinitiation complex of proteins is sufficient to enable a basal level of transcription.  
The DNA-binding domain of a transcription factor binds a regulatory site, often 
regardless of its orientation relative to the transcriptional start site, and the activation 
domain interacts with the preinitiation complex or with RNA polymerase II.  These 
interactions stabilize the binding of RNA polymerase to DNA and promote successful 
completion of transcription initiation; the stronger the interactions, the greater the 
frequency with which initiation is completed (3).  Transcription factors can also recruit 
other proteins to these regions, for example proteins that modify the architecture of 
surrounding chromatin to be in a more open or closed conformation. 
Technological advances have allowed researchers to study the complex, wide-
ranging effects of transcription factors in greater detail.  Not only is there local 
organization of transcription factors at the loci that they bind, but also 3-dimensional 
organization of factors within the nucleus.  This has been demonstrated through 
chromosome conformation capture, which uses a ligand efficiency-based measure to 
determine how frequently two regions are in close enough proximity to be cross-
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linked (4). Chromosome conformation capture in combination with fluorescence in situ 
hybridization has been used to demonstrate how two distant regions can be connected by 
transcription factors.  In one scenario the factor binds to both a regulatory sequence and 
to transcriptional machinery at a distant transcriptional start site through bending of 
intervening chromatin (5).  In another scenario, two genes may be transcribed by the 
same transcription 'factory' (region of nucleus containing a high concentration of 
transcriptional machinery) (6,7).  Through such mechanisms, distant intra- and inter-
chromosomal sequences can be adjacent to one another.  Whole-genome technologies 
have demonstrated that this is a highly regulated process that allows areas of the nucleus 
to contain high concentrations of factors engaged in transcribing functionally related 
genes (5-7). 
 Surprisingly, despite this complexity of nuclear architecture, and the observations 
that binding events for any given transcription factor vary widely between species (8), the 
DNA sequence itself seems sufficient to recruit and activate transcriptional machinery.  
This has been demonstrated using a mouse model of Down syndrome, in which mice 
stably transmit the human chromosome 21 as an extra chromosome to the full 
complement of mouse chromosomes (9).  Mice from this strain, maintained for 
generations in a laboratory, were analyzed to determine the effect on a human 
chromosome of incubation in the milieu of a mouse nucleus.  Surprisingly, in the mice 
carrying the ectopic human chromosome, transcription factors were recruited onto the 
human chromosome in a human pattern, rather than in the patterns of binding they 
exhibited on orthologous mouse sequences (9).  This resulted in a human pattern of gene 
expression from the chromosome.  In addition, the mouse epigenetic machinery was 
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maintaining a human-like epigenetic pattern.  These results suggested that it is the DNA 
sequence itself and not nuclear context or architecture that determines transcription factor 
binding and activity.  Because extant bioinformatic tools are unable to predict 
transcription factor binding sites with great fidelity, it is clear that there is much we do 
not know about sequence-based regulation of transcription factor binding and activity. 
 A greater understanding of this activity would have broad implications.  The 
import that even a single transcription factor can have is illustrated by experiments in 
human stem cells.  Expression of just one to four transcription factors is sufficient to 
induce stem cell-like pluripotency in adult fibroblasts (10), or induce transdifferentiation 
of adipose cells into muscle cells (11).  In fact, even a single transcription factor binding 
site can have a significant impact at both a cellular and whole-organism level.  For 
example, changing a single enhancer in a transgenic mouse model recapitulated the 
classic Darwinian model of evolution that describes small differences between the human 
arm, bat wing, and whale flipper.  By swapping an enhancer upstream of the Prx1 gene 
promoter in mice with the orthologous bat enhancer, mice were created with only one key 
phenotype: longer forearms (12).  That is the first of many evolutionary steps that would 
be needed to transition from running on a forearm (mouse) to flying with a forearm (bat).  
Experiments such as these demonstrate the impact of transcription factor binding sites.  
However, in situ experiments are intensive and can only be performed by altering one 
binding site at a time. 
Using genomic technologies described below, researchers began mapping 
transcription factor binding sites in a comprehensive manner.  Such studies revealed that 
distinct transcription factors can bind thousands of sites in the human genome.  These 
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studies allow greater exploration of sequence-based determinants of transcription factor 
activity, and, when coupled with microarray analyses, gene expression resulting from this 
activity.  By considering a collection of transcription factor binding sites as a profile, one 
can gain insight to the biologic import of these protein-DNA interactions. 
 
Gene Regulatory Networks 
 
High-throughput detection of protein-DNA complexes 
 Chromatin immunoprecipitation (ChIP)-based techniques allow detection of 
specific protein-DNA interactions.  There are two basic principles in ChIP.  First, cells 
are cross-linked using an agent that induces reactive bond formation such as 
formaldehyde in order to trap transcription factors at cognate binding sites.  Second, 
chromatin is fragmented and antibodies are used to isolate proteins of interest along with 
any sequences of DNA to which they are bound.  After the cross-links are reversed, 
associated DNA fragments can be detected using a variety of methods such as 
polymerase chain reaction (PCR), hybridization, or direct sequencing.  A transcription 
factor will have varying affinity for different DNA sequences; thus a factor will spend 
different amounts of time occupying distinct binding sites.  Based on this principle, 
quantitative information can be gained from some ChIP methods. 
 Thousands of protein-DNA interactions can be detected in a single experiment by 
traditional sequencing of tags (~40-50 bp in length) in the DNA fragments followed by 
alignment of these sequences to the genome.  This method is cost-effective, and has been 
extensively validated.  However, it is not comprehensive, may contain some bias due to 
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preferential sequencing, and is not quantitative (13).  This method has been called 
ChIPSeq, although this should be distinguished from newer sequencing-based methods 
described below. 
Whole-genome ChIP can also be performed by hybridizing a pool of ChIP-
enriched DNA fragments to tiling oligonucleotide arrays.  This is called ChIP-on-Chip 
and provides quantitative information based on the level of enrichment of DNA 
sequences after ChIP compared to input.  ChIP-on-Chip has additional advantages: it has 
been extensively tested in large multi-institutional studies and has been proven 
reproducible (14).  ChIP-on-Chip analyses were originally performed with limited arrays 
that only detected binding events in human promoters.  Technologic advances lead to the 
development of comprehensive whole-genome tiling arrays which demonstrated that 
most transcription factor binding sites do not actually occur in promoters (15).  Both 
ChIP-Seq and ChIP-on-Chip are described in additional detail in later sections. 
Finally, ChIP coupled with massively parallel sequencing platforms enables 
sequencing of millions of fragments; saturation is obtained and quantitative binding 
information achieved (16).  This technique is currently too expensive for routine use by 
most laboratories, and has not been tested in a multi-institutional study like ChIP-on-
Chip, so reproducibility is unknown and sequencing bias is not yet fully understood (14).  
However, as the latter technology becomes more affordable it has the potential to replace 
ChIP-on-Chip as the technique of choice for mapping genomic binding sites. 
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Determinants of transcription factor activity 
 As a growing number of transcription factor binding profiles are analyzed using 
these high-throughput techniques, aspects of transcription factor biochemistry are being 
re-evaluated given an unexpected level of complexity.  All told, a multi-layered model 
explains how cells both regulate transcription factor binding and establish the loci at 
which transcription factors are active. 
 DNA Response Elements:  Transcription factors bind specific DNA motifs, or 
response elements.  These sequences can be highly precise or degenerate.  Through a 
combination of in vitro and in vivo techniques, hundreds of such motifs have been 
measured (17).  Response elements were originally reported as consensus 'strings' that 
give the most frequent nucleotide at each position in the motif.  An even greater amount 
of information can be conveyed through matrix representations, which give the complete 
nucleotide occurrence probability for each position in the motif.  These motifs are tools 
that can be used to scan the genome to identify novel candidate transcription factor 
binding sites.  However, such methods have a high rate of error.  Transcription factors 
can bind regions without a classical motif, or with a highly degenerate motif.  
Conversely, perfect motifs may not be bound at all by the cognate transcription factor.  
Often transcription factors bind only a small fraction of potential binding sites at a given 
time.  
 Epigenetic milieu:  Another layer of regulation occurs through epigenetic marks 
such as DNA methylation, histone methylation, and histone acetylation that modify 
chromatin in distinct and complex patterns.  This provides a 'code' that can alter 
transcription factor binding and activity.  Multiple whole-genome analyses support this 
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model, most notably ChIP-on-Chip experiments through the ENCODE Project 
Consortium, and ChIP-Seq experiments in a variety of human cells (18,19). 
 One key mark that distinguishes distal enhancer elements is monomethylated 
histone H3 lysine 4 (H3K4me1).  This was confirmed by ChIP-Seq measurements of 
STAT1 binding in HeLa cells before and after stimulation with interferon-gamma (18).  
H3K4me1 marked sites in untreated cells to which STAT1 subsequently bound after 
interferon-gamma treatment (18).  These data, in conjunction with other studies of 
transcription factor binding, suggest that H3K4me1 is a dominant indicator of distal 
regulatory regions. 
 How are such marks maintained?  Much remains unknown, however it is likely 
that the cell's epigenetic machinery transitions regulatory sequences from a 'poised' status 
to an active or repressed status.  For example, cells maintain a 'bivalent mark' of both 
H3K4me3 and H3K27me3 at regulatory regions of development-specific genes in stem 
cells (20).  As cell fate decisions are made, lineage-specific regions may become either 
actively marked (H3K4me3) or repressively marked (H3K27me3 or no mark).  
Furthermore, regulatory regions such as enhancers usually contain multiple transcription 
factor binding sites.  Thus many factors could be recruiting histone modifying proteins in 
an additive manner at any given location.  Indeed, analysis of STAT1-bound loci 
identified nearby motifs that could be bound by other transcription factors and cofactors 
during cellular maintenance and homeostasis (18).  Given the massive combinations of 
histone and DNA modifications that mark regulatory regions, active regions, closed 
regions, etc., there is the potential for exquisite regulation of transcription factor binding. 
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 Association with co-factors:  As mentioned above, multiple transcription factors 
often bind in the same regulatory locus.  These factors modify surrounding chromatin, 
but also interact with one another.  Such interactions can either mediate recruitment of 
additional factors, stabilize factor binding, or inhibit factor binding to fine-tune 
transcriptional responses.  One of the most striking examples is the pioneer factor FoxA1, 
that is capable of binding to chromatin even if it is in the 'closed' conformation, 
unwinding chromatin and allowing for subsequent binding events (21).  FoxA1 binds 
predominantly to distal enhancer regions and epigenetic marks such as H3K4me1 are the 
major determinant of its binding (21).  In breast cancer cells, FoxA1 binds H3K4me1-
marked regions and then recruits the estrogen receptor to the same loci.  Interestingly, in 
prostate cancer cells FoxA1 binds a different set of loci, which are also marked with 
H3K4me1.  In prostate, FoxA1 recruits the androgen receptor to these loci to regulate 
tissue-specific gene expression.  Thus, specific transcriptional programs can depend on 
differential regulation of epigenetic machinery as well as distinct expression of 
collaborative transcription factors (21).  We applied such principles to our analysis of the 
p53 homolog, p73, as described in Chapters IV and V. 
 
p73 Signaling During Development and Tumorigenesis 
 
The p53 family of transcription factors: p53, p63 and p73 
 The mammalian p53, p63, and p73 genes descended from an ancestral gene, and 
share a common domain architecture and significant sequence identity (22).  However, 
their differences in vivo are striking.  While p53 is mutated in over 50% of human 
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tumors, p63 and p73 are rarely mutated (23).  Instead, the p63 locus is amplified in a 
small percentage of squamous carcinomas (24-26), and p73 is over-expressed in several 
tumor types (23).  In addition, while p53 null mice have an increased frequency of 
spontaneous tumor formation, p63 and p73 null mice die tumor-free from developmental 
defects (27,28), as discussed further below.  Although p63 and p73 can engage apoptotic 
pathways in vitro (29-34), it is clear that they are not classic Knudson-like tumor 
suppressors like p53. 
 One possibility is that p63 and p73 are tumor suppressors that are inactivated 
during tumorigenesis by a non-classical mechanism.  Investigation of this possibility is 
complicated by the complexity of RNA isoforms expressed and the potential for tissue-
specific expression.  There are nine possible isoforms for p53, six for p63, and thirty-five 
for p73 that can arise through a combination of promoter usage and alternative splicing 
(35,36).  For p63 and p73, two classes of isoforms exist that either contain (TA) or lack 
(∆N) the N-terminal transactivation domain required for full activation of target genes 
(37) (Figure 1).  All isoforms contain a DNA-binding domain, nuclear localization signal, 
and tetramerization domain (Table 1).  At the C-terminus, p53 contains a basic domain, 
whereas p63 and p73 contain sterile alpha motifs that undergo extensive alternative 
splicing.  These domains are described in greater detail below: 
 Transactivation Domain:  The N-terminal domain of p53 contains two activation 
domains termed AD1 and AD2 (38).  These domains interact with basal transcriptional 
machinery and are essential for p53 function.  In addition, nuclear magnetic resonance 
spectroscopy demonstrated that these domains are unstructured, and likely remain so 
unless they are bound by a p53 regulatory protein (38).  Proteins that interact with AD1  
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and AD2 include the negative regulator mdm2 (an E3 ligase) and the positive regulator 
p300 (an acetyltransferase).  Such interactions not only alter p53 activity, but also modify 
histone acetylation at p53-bound chromatin (39).  Interestingly, recent evidence suggests 
that p53 can undergo alternative splicing to create a protein that lacks AD1 but retains 
AD2 (Figure 1A).  This isoform is impaired in the ability to induce cell cycle arrest but 
retains potent apoptotic activity.  Some of this effect is due to increased stability of p53 
secondary to decreased interaction with mdm2 (36,40). 
 Full-length TAp63 and TAp73 have only one activation domain, AD1, that is 
22% and 29% homologous to the AD1 of p53.  The AD1s of p53, p63, and p73 share 
similar interacting proteins and functional effect.  Cryptic promoter usage and alternative 
splicing can yield truncated ∆Np63 and ∆Np73 proteins that lack AD1 (41).  These ∆N 
proteins contain 13 or 14 unique residues, which in conjunction with a proline-rich 
domain act as an AD2 (42).  AD2 is weaker than AD1, thus ∆N isoforms act as 
dominant-negatives to TA isoforms, at least in some contexts.  (This results from ∆N:TA 
hetero-dimerization and sequestration of TA proteins from binding sites.)  There is 
evidence that TAp73 binds and regulates the ∆N promoter in some cell lines and tumor 
types (43).  However, the determinants of cryptic promoter usage and particularly of 
alternative splicing are largely unknown. 
 DNA-Binding Domain:  The DNA-binding domain is the most conserved domain 
between p53 family members and across species.  Crystal structures of this region 
demonstrate that it is composed of a core antiparallel β-sheet that serves as a scaffold for 
both the protein loops that contact DNA and the zinc atom in this domain (41).  
Importantly, key residues that contact DNA are conserved in p53, p63, and p73; missense 
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mutations in these residues abolish binding of p53 to DNA (41).  Although p63 and p73 
are not mutated during tumorigenesis, missense germline mutations in p63 in some of the 
same residues lead to autosomal dominantly inherited syndromes that display features 
such as limb malformations, facial clefting, and ectodermal displasia (44). 
 Subtle differences in the DNA binding domain may result in sequence-specific 
binding differences between p53, p63, and p73.  All family members can bind the 
canonical p53 response element that contains two half sites of RRRCWWGYYY, 
separated by a spacer of up to 13 bp (where R = purine, C = cytosine, W = adenine or 
thymidine, G = guanine, and Y = pyrimidine) (45,46).  However, p63 and p73 contain 
some differences in the residues of the protein loops that contact DNA (39).  And p63 
preferentially recognizes the half-site RRRCGTGYYY, indicating that differences in 
sequence-specific binding may be the result of these subtle structural differences (47,48).  
Our analysis of p73 sequence-specific binding is presented in Chapter IV. 
 Nuclear targeting regions:  p53 contains a bipartite nuclear localization signal 
(NLS) at residues 305-322 and nuclear export signal (NES) at residues 11-27 and 340-
351.  These sequences allow p53 to shuttle between the nucleus and cytoplasm, and are 
conserved in both p63 and p73 (38).  For p53 and p73, these domains are sufficient for 
the nuclear import and export of reporter proteins (49,50).  Interestingly, residues in these 
domains can be post-translationally modified in p53, leading to enhanced binding to 
response elements.  The residues that are post-translationally modified in p53 are not 
conserved in p73, suggesting distinct activities for these two family members (38). 
 Oligomerization domain:  Each p53 family member binds to DNA as a dimer of 
dimers, mediated by secondary structures within the oligomerization domain.  Monomers 
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bind each other through antiparallel β-sheet and antiparallel helix interactions.  Dimers 
bind each other through parallel helix-helix interactions (38).  Tetramerization is required 
for many of the known functions of these family members, and may also be the 
mechanism by which ∆N isoforms act as dominant negatives against their full-length 
counterparts.  Interestingly, p53 cannot hetero-tetramerize with either p63 or p73, but in 
vitro studies demonstrate that p63 and p73 can weakly interact with one another (51). 
 C-terminal domains:  p53 family members contain intriguing differences in their 
C-terminal domains.  p53 has a basic domain, which is a regulatory structure that 
undergoes extensive post-translational modification.  p63 and p73 contain C-terminal 
sterile alpha motif (SAM) domains.  The SAM domain is a conserved transcription factor 
motif implicated in protein-protein interactions.  It was originally named 'Sterile' based 
on its presence in four proteins crucial for yeast sexual differentiation and 'Alpha' based 
on secondary-structure predictions of high -helical content.  Over 1300 proteins in all 
genomes contain SAM domains that are linked to diverse and wide-ranging functions 
(52).  In p63, the SAM domain is mutated in developmental syndromes associated with 
ectodermal dysplasia and facial clefting (44).  In p73, the SAM domain binds to both 
anionic and zwitterionic lipids (53), although the functional implications of these 
interactions are unknown.  In both p63 and p73, the C-terminal domains can act as 
inhibitory domains, possibly by preventing association between transcriptional co-
activators and the N-terminus (54).  The SAM domains also undergo extensive 
alternative splicing, leading to three isoforms in p63 (α-γ) and at least seven in p73 (α-η).  
Select isoforms of p73 are depicted in Figure 1.  Unlike the TA and ∆N N-terminal 
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isoforms, which are defined by the presence or absence of the transcriptional activation 
domain, the functions of the C-terminal isoforms are unknown. 
 
p53 family isoforms in tumorigenesis 
The various isoforms of p53 family members play differential and often opposing 
roles during tumorigenesis.  The purported active isoform of p73, TAp73, is of particular 
interest because it is frequently expressed in human cancers (37) and can be inhibited by 
either ∆Np63 or ∆Np73 (37,55) (Figure 1C).  In particular, ∆Np63:TAp73 complexes 
that inactivate TAp73 exist in head and neck squamous cell carcinoma (HNSCC) and 
‟basal-like‟ breast cancer cell lines, and evidence suggests these complexes occur in vivo 
in the corresponding tumor types (56-58).  In addition, tumor-specific mutant forms of 
p53 have the ability to bind and inhibit p73 (59) (Figure 1A).  Thus the ability of ∆Np63, 
∆Np73, or mutant p53 to inhibit TAp73 may obviate the need for mutation of p73 during 
tumorigenesis.  A single mutation in p53 might decrease both p53 and p73 activities.  
Similarly, an increase in ∆Np63 or ∆Np73 levels could be another means of inactivating 
TAp73, ultimately preventing TAp73 from engaging in tumor suppressive activities. 
 Even though recently discovered p53 isoforms can inhibit p53 transcriptional 
activity, p53 is mutated in cancers (36,40).  The p53 locus can undergo alternative 
splicing and contains two promoters, thus creating two classes of isoforms that also either 
contain or lack an N-terminal transactivation domain.  Those isoforms that lack the 
transactivation domain have been shown to inhibit full-length p53 in co-transfection 
experiments (36), and are over-expressed in tumors (36,60-62).  Thus the p53, p63, and 
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p73 genes share similar organization and can each give rise to active and inhibitory 
isoforms. 
Why might inhibitory isoforms have a differential effect on the need for mutation 
of p53 versus p73?  Three possible answers are: 1) TAp73 is not a tumor suppressor, or is 
a much weaker tumor suppressor than p53.  2) Tissue-specific and context-dependent 
upstream signals and regulators control whether p53 and/ or p73 is active in tumor 
suppression.  3) ∆Np73 has oncogenic properties that are separate from its ability to 
inhibit p53 family members.  Even the first of these possibilities, whether or not TAp73 
is a tumor suppressor, was surprisingly difficult to demonstrate conclusively (63), and 
multiple mouse models were required to shed light on this issue. 
 
Manifestations of p73 null mice 
 Mouse models with inactivation of p53 family members are an invaluable 
resource, providing clues to if and when p53, p63, and p73 act as tumor suppressors in 
vivo.  p63
-/-
 mice that do and do not develop cancers have been described in detail (64).  
For p73, there is greater consensus, as mice deficient for the TAp73 isoform of p73, and 
p73 heterozygous mice, demonstrate that it is indeed a tumor suppressor. 
 The first p73 transgenic mice that were studied were deficient for all isoforms of 
p73 (28).  These mice survived to birth and had severe developmental abnormalities 
including: 1) hippocampal dysgenesis, 2) hydrocephalus due to excessive neuronal death, 
3) loss of pheromone sensing and lack of mating, 4) massive sinus inflammation and 
infection, 5)  gastrointestinal erosion and excessive mucosecretion, and 6) runting (28).  
The deficient or faulty mechanisms behind many of these phenotypes remain unknown.  
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For example, it is unclear if immune infiltration in the nasal cavity is due to defects in the 
immune system, or epithelial dysfunction leading to excessive mucus secretion or 
infection.  The majority of p73-deficient mice lived to be only 4-6 weeks old, dying from 
gastrointestinal or cerebral hemorrhage (28).  During this shortened lifespan, there was no 
increase in spontaneous tumor formation. 
 According to the subsequent TA isoform-specific knockout p73 mouse model, 
p73-depleted animals may display complex tumor phenotypes due to the loss of both an 
oncogene (∆Np73) and a tumor suppressor (TAp73) that can lead to a multitude of 
intermediate phenotypes.  In addition, tumor analysis of p73-deficient animals is 
complicated by the severe developmental problems that lead to an early demise, largely 
attributed to loss of the ∆Np73 isoform that is expressed during development (28).  Mak 
and colleagues circumvented these issues, using a gene targeting approach that deleted 
exons that specifically encode the transactivation domain of p73.  Because the p73 gene 
contains a second promoter from which ∆Np73 can be transcribed, this approach led to a 
selective deficiency of all TAp73 isoforms.  The developmental defects of the resulting 
mice were less severe than their p73
-/-
 counterparts.  Subsequent analysis revealed an 
increased incidence of both spontaneous and carcinogen-induced tumors in the TAp73
-/-
 
mice, showing that TAp73 is a tumor suppressor (65). 
In part, the TAp73
-/-
 tumors provided critical validation of previous work that 
demonstrated an increased rate of spontaneous tumors in p73
+/-
 mice (66).  Interestingly, 
this same study demonstrated that p63
+/-
 mice develop spontaneous tumors, and that 
p53
+/-
 p63
+/-
 mice have an enhanced rate of tumor formation compared to p53
+/-
 mice 
(66).  This is in contrast to another study using a distinct, inactivated p63 allele that 
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demonstrated a lack of tumors in p63 heterozygous mice (67).  This second model also 
showed a decreased rate of tumor formation in mice heterozygous for both p53 and p63 
(67).  The contradictory results of this second study may be due to expression of 
truncated p63 proteins that appear to be expressed from the transgenic allele (68).  
Regardless, the opposing results in different p63-deficient mice heightened the need for 
validation and additional characterization of the p73-deficient phenotypes. Although 
there seem to be some differences in tumor spectrum, in general the TAp73-deficient 
mice recapitulated the tumor-prone phenotype of the p73
+/-
 mice (65). 
 Decreased TAp73 inhibits p53 function in vitro in a context-dependent manner.  
For example, studies in E1A-transformed mouse embryonic fibroblasts (MEFs) suggested 
that p63 and p73 are required for p53-mediated apoptosis (69).  This finding was 
contradicted by a second study in T-cells showing that p63 and p73 are dispensable for 
p53-mediated apoptosis (70).  In the TAp73 null mice, E1A-transformed MEFs and T-
cells did not demonstrate any alteration in p53 activity, suggesting that p73 is dispensable 
for p53 function, or that ∆Np73 compensates for the loss of TAp73 in E1A-transformed 
MEFs.  It would be interesting to determine the effect of TAp73 loss on p53 function in 
an in vivo model in which p53 activity is dependent on both p63 and p73, such as during 
ionizing radiation-induced central nervous system apoptosis (69).  This would be 
particularly relevant because all three p53 family members contribute to neuron 
development and function (71).  Indeed, the TAp73
-/-
 mice support a model that ascribes 
distinct roles for ∆Np73 in the survival of neurons after injury (71), and for TAp73 
during hippocampal development.  How this system is perturbed during genotoxic stress 
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would provide insight to the roles of the p53 family members in the nervous system and 
during tumorigenesis. 
 A possible mechanism for TAp73 tumor suppressive function came from a second 
phenotype of TAp73-deficient mice: infertility.  Unlike the p73 heterozygotes, which do 
not mate due to lack of pheromone sensing (28), the TAp73 null mice mate normally but 
are infertile (65).  Female infertility was due to genomic instability of the oocyte.  This 
genomic instability may have lead to retention during folliculogenesis and decreased 
viability, and may be similar in effect to the decreased oocyte quality that occurs with 
natural aging.   
 p63 also plays a role in the female oocyte; TAp63 is expressed and is essential for 
DNA damage-induced oocyte death that does not involve p53 (72).  Thus, the p53 family 
emerges as a central player in maintaining fidelity of the female germ line.  TAp73 
prevents genomic stress, and loss of TAp73 during aging may contribute to the decline in 
oocyte viability.  In contrast, TAp63 is activated by genotoxic agents to induce apoptosis 
in oocytes that have sustained genomic damage (72).  Whether p73 cooperates with p63 
during this process, and the roles that these family members may play in the male germ 
line (TAp73
-/-
 male mice are also infertile), remains unknown. 
 Thus the two major phenotypes of the TAp73-deficient mice, cancer and 
infertility, are both associated with genomic instability.  These data suggest that 
maintaining the fidelity of the genome is a key molecular function of TAp73 at least in 
some tissues.  The balance between TAp73 and ∆Np73 protein levels may be the ultimate 
determinant of tumor formation.  An understanding of the functions of ∆Np73 in adult 
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tissues, and how ∆Np73 alters tumor incidence, are unknown and await the development 
of conditional p73 mouse models. 
 
p73 expression in human cancers 
 Additional in vivo analysis of p73 has come from the study of p73 in human 
tumors.  These analyses are complicated by the poor quality of p73 antibodies and the 
number and complexity of p73 isoforms.  p73 loss of heterozygosity (LOH) has been 
observed in approximately 20% of examined patients; however, LOH does not correlate 
with a decrease in p73 expression level and seems to be driven by selection for allelic 
loss of another tumor suppressor near the p73 locus (73).  In addition, only very rare 
mutations of p73 have been detected (~0.6% of reported patients in one meta-analysis) 
(74).  Polymorphisms of p73 have been reported to both increase and decrease tumor risk 
in different populations (74).  Taken together, these data argue against p73 as a classic 
Knudson-like tumor suppressor. 
 In contrast, increased p73 RNA and protein levels have been detected in a number 
of cancer types.  In addition, specific antibodies against accumulated p73 protein have 
been identified in cancer patients (75).  Overexpression of p73 or ∆Np73 isoforms has 
been associated with poor prognosis in patients with hepatocellular, colorectal, breast, 
ovarian, and lung cancers (74).  In malignant myeloproliferations, for example, 
overexpression of p73 is a frequent event.  In one such disorder, chronic myeloid 
leukemia, overexpression specifically of the epsilon isoform of p73 is observed, an 
expression pattern that appears to be unique to this tumor type.  In contrast, in malignant 
lymphoproliferative disorders the p73 gene is hypermethylated resulting in decreased p73 
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expression relative to myeloproliferations (74).  These studies highlight the diversity of 
p73 expression patterns in human tumors. 
 Large cohorts of breast and colon tumors have also been assessed for p73 RNA 
expression levels.  One study revealed tumor-specific upregulation of both TAp73 and 
∆Np73 (76).  Interestingly, correlations between p73 levels and specific molecular 
alterations and tumor characteristics were observed.  There was association between 
wild-type p53 and upregulation of p73 isoforms (TAp73 and ∆Np73 in colon cancer and 
∆Np73 in breast cancer), suggesting that there may be redundancy in the functions of 
these family members, thus alleviating selective pressure for dysregulation of both p53 
and p73 in the same tumor, or that ∆Np73 can inhibit p53.  Correlations were also found 
between TAp73 and E2F-1 RNA levels, and indeed in vitro studies show that the p73 
promoter is regulated by E2F-1 (77,78).  In colon cancer, ∆Np73 levels increased in 
parallel with increasing tumor stage.  Correlations with tumor stage have also been 
observed in hepatocellular carcinoma, chronic lymphocytic leukemia, and lung cancer 
(76). 
 Interestingly, the increased p73 protein may alter tumor chemosensitivity, 
depending primarily on the ratio of p73 isoforms that are over-expressed.  In most tumor 
types, ∆Np73 expression is associated with chemoresistance and TAp73 expression is 
associated with chemosensitivity (79,80).  These results suggest that TAp73 is a potential 
therapeutic target in specific types of cancer, as discussed further below. 
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p73 target genes, with comparison to p53 
 p73 can activate the transcription of many p53 target genes such as MDM2, p21, 
BAX, and GADD45A (81), and hundreds of p53-bound genes can also be bound by p73 
(82).  This is in concordance with in vitro experiments that demonstrate that p73 
regulates apoptosis and cell cycle arrest.  Interestingly, there are some differences in 
transactivation efficiency between p53 and p73.  For example, p73 mediates higher 14-3-
3σ and GADD45A induction and lower p21 induction compared to p53 (81).  Another 
interesting example is alpha fetoprotein (AFP), a target gene that is expressed during liver 
development.  AFP is a target of p53 and p73 (but not p63) transcriptional repression 
(83).  Both p53 and p73 bind to the promoter region of AFP simultaneously and modify 
surrounding chromatin to inhibit transcription initiation.  However, there are some 
differences in the activities of p53 and p73; p73 has a decreased ability to repress AFP 
transcription compared to p53 (83). 
 Analysis of individual genes has made it clear that p73 regulates target genes 
distinct from those regulated by p53.  For example, aquaporin 3 is a water and glycerol 
transporter whose expression is induced by p73 but only very weakly by p53 (84).  This 
target gene contains three p53-responsive half-sites in its promoter.  Similarly, JAG1 and 
JAG2, which express ligands of the notch receptor, are p63 and p73 target genes that are 
not regulated by p53 (85).  These genes contain four half-sites of the p53 responsive 
element in intron 2 that are likely used by p73 to regulate transcription.  The full extent of 
shared versus unique p53 and p73 target genes is presented in Chapter IV. 
 Several high-throughput analyses of p53 and p63 target genes have been 
performed; these studies lay the groundwork for comparison to p73.  One of the most 
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notable was a paired-end ditag ChIP-sequencing approach developed by Wei and 
colleagues that identified hundreds of p53 binding sites in Hct116 cells treated with 5-
fluorouracil (86).  As described in greater detail in later chapters, this study identified key 
determinants of p53 binding and function.  It also provided a resource for further studies 
of p53 binding.  For example, another group created an array for ChIP-on-Chip that only 
detects binding events at p53 target genes identified in the Wei et al. study.  This focused 
array was used to confirm the results of the original study, and to study p53 binding in 
multiple cell types in response to cellular stresses (87). 
 In primary cells, two sets of p53 binding sites were identified (87).  One set was 
bound by p53 both at baseline and after p53-inducing cellular stress, and the binding 
level of p53 did not change after stress.  At the second much larger set of sites, p53 
binding was only detected after stress.  In contrast, in three established cell lines p53 
bound to almost all of its target genes both at baseline and after a variety of p53-inducing 
cellular stresses.  Importantly, the binding level at all sites correlated with the amount of 
p53 protein in the cell, both after induction and after RNAi-mediated depletion of p53 
(87).  In these cancer cell lines, binding did not seem to be the critical determinant of p53 
transcriptional activity.  It will be important to evaluate this model of p53 binding and 
activity in additional tissues and cancer cell lines, particularly because p53 occupancy of 
promoters at baseline has been observed in other normal cell types (88).  Furthermore, we 
present a different model for p73 binding in response to cellular stress in Chapter IV. 
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Signaling pathways upstream of p73 
 The differential phenotypes of the p53 family mouse models suggest that different 
upstream signals regulate this family – temporal, tissue-specific, and context-dependent 
cues lead to separation of function in the p53 family.  This might occur, for example, 
through the E3-ubiquitin ligase Mdm2 which triggers the degradation of p53 but not 
p73 (89).  Or it may occur through the cofactor YAP, which binds to p73 but not p53, 
enhancing p73 activity as well as recruiting p73 to specific target genes during apoptosis 
(90-92).  By mechanisms such as these, differential activation of p53, p63, and p73 
isoforms can be achieved.  Ultimately, the settings in which p53 family members are 
active will select for their inactivation in human tumors. 
 In terms of upstream signals, the DNA Damage Response (DDR) signaling 
pathway is the classic activator of p53.  Initial analyses of DDR pathways were 
performed in the TAp73
-/-
 mice.  Intriguingly, DNA damaging agents such as irradiation, 
etoposide and cisplatin were ineffective at inducing TAp73-dependent cell death in either 
T-cells or MEFs, suggesting a clear differential response to DNA damage between p53 
and p73 (65).  This was in contrast to in vitro evidence that p73 can be activated by a 
subset of DDR-inducing agents, and regulated by kinases in the DNA Damage pathway 
such as Chk1 and Chk2 (93).  Perhaps p73 responds to genotoxic stress in a tissue-
specific or context-dependent manner, for example only in the absence of p53 (94). 
 There is evidence that the DNA damage response activates p73 through different 
mechanisms than p53.  For example, cisplatin-mediated induction of p73 occurs at the 
protein level and, at least in some contexts, is dependent on an intact mismatch repair 
(MMR) pathway (32).  It has been suggested that some proteins in the MMR complex act 
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as sensors of cisplatin-DNA adducts, while other proteins act as adaptors to recruit, 
modify, and stabilize p73 (95).  The kinase c-abl is also required for cisplatin-mediated 
induction of p73 but not p53; c-abl phosphoryates p73 on tyrosine 99 in the 
transactivation domain (31,32,34).  In Chapter III we show that mTOR inhibition leads to 
induction of p73 but not p53.  Because genotoxic agents can inhibit mTOR (96), this may 
be an additional mechanism by which the DNA damage response regulates p73, and may 
explain some discrepancies in the literature about p73 activation. 
 Careful dissection of p73 changes in response to a variety of genotoxic stresses 
suggests that p73 can be induced by some agents, but not others such as ultraviolet 
radiation, and that different doses and time windows are needed to activate p73 in 
comparison to p53.  For example, low doses but not high doses of several DNA 
damaging agents were found to activate p73 (97).  Our preliminary data suggests that 
neither γ-irradiation nor adriamycin increases p73 levels in select mouse tissues 
(unpublished observations).  Further inquiry in vivo is required to understand these 
conflicting data on p73 and genotoxic stress in multiple contexts. 
There was clear evidence of tissue-specific function in the TAp73
-/-
 mice.  Loss of 
TAp73 led to the development of genomic instability, but only in select tissues.  Cells 
isolated from the lung but not the thymus were aneuploid in the absence of TAp73.  This 
correlated with the development of lung tumors but not thymic tumors, and was highly 
suggestive of a causal relationship (65).  Through such data, a model has been proposed 
in which p53 is activated by environmental and/or genotoxic stress, and cells in this 
setting select for p53 mutations.  In contrast, p73 may be activated by other types of 
stresses, in distinct contexts, leading to different routes of inactivation (98).  Perhaps 
27 
 
lessons learned from p63/p73 biology will shed further light on p53 function.  p53 
inhibitory isoforms are expressed in human cancer types with lower p53 mutation rates: 
breast cancer, Acute Myeloid Leukemia, and HNSCC (99).  Because different cancers are 
promoted by different environmental stresses, these correlations suggest that upstream 
signals determine if p53 family members are inactivated by mutation or by inhibitory 
isoforms. 
 What are the alternative upstream signals, outside of classic DDR signaling?  
Results from a fibroblast model of step-wise tumorigenesis suggest that TAp73 and 
∆Np73 are engaged at different stages of tumorigenesis, and that the function of TAp73 
is to contribute to contact inhibition in high density cell cultures (100).  Loss of TAp73 
enabled anchorage-independent growth, unlike p53 depletion that allowed cells to escape 
cell-cycle arrest and apoptosis.  In this model, p53 and p73 performed different molecular 
functions that both lead to tumor suppression, and were activated during different stages 
of tumorigenesis. 
 As described in Chapter III, we developed an approach to identify upstream 
regulators of transcription factors using downstream gene signatures.  Using this 
approach, mTOR was identified as a negative regulator of p73.  Notably, pharmacologic 
inhibition of mTOR in primary human mammary epithelial cells resulted in differential 
regulation of p53 family members.  Cells exhibited selective upregulation of TAp73, 
whereas ∆Np63 and p53 levels both decreased.  Since mTOR is a master regulator of 
energy homeostasis and cell growth, and is often active in tumors (101,102), this suggests 
that mTOR may inhibit TAp73 in tumors.  In general, cancer cells may use upstream 
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kinases or cofactors to inhibit p53 family members in different cellular contexts, 
ultimately maintaining proliferation and survival. 
 
The mTOR Kinase Pathway 
 
The two mTOR kinase complexes 
 The mammalian Target of Rapamycin (mTOR) kinase is a ubiquitous protein 
kinase that integrates multiple signals to control cellular growth and proliferation.  There 
are two mTOR complexes, called mTORC1 and mTORC2, with different substrates and 
upstream regulators.  Both complexes contain mLST8/GL, an essential component that 
stabilizes the complex and contains potential protein docking sites, and FRAP1, the 
catalytic kinase subunit (103).  mTORC1 also contains PRAS40, which is involved in 
Akt-dependent activation of mTOR, and Raptor, which contains the substrate docking 
site (104).  mTORC2 also contains SIN1, which stabilizes the complex, PROTOR/PRR5, 
a protein of unknown function, and Rictor, which provides the substrate docking site 
(105,106).  In this dissertation 'mTOR' refers to mTORC1 unless otherwise noted. 
 Two primary substrates of mTORC1 are the eIF-4E-binding protein 1 (4EBP1) 
and p70 S6 kinase (S6K) that play a role in the translation regulation of mRNAs, 
including those involved in G1-phase progression.  mTORC1 also phosphorylates other 
substrates such as ULK1, a regulator of autophagy (107,108).  Less is known about the 
substrates of mTORC2.  Only two mTORC2 substrates have been identified to date: 
SGK1, involved in the cellular stress response, and Akt, a key protein that integrates 
growth factor signals (109). 
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 mTORC2 phosphorylates Akt on Serine 473.  However, two phosphorylation 
events are required for full activation of Akt.  Insulin-like growth factor 1 (IGF1) binds to 
its receptor (IGFR), resulting in recruitment of phosphoinositide-3 kinase (PI3K) to the 
cell membrane, and an accumulation of phosphoinositides.  PI3K is counteracted by a 
lipid 3' phosphatase, phosphatase and tensin homolog (PTEN).  The lipid second 
messengers generated by PI3K serve as docking sites for a 3-phosphoinositide dependent 
protein kinase (PDK), PDK1, and for Akt, resulting in PDK1-mediated phosphorylation 
of Akt on Threonine 308 (110).  mTORC2 is the previously elusive PDK2 that is also 
recruited to the cell membrane to phosphorylate Akt on Serine 473, resulting in full 
activation of Akt (111). 
 Interestingly, Akt activates mTORC1 by inhibiting its gatekeeper, the tuberous 
sclerosis complex (TSC) that contains two proteins called TSC1 and TSC2.  (Akt 
specifically phosphorylates and inactivates TSC2.)  The TSC complex is a GTP-
Activating Protein (GAP) for the RHEB G-protein, which is an activator of mTOR (110).  
Through this mechanism, the TSC proteins serve as integrators of numerous signals that 
all feed into mTORC1; TSC-mediated inhibition of mTORC1 may be released depending 
on the status of these signals.  The other major kinase that feeds into the TSC complex is 
AMPK, which is a major sensor of cellular AMP levels and thus energy status.  Glucose 
deprivation results in an increase in AMP, which serves as a coactivator of AMPK, and in 
activation of the LKB1 tumor suppressor kinase, which phosphorylates AMPK.  AMPK 
phosphorylates TSC2, but unlike Akt-mediated phosphorylation this is an activating 
signal (112).  Through these upstream kinases, mTORC1 responds to low energy and 
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growth factor levels by inhibiting translation of specific mRNAs and increasing 
autophagy, a process described in greater detail below. 
 Thus, mTORC2 is upstream of mTORC1, but the factors that regulate mTORC2 
activity are unknown.  mTORC2 plays roles in cytoskeleton reorganization and fat 
metabolism (106,113,114).  In addition, mouse models of prostate cancer in which PTEN 
is deleted demonstrated that mTORC2 activity is required for the formation of at least 
some tumor types, likely through its phosphorylation of Akt (115). 
 
Cross-talk with p53 
 The p53 and mTOR signaling pathways are multiply inter-connected.  In general, 
these connections comprise either a fast response or a slow response to DNA damage and 
cellular stress, resulting in a p53-dependent decrease in cell growth and proliferation and 
increase in cellular autophagy.  The genes in these pathways (p53, PTEN, TSC2, PI3K, 
Akt, MDM2, AMPK, and mTOR) are the most frequently deregulated genes in human 
tumors, highlighting their importance as critical control mechanisms. 
 The fast response between mTOR and p53 occurs within minutes after cellular 
stress.  Glucose starvation results in Ser-15 phosphorylation of p53, mediated by AMPK.  
A Ser-15 p53 phophatase, α-4 PP2A, is activated through phosphorylation by mTOR.  
Theoretically this should create a positive feedback loop resulting in sustained p53 
activation, although in vitro experiments suggest that many time and dose-dependent 
variables affect this response (110).  In contrast, after DNA damage, activated p53 
activates AMPK.  This occurs through sestrin-1 and sestrin-2, p53 target genes, that bind 
to both p53 and AMPK and promote AMPK activity (96).  Thus, DNA damage activates 
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p53, which activates AMPK, and the latter downregulates mTOR, resulting in decreased 
translation of select mRNAs and increased autophagy levels. 
 There is also a slow response, due to inter-connections between p53 and mTOR 
that do not occur until hours after initiation of cellular stress.  Both PTEN and TSC2 are 
p53 target genes, although their regulation by p53 appears to be highly cell type and 
context specific (116).  The expression products of both of these genes, as described 
above, inhibit mTOR.  In addition, REDD1 is a p53 target gene that is activated in 
response to hypoxia, and inhibits mTOR through TSC2 (117,118).  Thus, these target 
genes cause decreased cellular growth and proliferation, often in a p53 and mTOR-
dependent manner. 
 p53 can act both downstream and upstream of mTOR signaling.  Hamartomas 
contain constitutively active mTOR signaling (in familial syndromes this occurs due to 
genetic inactivation of TSC1 or TSC2), and also have high levels of active p53 (119).  
Elevated p53 levels may be due to downregulation of Mdm2 secondary to decreased 
translation of Mdm2 mRNA.  While the kinase Akt phosphorylates Mdm2, leading to 
Mdm2 activation and downregulation of p53 activity, PTEN
-/-
 cells have increased p53 
activity (110).  Similary, we have observed a slight decrease in p53 levels after 
pharmacologic inhibition of mTOR (discussed in later chapters).  The functional 
consequences of p53 downstream of mTOR remain unknown. 
 
Role in tumorigenesis and cancer therapy 
 mTOR inhibitors are currently in clinical trials for a broad range of tumor types.  
As single agents, rapamycin analogs have generally not shown strong efficacy (102).  
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Given the importance of mTOR in tumorigenesis, three strategies have been proposed to 
improve clinical response to these agents.  First, because mTOR inhibitors have the 
ability to synergize with a large number of genotoxic agents, they are being pursued in 
combination therapies.  Second, since a small subset of patients show striking reductions 
in tumor volume after treatment with rapamycin analogues, marker-based prediction of 
patients that will respond to mTOR-targeting therapies could guide treatment regiments.  
Third, mTOR inhibitors evaluated in clinical trials were mTORC1 inhibitors.  Based on 
feedback loops such as those described above, inhibitors that target FRAP1, the catalytic 
kinase subunit in both mTORC1 and mTORC2, may show greater efficacy as cancer 
therapies than rapamycin analogues and several pharmaceutical companies have these 
dual inhibitors under development. 
 mTOR inhibitors block cellular proliferation and in combination enhance 
apoptosis, particularly in synergy with other agents (120-123).  Both of these functions 
would inhibit tumor cell growth.  In addition, mTOR inhibitors increase autophagy, a 
catalytic process in which double-membrane vesicles surround proteins and organelles 
and digest them into components for re-use (reviewed in (124)).  Autophagy allows cells 
to survive periods of starvation, as this catalytic process increases cellular nutrient pools.  
Autophagy is also a normal homeostatic process, and inactivation of key autophagy genes 
in transgenic mouse models causes either embryonic lethality, perinatal lethality from 
starvation, or severe tissue dysfunction from intracellular inclusions (124).  
Haploinsufficiency of some of the same genes leads to an elevated frequency of tumor 
formation; thus, autophagy is a critical process that maintains cellular fidelity.  Finally, 
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autophagy can be associated with tumor cell death due to excessive catabolism, or as a 
supplemental process that occurs as a 'clean up' mechanism during apoptosis (124). 
 DNA damage-induced activation of p53 induces autophagy through the p53 target 
gene and lysosomal protein DRAM, and also through AMPK-mediated inhibition of 
mTOR (125).  (Of note, cytoplasmic p53 inhibits autophagy at baseline, in a manner that 
does not seem to be induced by DNA damage (126).)  Thus, autophagy will likely play a 
critical role in anti-tumor strategies that target mTOR or p53. 
 
Anti-Cancer Strategies Targeting p73 
 Several anti-cancer approaches have targeted p53.  However, there has been 
increasing interest in p73 as a target based on its expression in tumors that have 
inactivated p53.  This is highlighted by two studies.  First, a high-throughput based 
screen identified small molecules that activate p53 target genes and apoptosis in p53-null 
cells.  Two of the small molecules mediated their activity through TAp73, as 
demonstrated using TAp73-specific RNAi (127).  In a separate study, a novel p53-
derived peptide (37AA) was identified that stimulates cell death through activation of p53 
family target genes.  It functions by preventing TAp73 from interacting with an inhibitor, 
iASPP, resulting in TAp73 activation in p53-null cell lines and xenografts (128).  The 
discoveries from these two approaches show the promise of directly targeting p73 for 
therapeutic gain. 
In vitro studies have used adenoviruses to grossly increase TAp73 levels, 
overcoming potential regulatory mechanisms and leading to apoptosis of cancer cells 
(129,130).  However, a greater understanding of the signaling pathways upstream of 
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TAp73 could lead to approaches that selectively modulate TAp73 to engage tumor cell 
death and was a major goal of the dissertation research presented herein.  In addition, it is 
thought that inhibitory signals such as ∆Np63 and ∆Np73, as well as unknown signals, 
are present in tumor cells and are inhibiting TAp73 function (37).  Strategies that tip the 
balance of these isoforms and increase TAp73 levels and activity would be effective at 
eliciting a p53-type response in tumor cells that have inactivated p53.  There is a critical 
need to understand genes and ncRNAs regulated by p73, and how they change during 
treatment regimens.  We have identified mTOR as a regulator of p73, defined the p73 
genomic binding profile, and demonstrated its modulation by the mTOR inhibitor 
rapamycin.  mTOR-p73 gene signatures classified tumors by clinical subtype and 
outcome.  Similar signatures might inform the use of cancer therapies such as mTOR 
inhibitors that engage p73 and are affected by differential p73 activities in tumor 
subtypes. 
 
Understanding p73 Signaling 
 Transcription factors regulate highly complex gene networks.  This is exemplified 
by the p53 gene family, which contains three members, p53, p63, and p73 that 
collectively can encode over 50 protein isoforms, all with the ability to bind DNA.  A 
major goal of this dissertation research was to understand p73 biology through its 
essential function as a transcription factor, the gene expression that it regulates.  In this 
thesis I analyzed p73 signaling using whole-genome technologies.  As more researchers 
use advanced genomic technologies and make their findings publicly available, it 
becomes increasingly possible to perform meta-analyses, annotate datasets, and recognize 
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patterns of genes.  This dissertation research has contributed significantly by using an 
integrative genomic approach in a mesenchymal cell line to define the p73 cistrome (the 
comprehensive set of binding sites of a transcription factor across the non-repetitive 
genome), and the p73 transcriptome (the comprehensive set of transcripts regulated by a 
transcription factor), creating valuable resources of p73 target genes. 
 How tumors tolerate over-expression of p73, a protein with tumor suppressive 
properties, is unclear.  I had hypothesized that signaling pathways upstream of p73 inhibit 
its activity in tumors.  In Chapter III I devised an approach, based on recognition of 
patterns within the p73 gene signature, that identified mTOR as an upstream regulator of 
p73.  Regulation by mTOR may provide an explanation for the seemingly contradictory 
in vitro effects of p73 on apoptosis and autophagy, and in vivo status of p73 in human 
tumors.  In Chapters IV and V, mTOR inhibition was shown to alter p73 binding and 
activity in a selective manner that was extensively detailed.  In Chapter VI, I explored the 
mechanism by which the mTOR pathway regulates p73; kinases involved in mTOR 
signaling were tested for their ability to phosphorylate p73, and p73 was found to interact 
with FRAP1, the catalytic subunit of mTOR.  Finally, in Chapter VII I created models 
that will be useful for dissection of the in vivo consequences of these findings.  The 
mTOR and p73 gene signatures created herein have clinical utility, as they can predict 
outcome and classify tumor sub-types.  In Chapter VIII I discuss the implications of these 
findings for transcription factor signaling, and describe a potential anti-cancer strategy 
that targets p73 using mTOR inhibitors in combination with other p73-inducing 
chemotherapies in predefined cancer subgroups. 
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CHAPTER II 
 
MATERIALS AND METHODS 
 
Cell culture and treatment 
The rhabdomyosarcoma cell line Rh30 was provided by P. Houghton (St. Jude 
Children‟s Research Hospital, Memphis, TN), and cultured in RPMI Medium 1640 
(Invitrogen, Carlsbad, CA).  Human Mammary Epithelial Cells (HMECs) were purified 
from normal breast tissue obtained from the Vanderbilt-Ingram Cancer Center Human 
Tissue Acquisition and Pathology Shared Resource by Kimberly Johnson, and cultured in 
DMEM/F12 medium 1:1 supplemented with 1.0 g/ml hydrocortisone (Sigma, St. Louis, 
MO), 10 g/ml ascorbic acid (Sigma), 12.5 ng/ml human recombinant EGF (Gibco BRL, 
Gaithersburg, MD), 10 g/ml apotransferrin (Sigma), 0.1 mM phospho-ethanolamine 
(Sigma), 2.0 nM -estradiol (Sigma), 10 nM 3,3‟,5-triiodo-L-thronine sodium salt 
(Sigma), 15 nM sodium selenite (Sigma), 2.0 mM l-glutamine, 1% penicillin-
streptomycin, 1 ng/ml cholera enterotoxin (ICN Biomedicals, Inc., Aurora, OH), 1% fetal 
bovine serum, and 35 g/ml bovine pituitary extract (Gibco BRL).  MDA-MB-231 cells 
[American Type Culture Collection (ATCC), Manassas, VA] were cultured in McCoy‟s 
5A Medium (Invitrogen), MDA-MB-468 cells (ATCC) were cultured in 1:1 McCoy‟s 
5A:DMEM (Invitrogen), and 293T cells (ATCC), 293A cells (ATCC), H1299 cells 
(ATCC), and HaCat cells (kindly provided by P Boukamp, Deutsches 
Krebsforschungszentrum, Heidelberg, Germany) were cultured in DMEM (Invitrogen) 
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(131,132).  All medias were supplemented with 10% fetal bovine serum unless otherwise 
described. 
Cisplatin (APP Biopharmaceuticals, Schaumburg, IL) was used at 25 M, 
paclitaxel (Sigma) was used at 100 nM, and RAD001 (everolimus, Novartis, Basel, 
Switzerland) was used at 20 nM.  Rapamycin (Calbiochem, Darmstadt, Germany), 
metformin (Sigma), and pyrvinium (United States Pharmacopeial Convention, Rockville, 
MD) were used as described.  For experiments involving rapamycin, cells were plated at 
3-4 x 10
5
 cells per 10 cm
2
 dish.  (HMECs were plated at 5 x 10
5
 cells per 10 cm
2
 dish.)  
After cells attached, media was changed 12 h prior to addition of drug [to avoid 
experimental variation due to the effect of media replacement on mTOR (133)], or drug 
was added to serum-free media as described.  Media without antibiotics was used for 
treatment. 
For cell growth experiments, MDA-MB-231 cells were plated in triplicate and 
treated with shRNA-expressing lentivirus, as described below.  After 2 d, cells were 
treated with 20 nM rapamycin or vehicle-control and total cell number was measured at 
the indicated times. 
 
Cell transfection/infection and shRNA 
The following sequences were used for small interfering RNA (siRNA):  p73-1: 
5‟- GCAATAATCTCTCGCAGTA -3‟, p73-2: 5‟- GAGACGAGGACACGTACTA -3‟, 
TAp73-1, 5‟- GAACCAGACAGCACCTACT -3‟, TAp73-2, 5‟ -
GGATTCCAGCATGGACGTC -3‟, GFP: 5‟- GAAGGTGATACCCTTGTTA -3‟, 
mTOR (FRAP1): 5‟- GCATTTACTGCTGCCTCCTAT -3‟, and p73: 5‟- 
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TCAAGGAGGAGTTCACGGA -3‟.  293T cells were transfected using Fugene 6 
(Roche, Indianapolis, IN).  For knock-down of p73, the pSicoR lentivirus system was 
used (134).  For knock-down of mTOR (FRAP1), the pGIPZ system was used according 
to the manufacturer‟s protocol (OpenBiosystems, Huntsville, AL).  p70S6K was depleted 
using Dharmacon SmartPools, and Rictor and Raptor were depleted using Qiagen 
siRNAs, according to the manufacturer's instructions.  
For microarray and ChIP, MDA-MB-231 cells were infected with adenovirus 
expressing HA–TAp73 (pAdEasy-1:HA-TAp73) or with a control adenovirus, and the 
cells were harvested after 80% transduction efficiency was reached, as monitored by GFP 
fluorescence.  The recombinant adenoviruses were generated using pAdEasy kindly 
provided by B Vogelstein (Johns Hopkins University, Baltimore, MD) (135).  The cDNA 
of interest was cloned into the shuttle vector pAdTrack and transferred into the 
adenoviral vector pAdEasy-1 through recombination events in bacteria.  293A cells were 
transfected with adenoviral vector, cells were monitored by fluorescence, and once 100% 
of cells were fluorescing viral particles were harvested by freeze-thaw lysis of the cells.  
Over-expression of multiple p73 isoforms was performed using the pcDNA3 backbone 
[kindly provided by C. Backendorf and G. Melino (136,137)], and transfection was 
performed using Lipofectamine (Invitrogen) according to the manufacturer‟s instructions. 
 
Protein lysate preparation and Western analysis 
Cells were washed in ice-cold phosphate-buffer saline, and protein extrates were 
prepared by harvesting cells in radio immunoprecipitation assay (RIPA) buffer (150 mM 
NaCl, 1% Nonidet P-40, 0.5% deoxycholate, 0.1% SDS, 50 mM Tris [pH 8.0], 5 mM 
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EDTA).  Lysis buffers were supplemented with phosphatase inhibitors 50 mM NaF, 0.2 
mM NaVanadate, 10 mM p=nitrophenyl phosphate, and the protease inhibitors antipain 
(10 g/ml), leupeptin (10 g/ml), pepstatin A (10 g/ml), chymostatin (10 g/ml) 
(Sigma), and 4-(2-aminoethyl)-benzenesulfonylfluoride (200 g/ml) (Calbiochem).  Cells 
were incubated on ice 30-45 min, and the protein supernatant was cleared by 
centrifugation at 13,000 x g for 10 min at 4C. 
Protein lysates were boiled in 1x Laemmli sample buffer, separated by SDS-Page, 
and transferred them to Immobilon-P membranes (Millipore, Billerica, MA) for Western 
analysis.  Membranes were blocked with 5% non-fat dry milk in TTBS (100 mM Tris-
HCl [pH 7.5], 150 mM NaCl, 0.1% Tween-20) and incubated with the following 
antibodies: p73 monocolonal antibodies IMG-246, IMG-259, IMG-313 (Imgenex, San 
Diego, CA), p73 monoclonal antibody cocktail Ab-4 (Neomarkers, Fremont, CA), mdm2 
monoclonal antibody SMP14, -actin polyclonal antibody I-19, mTOR polyclonal 
antibody N-19 (-FRAP), p63 monoclonal antibody 4A4, p53 monoclonal antibody DO-
1 (Santa Cruz Biotechnology, Santa Cruz, CA), GAPDH monoclonal antibody MAB374 
(Chemicon, Temecula, CA), p21 monoclonal antibody Ab-1 (Calbiochem, San Diego, 
CA), phospho-4EBP1 Thr37/46 polyclonal antibody, PARP antibody, Caspase-3 
antibody, puma antibody, p70S6K antibody, phospho-p70S6K (Thr389) antibody, 
phospho-Akt (Ser473) antibody, Akt antibody, phospho-AMPK (Thr172) antibody, 
AMPK antibody, phospho-S6 Ser235/236 polyclonal antibody 2F9, total S6 monoclonal 
antibody 54D2 (Cell Signaling Technology, Danvers, MA), MAP1LC3B antibody 
(Abgent, San Diego, CA), and p73 antibody (Bethyl Laboratories, Montgomery, TX).  
p73 was immunoprecipitated for ChIP with Ab-4 or p73 antibody using conditions 
40 
 
previously described (138), and as outlined further below.  mTOR complex components 
were immunoprecipitated as previously described (139).  A Fluor-S Max MultiImager 
(Bio-Rad, Hercules, CA) was used to quantify Western signals. 
For analysis of protein levels in ChIP-on-Chip duplicate samples, fixed cells were 
resuspended in cell lysis buffer (5 mM PIPES pH 8.0, 85 mM KCl, 0.5% NP40, and 
protease and phosphatase inhibitors [10 ug/ml chymostatin, 10 ug/ml leupeptin, 10 ug/ml 
antipain, 10ug/ml pepstatin A, 0.2 ug/ml AEBSF, 0.2 mM NaVanadate, and 8 mM 
NaFluoride]) and dounce homogenized.  Nuclear pellets were resuspended in sonication 
buffer (50 mM Hepes pH 7.9, 140 mM NaCl, 1mM EDTA, 1% Triton X-100, 0.1% Na-
deoxycholate, 0.1% SDS, and protease and phosphatase inhibitors as above), and 
Western analysis was performed on a chromatin-enriched fraction as above. 
 
Systematic evolution of ligands by exponential enrichment 
 Systematic evolution of ligands by exponential enrichment (SELEX) was 
performed as described in (48).  Briefly, a library of random-sequence 33-mer DNA 
oligonucleotides, flanked by fixed sequences complementary to PCR primers with BglII 
rescriction enzyme sites, was obtained from Carmen Perez.  A pool of ~2 x 10
14
 random-
sequence 87-mers was converted to a double-stranded DNA library by PCR.  The PCR 
products were ethanol precipitated and resuspended in 100 μl of Annealing Buffer (20 
mM Tris, 2 mM MgCl2, 10 mM NaCl).  p73-binding sequences were selected from this 
library by performing a DNA-binding assay using immunopurified p73 (from H1299 
cells infected with adenovirus expressing HA-TAp73β as above), purified using 
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QIAquick PCR purification kit (Qiagen), digested with BglII, cloned into the pBluescript 
II SK vector (Stratagene), and a fraction of the clones were sequenced. 
 
Flow cytometry 
Flow cytometry was performed by incubating 1 x 10
6
 cells in 20 g/mL 
propidium iodide (Sigma-Aldrich) and measuring DNA content for 15,000 events with a 
FACSCaliber instrument (Becton, Dickinson & Co, Franklin Lakes, NJ).  Flow 
cytometry data were plotted using CellQuest software (Becton, Dickinson & Co). 
 
Quantitative reverse transcription-PCR 
Total RNA was purified, reverse transcribed, and quantitative real-time PCR 
performed as follows. RNA was isolated using the Aurum Total RNA Mini kit (Bio-
Rad), and reverse transcription of 100 ng of mRNA was performed using he TaqMan 
Reverse Transcription Reagents kit (Applied Biosystems, Carlsbad, CA) to generate 
cDNA samples.  The cDNA samples were diluted at 1:5 and 2 l were used for qRT-
PCR.  Reactions were performed using iQ SYBR-Green Supermix (BioRad).  For qRT-
PCR of MDA-MB-231 RNA, all primer sequences were obtained from the PrimerBank 
resource (140,141), and can be found at: (http://pga.mgh.harvard.edu/primerbank/).  
Using an iCycler Thermal Cycler (Bio-Rad), 40 cycles of PCR were performed after an 
initial 3 min at 95C, each cycle consisting of 10 s at 95C and 45 s at 54-60C. 
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miRNA isolation and expression analysis 
 miRNA analyses were performed as follows:  Rh30 cells were treated with 
vehicle or 40 nM rapamycin for 24 h after infection with lentivirus expressing shRNA 
targeting GFP or TAp73 for 3 d, and RNA was isolated using the miRVana minikit 
(Applied Biosystems).  Duplicate samples were sent to the Vanderbilt-Ingram Cancer 
Center Microarray Shared Resource (VMSR) for quality control.  The RNA was reverse 
transcribed, and cDNA hybridized to TaqMan Low Density Array version 2.0 cards A 
and B without pre-amplification for MultiPlex quantitative real-time PCR analysis, 
according to the manufacturer‟s instructions (Applied Biosystems).  Data were analyzed 
and normalized using the ΔΔCT method, by averaging sample values from two 
independent experiments.  miRNAs with low copy number (CT > 35) were excluded. 
 For miR-133b and RNU19 qRT-PCR analysis, RNA samples from three 
independent experiments were harvested as above, reverse transcription was performed 
using the TaqMan Reverse Transcription kit, and real-time PCR was performed using the 
TaqMan MicroRNA Assays according to the manufacturer‟s instructions (Applied 
Biosystems). 
 
RNA isolation, microarray experiments, and statistical analyses 
Over-expression microarray experiments were performed in duplicate as follows: 
H1299 cells were infected with adenoviruses expressing GFP or TAp73 for 5 h, RNA 
was isolated using the Aurum Total RNA Mini kit (Bio-Rad) and submitted to the VMSR 
for quality control.  The RNA was processed and microarray was hybridized by VMSR.  
Microarray data analyses were performed using the ArrayAssist software platform 
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(Stratagene, La Jolla, CA).  A list of probes was created with fold-change in gene 
expression for p73-overexpressing samples versus GFP controls.  The following software 
programs were used for statistical analyses, gene annotations, and determination of 
categorical enrichment as indicated: ArrayAssist (Stratagene), WebGestalt 
(Bioinformatics Resource Center at Vanderbilt University) (142), Ingenuity Pathway 
Analysis (Ingenuity Systems, Redwood City, CA), NCBI DAVID, and the Connectivity 
Map (143).  KEGG and gene ontology analyses was accessed through WebGestalt, using 
statistical tests coupled to the WebGestalt interface (142).  Comparison of the over-
expression p73 gene signature to publicly available datasets, and to gene expression data 
from the VICC 9936 clinical trial (provided by J. Bauer) was performed using 
ArrayAssist. 
 Rapamycin/ knock-down microarray experiments were performed in duplicate in 
Rh30 cells treated as above, and RNA was isolated using the Aurum total RNA minikit 
(Bio-Rad) and submitted to the VMSR for quality control.  The RNA was processed, and 
Affymetrix Hu Gene 1.0 ST microarrays were hybridized according to 
VSMR/Affymetrix protocols (144). 
Probe summarization algorithms (ExonPLIER16) were used to identify changes 
in transcript expression levels.  Expression levels have been log transformed.  
GeneSpring GX software (Agilent, Santa Clara, CA) was used for statistical analyses and 
transcript annotations, and for algorithms involved in: hierarchical clustering, Venn 
analysis, classification, box plots, bar charts, statistical similarity of gene lists, and 
Benjamini-Hochberg multiple testing-corrected t- and ANOVA testing.  Methods used 
for comparison to publicly available datasets and survival analyses are detailed below. 
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H1299 ChIP and ChIPSeq 
Formaldehyde crosslinking, chromatin preparation and immunoprecipitation 
(ChIP) were carried out as follows.  Growth media was aspirated from cells and replaced 
with a 1.6% formaldehyde (EM Science, Gibbstown, NJ) solution in PBS.  Cells were 
incubated in formaldehyde for 10 min at room temperature, followed by inhibition of the 
crosslinking reaction by the addition of glycine for a final concentration of 0.125 M.  
After 2 min incubation, cells were washed twice with PBS.  Exctracts were prepared by 
scraping cells in 1 ml of RIPA buffer, as above. 
Sonication of the cell lysates was performed to yield chromatin fragments of 
~500-1000 bp, and debris was pelleted by centrifugation for 10 min at 13,000 x g, and 1 
to 1.5 mg of total protein extracts was pre-cleared with 10 μg of mouse immunoglobulin 
G (Pierce, Rockford, IL) bound to PAS for 1 h with rocking at 4C.  After centrifugation 
for 2 min at 13,000 x g, supernatants were transferred to a new tube.  The extracts were 
immunoprecipitated with 1 μg of Ab-4 antibody (Calbiochem) by rocking overnight at 
4C.  Immunocomplexes were washed twice with RIPA buffer, four times with wash 
buffer (100 mM Tris [pH 8.5], 500 mM LiCl, 1% Nonidet P-40, 1% deoxycholic acid), 
followed by two washes in RIPA buffer.  The protein was degraded in digestion buffer 
(120 μg/ml Proteinase K, 10 mM Tris [pH 7.5], 5 mM EDTA, and 0.5% SDS) at 56C 
overnight, and then incubated at 65C for 30 min.  The DNA was resuspended in 40 l 
water, and 2 μl of each sample were used for PCR amplification.  The p21 and mdm2 
ChIP primers correspond to those previously published (145). 
45 
 
For ChIPSeq and semi-quantitative ChIP experiments, cells were crosslinked and 
submitted to GenPathway, Inc. (San Diego, CA) according to their FactorPath protocol.  
Potential response elements for p53 family members were identified by using the p53MH 
and p63MH algorithms to scan sequences for the p53 and p63 motifs (48,146). 
 
Rh30 ChIP, ChIP-on-Chip, and the FactorPath  protocol 
The following antibodies were used for immunoprecipitation of p73-DNA 
complexes in Rh30 cells: anti-TAp73 A300-126A (Bethyl, Montgomery, TX) that 
recognizes an epitope within amino acids 1-62 of TAp73 isoforms, anti-p73α ER-13 (Ab-
1, Calbiochem) that recognizes an epitope within amino acids 495-637 that is unique to 
p73α, and anti-p73β GC-15 (Ab-3, Calbiochem) that recognizes an epitope in amino 
acids 380-499 that is unique to p73β.  Antibody specificity was confirmed using cells in 
which different p73 isoforms had been over-expressed as described above.  For ChIP-on-
Chip and semiquantitative ChIP experiments, cells were cross-linked and submitted to 
GenPathway, Inc., according to their FactorPath protocol. 
For ChIP-on-Chip, probe signal and enrichment analysis was performed using 
Affymetrix Tiling Analysis Software (Affymetrix, Santa Clara, CA).  An estimate of fold 
enrichment was obtained by computing the ratio of signal for each probe on the ChIP 
array to each corresponding probe on an input (unenriched) array.  These ratios were 
made more significant by applying a series of averaging and ranking steps to probes 
within a 400 bp sliding window; p73 binding sites were those that exhibited > 2.5-fold 
enrichment for at least 180 bp of consecutive probes (GenPathway FactorPath Protocol). 
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The following software programs were used for statistical analyses, gene 
annotations, and determination of categorical enrichment as indicated: UCSC genome 
browser and tables (hg18; http://genome.ucsc.edu), Ingenuity Pathway Analysis 
(Ingenuity Systems, Redwood City, CA), Integrated Genome Browser (Affymetrix), 
NCBI DAVID, and WebGestalt (Bioinformatics Resource Center at Vanderbilt 
University) (142).  De novo identification of enriched sequence motifs was performed 
using MEME (147).  CEAS (148) was used for conservation analysis, annotation of 
functional elements, and identification of TRANSFAC and JASPAR enriched motifs. 
 
Locations of rhabdomyosarcoma and related publicly available datasets 
Publicly available data sets for analysis of rhabdomyosarcoma sub-types and 
clinical outcomes, and for comparisons to biologic processes, were obtained from various 
locations as follows.  The Wachtel et al. (149) and Davicioni et al. (150) datasets are 
based on Affymetrix chips (HG-U133A) and are available at EBI ArrayExpress database 
(E-MEXP-121) and the National Cancer Institute Cancer Array Database (trich-00099) 
respectively.  Oncomine Research Platform (151) was used to access and analyze the De 
Pitta et al. dataset (152), which is based on a custom muscle cDNA array.  Mesenchymal 
Stem Cell and epithelial-to-mesenchymal transition datasets were obtained from the 
National Center for Biotechnology Information Gene Expression Omnibus under the 
accession numbers GSE9764, GSE6460, GDS3220, and GSE8240. 
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Survival analyses of rhabdomyosarcoma patient cohorts 
 A total of 134 patients in the Davicioni et al. cohort that had alveolar or 
embryonal rhabdomyosarcoma and a known survival time were included in survival 
analyses (150,153).  These tumors had been profiled using Affymetrix HG U133A arrays.  
Expression data were extracted from the Davicioni et al. dataset for 18 probes 
(corresponding to 17 genes) that are indicated in orange text in Figure S9A; these are the 
direct p73 target genes from among all p73-regulated genes that clustered alveolar 
rhabdomyosarcomas by clinical outcome (alive versus deceased).  The relationship 
between this 17-gene p73 signature and overall clinical survival time was examined 
further using 10,000 re-sampling tests. 
 Expression data for each Affymetrix probe set were treated as the independent 
variable, and the Cox proportional hazard model was used for survival analyses.  The 
number of significant probes with Wald P value <= 0.01 was saved as the observed 
number of significant probes.  Beta (from Cox model) and Wald statistics for each 
Affymetrix probe set were used along with expression data to build up a compound score 
for each patient.  The compound score was used as the independent variable to perform 
overall survival analysis based on the Cox model.  The compound score for patient i is 
defined as Σ j  Wj • Xij, where Wj = Wald statistic score for probe j, and Xij = log2 probe j 
expression level for patient i.  The Wald test P value was saved as the observed P value. 
For the re-sampling test, we randomly selected 18 probes without replacement among all 
possible Affymetrix probes in the array (22,283 probes), and repeated the above 
procedure of determining the number of significant probes, building up a compound 
score and calculating a Wald test P value.  We repeated the re-sampling and survival 
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analysis procedure 10,000 times, generating 10,000 re-sampling numbers of significant 
probes and Wald test P values, to confirm that our observed values were outside of the 
range of values that occur by chance.  For alveolar tumors, only 0.18% of the 10,000 re-
sampling P values were smaller than the observed P value.  In contrast, for embryonal 
tumors 73.5% of the 10,000 re-sampling P values were smaller than the observed P value 
and none of the probes were significant.  Thus, the 18-probe p73 signature segregates 
alveolar rhabdomyosarcomas but not embryonal rhabdomyosarcomas by clinical 
outcome. 
Next, we performed Kaplan-Meier analysis for the 64 patients with alveolar 
rhabdomyosarcoma in the cohort.  For a given set of patients with compound scores, we 
divided the patients into two groups based on the median of the compound score.  We 
plotted survival curves based on this grouping.  The P value of the log-rank test based on 
this grouping was shown.  Validation of the model was performed using the c-index, also 
indicated on the plot.  The c-index is the probability of concordance between predicted 
and observed survival, with c = 0.5 for random predictions, and c = 1 for a perfectly 
discriminating model. 
 
Purification of GST-fusion proteins 
 Bacterial expression was performed in BL21 codon plus Escherichia coli after 
electroporation of a bacterial expression plasmid (pBG101, Vanderbilt University Center 
for Structural Biology) encoding GST in-frame with the protein of interest.  To induce 
expression, bacteria were grown at 37C in 200 mL of LB until an OD600 of 0.5 was 
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reached, 200 L of 1M IPTG was added and cultures were incubated at 25C for 4 hours, 
and bacteria were pelleted. 
 Bacterial pellets were resuspended in 15 mL cold NET buffer (25 mM Tris pH 
8.0, 100 mM NaCl, 0.1 mM EDTA, 5% Glycerol, 1 mM DTT) with protease inhibitors, 
sonicated for 20 sec 3 times, and mixed with 780 L of 20% Triton X-100.  This 
suspension was incubated for 30 min on ice, centrifuged at 5000 g for 15 minutes at 4C, 
and the supernatant was incubated with 200 L of pre-washed glutathione sepharose 
beads (GE Healthcare).  The beads were recovered and washed three times with NET 
buffer.  Proteins were eluted by incubation in elution buffer (75 mM Tris-Hcl, 15 mM 
glutathione, 0.1 g/mL leupeptin) for serial elutions.  Desired elutions were combined, 
dialyzed at a molecular weight cutoff of 10 kDa molecular weight, aliquoted and stored at 
-80C. 
 
Kinase assays 
 The following kinases were purchased for assessment of p53, p63 and p73 
phosphorylation: the mTOR catalytic subunit FRAP1, Akt, AMPK, and RSK1 
(Invitrogen), GSK3β and p70S6K (Cell Signaling, Beverly, MA).  Kinase assays were 
performed in kinase buffer (10 mM HEPES at pH 7.5, 50 mM NaCl, 50 mM β-glycerol 
phosphate, 1 mM sodium vanadate, 1 mM DTT, 10 mM MgCl2 or MnCl2) with ATP and 
substrate, typically incubated at 30C for 20 minutes.  Kinase reactions were analyzed by 
SDS-PAGE and autoradiography. 
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Recombineering in EL350 bacteria 
 The recombineering-based method for generation of a p73 targeting vector is 
described in detail in Chapter VII.  Restriction digests were performed to remove the 
cassette (containing loxP) to be introduced into the target sequence.  The vector was 
treated with calf intestinal alkaline phosphatase (New England Biolabs, Ipswich, MA), 
and the linearized fragment was gel purified using the Qiagen gel purification kit 
according to the manufacturer's instructions.  EL350 cells containing the target plasmid 
were grown in LB with antibiotics overnight at 32C with shaking.  The next day 1 mL of 
the overnight culture was transferred into a flask containing 20 mL of LB, and the 
mixture was incubated at 32C with shaking for 2 hours. 
 Next, 10 mL of the culture was transferred to a new flask, with the remaining 
culture stored on ice to be used as a negative control for recombineering.  The cells were 
heat-shocked for 15 minutes at 42C to induce the production of proteins required for 
recombineering, then the cells were chilled immediately on ice.  Both sets of cells 
(negative control and recombineering-ready) were centrifued at 4C for 5 minutes, and 
each pellet was resuspended in 880 l of ice cold water and transferred to an Eppendorf 
tube.  The tubes were spun in a microcentrifuge at 5000 rpm for 4 minutes to pellet the 
cells.  Cells were washed three times with ice cold water, and electroporated with 50 ng 
of the linearized, purified vector fragment.  Bacteria were grown overnight at 32C on LB 
plates containing antibiotics to select for bacteria in which recombineering was 
successful.  Recovered plasmids were checked by sequencing across all junctions. 
 For arabinose-induction of Cre, EL350 cells were grown in 10 mL LB without 
antibiotics overnight at 32C.  The 10 mL culture was added to 500 mL of LB in a 2 L 
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flask.  The culture was grown at 32C with shaking at 180 rpm until an OD600 of  0.4 was 
reached (~2 hours).  Then, 5 mL of 10% L(+)arabinose (Sigma) was added to the culture 
for a final concentration of 0.1%.  After another hour of shaking cells were collected and 
made electrocompetent as above. 
 
Analysis of p73 genomic sequences and Southern screening 
 The p73 genomic locus and our targeting vector were analyzed using Geneious 
(Biomatters Ltd, Auckland, New Zealand), VISTA homology 
(http://genome.lbl.gov/vista), and www.ensembl.org.  Southern blots were performed as 
described in Chapter VII and as follows.  A total of 12 μg of mouse genomic DNA was 
digested with HindIII (2 l, New England Biolabs) in 38 μl total volume for 1.5 hours at 
37C, then adding 2 l more enzyme and incubating for continued digestion overnight.  
Mouse BAC 176B7 was digested as well as a positive control.  DNA was run on 0.8% 
agarose gel at < 75 volts and a photograph was taken with a ruler for reference. 
 Gels were depurinated for 20 minutes in 0.25M HCl with rocking, rinsed with 
water 3 times, and denatured for 20 minutes in 1.5M NaCl, 0.5M NaOh with rocking.  
DNA was transferred as follows.  Glass plates were placed across a container full of 
0.4M NaOH transfer buffer.  A paper wick was placed across the plate with ends in the 
buffer.  The agarose gel was inverted onto the paper wick, and a pre-wet Zeta probe 
membrane was placed on the gel followed by two pieces of blotting paper.  A 4 inch 
stack of paper towels was tehn placed on top of the blotting papers, followed by glass 
plates.  Transfer was allowed to continue overnight, after which the membrane was 
rinced in 2x saline-sodium citrate (0.3M NaCl, 0.03M Trisodium Citrate).  The 
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membrane was air dried and UV crosslinked using a UV Stratalinker (Stratagene Cloning 
Systems, La Jolla, CA). 
 The strategy for designing the Southern probe was detailed in Chapter VII.  Probe 
was PCR-amplified from BAC template using the forward primer: 5'- 
CTGACCAGTACCGTATGACC-3', and the reverse primer: 5'- 
AGTGGCTCTCTGTCTCTGTG-3'.  Probes were run on a 1% agarose gel and gel 
purified using the Qiagen DNA gel purification kit (Qiagen, Germantown, MD).  Probe 
was labeled using the Stratagene Prime-It Random Primer Labeling Kit. 
 Blots were incubated in Sigma PerfectHyb plus for 1 hour at 65C.  Probes were 
boiled for 10 minutes and then snap chilled on ice, and 2 x 10
6
 counts per ml were used 
overnight at 65C.  Blots were washed briefly in 2x saline-sodium citrate, 1x in low 
stringency wash (2x SSC / 0.1% Sodium Dodecyl Sulfate) at 55-60C, and 1x in high 
stringency wash (0.5x saline-sodium citrate / 0.1% Sodium Dodecyl Sulfate).  Blots were 
covered with thick saran wrap and exposed to film at -80C with an intensifying screen 
for 2 d. 
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CHAPTER III 
 
A GENE-SIGNATURE BASED APPROACH IDENTIFIES MTOR AS A 
REGULATOR OF P73 
 
Introduction 
Mammalian transcription factors can bind to and regulate thousands of sites 
throughout the genome (13,15,86).  The sheer complexities of these gene regulatory 
networks make conventional methods an unsuitable choice for comprehensive analysis.  
The advent of genomic technologies, in particular DNA microarray profiling and 
Chromatin Immunoprecipitation (ChIP) coupled with high-throughput sequencing 
(ChIPSeq) or ChIP-on-Chip, has led to the identification of target genes and 
transcriptional networks on a genome-wide scale (16,154).  These techniques have been 
used to characterize the gene regulatory networks of a growing number of transcription 
factors (154). 
The integral role of p53 in tumor suppression has prompted many laboratories to 
perform extensive analyses of signaling pathways downstream of the p53 family of 
sequence-specific DNA binding transcription factors (p53 and its homologs p63 and 
p73).  It is estimated that p53 has 1,600 binding sites in the human genome, only 22% of 
which are near promoters (15,86).  A more recent study has identified ~5,800 binding 
sites for p63 (13).  Using integrative genomic tools, hundreds of novel target genes have 
been identified for all three family members (13,86,88,155-157).  Similar analyses with 
many transcription factors have led to an explosion of genomic binding site and target 
gene expression data (154).  These datasets hold great potential for much more than the 
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characterization of downstream pathways, in particular we predict that they can be used 
to define the signaling pathways that reside upstream of transcription factors of interest. 
Despite the ability of p73 to regulate many p53 family target genes, little is 
known about the specific pathways that modulate p73 during development, tumorigenesis 
and tumor therapy (63).  Unlike p53, which is mutated in more than 50% of human 
cancers, p73 is not mutated during tumorigenesis, but instead can be over-expressed 
(55,58,158-160).  There has been much interest in modulating p73, due to its high 
expression level in p53 deficient tumors and its ability to activate p53 target genes 
leading to apoptosis of tumor cells (33,69,129,161-163).  Given the above, drug-inducible 
pathways upstream of p73 are of therapeutic interest. 
We used gene expression signatures downstream of p73 to identify novel 
upstream regulators.  A p73 gene signature was created using a combination of genomic 
tools, and was queried against a database of drug-related profiles known as the 
Connectivity Map (143,164,165).  Pattern-matching software (143) was used to identify 
potential p73-activating drugs.  A link between p73 and mammalian target of rapamycin 
(mTOR), a kinase important in energy homeostasis and tumorigenesis, was identified and 
validated, demonstrating the utility of this approach to identify critical signaling nodes 
upstream of transcription factors. 
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Results 
 
Generation of gene signatures for identifying upstream pathways  
  With an overall goal of developing a gene signature-based approach for 
connecting signaling pathways to transcription factors, we first sought to identify known 
pharmaceutical activators of transcription factor signaling using publicly available 
expression profile datasets and the Connectivity Map resource.  Our ultimate goal was to 
use this strategy to identify novel upstream regulators of p73.  However, we thought it 
prudent to use well-defined transcription factors with known upstream signaling 
pathways to confirm that such pathways can be identified using the Connectivity Map 
within reasonable parameters. 
 As a starting point for feasibility testing, we analyzed two publicly available 
expression profile datasets.  In the first analysis, we made use of a list of genes up- or 
down-regulated by zinc-inducible p53 (166).  In the second, we generated a gene list 
from raw microarray data generated from NIH-3T3 cells in which PPAR had been 
overexpressed (167).  The lists of genes both induced and repressed by these transcription 
factors were queried against the Connectivity Map resource (143).  In brief, this resource 
consists of pattern-matching software that compares an input gene signature to a database 
of signatures from 164 small-molecule bioactive compounds (dubbed perturbagens), 85 
of which are classified as pharmaceutical drugs.  A connectivity score from +1 to -1 is 
assigned based on the degree of similarity or dissimilarity between the two signatures 
(143).  Thus, a drug with a high connectivity score has a gene signature very similar to 
the query signature, and might be hypothesized to act on a pathway in parallel with the 
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transcription factor that generated the query signature.  This score allows the user to 
choose perturbagens irrespective of p-value, which is of particular relevance because 
perturbagens are profiled at different doses, in different cell lines, or for a different 
number of experimental replicates (143).  Both the average connectivity score, and the 
maximum connectivity score (from the best instance of treatment, dose, and cell line) are 
informative; for example some cell lines might not express the target of interest, and 
some doses might not be effective, bringing down the average. 
 In this manner we evaluated the gene signatures of p53 and PPAR that we had 
created to test the feasibility of our approach.  Many of the well-studied chemical agents 
that activate p53 are not included in the Connectivity Map.  Nevertheless, when we 
analyzed the p53 gene signature, two known activators of p53 were identified: 
nocodazole, a microtubule inhibitor (168), and tioguanine, a chemotherapy drug known 
to induce p53-mediated autophagy (169,170).  These agents were ranked 6 and 18 out of 
all 85 pharmaceutical perturbagens by average connectivity score.  Analysis of the 
PPAR signature resulted in the identification of the PPAR activator, troglitazone, used 
to treat diabetes mellitus type 2.  Troglitazone was ranked 22 out of 85 compounds.  
Given these results, we considered the thirty highest-ranking perturbagens to be of likely 
relevance in terms of modulating a transcription factor of interest. 
Having ascertained the feasibility of the in silico arm of our approach, we sought 
to identify novel signaling upstream of the transcription factor p73.  To establish a 
collection of p73-regulated genes, Affymetrix GeneChips were used to quantify transcript 
levels after ectopic p73 expression in the H1299 lung carcinoma cell line.  This cell line 
does not have readily detectable expression of p53 family members (171), making it ideal 
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for an analysis of p73 without the confounding effect of its homologs.  Since p73 can be 
expressed as multiple isoforms, we ectopically expressed an isoform designated TAp73β 
that is capable of strong transactivation (137).  p73 transcriptional activity was evidenced 
by induction of known target genes p21 and Mdm2 (Figure 2), and 11 out of the top 20 
regulated genes by microarray are known p53 family targets (Table 2). 
In order to discriminate between direct and indirect regulation by p73, we also 
performed whole genome ChIP to identify sequences to which p73 is bound (ChIPSeq), 
using formaldehyde cross-linked samples that were replicates of those used for our 
microarray experiment.  Over 4,000 p73-bound DNA sequences were isolated, 
sequenced, and mapped to the mammalian genome using GenPathway FactorPath 
technology.  Tags that mapped within 10 kb of genes were considered for further 
analysis.  Overlay of our microarray dataset (562 genes that increased or decreased two-
fold with p73 overexpression) with our whole genome ChIP dataset (2,298 genes) gave a 
more refined list of candidate p73 target genes (121 genes) (Figure 3).  In order to 
validate our technique for identifying novel p73 target genes, we performed semi-
quantitative ChIP using a different p73 antibody from the original ChIPSeq dataset to 
immunoprecipitate DNA-protein complexes.  p73 bound to the promoter elements of both 
p21 and MDM2 (Figure 2).  Binding levels did not correlate with expression levels for 
these two genes (Figure 2), suggesting that other transcriptional modulators (e.g. 
transcription factors, cofactors) regulate gene expression in this system similar to what 
has been reported previously (13).  We chose 15 additional genes that were present in 
both the microarray and ChIPSeq datasets, and were able to validate that p73 bound 
promoter or intronic regions in all 15 genes (Figure 3). 
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Figure 2: Analysis of ectopic p73 expression and resulting modulation of
p21 and mdm2. H1299 cells were transduced with TAp73β or GFP expressing
adenoviruses. A) Protein lysates were harvested after transduction and p73,
GAPDH and downstream targets mdm2 and p21, were analyzed by Western
blot. B-C) p73 regulates known target genes when expressed in H1299 cells.
B) Total RNA was purified, reverse transcribed, and quantitative real-time PCR
performed with primers to p21 and mdm2. The samples were normalized to
GAPDH and the results are presented as fold-change over GFP control. Error
bars represent standard deviation from three experiments. C) For ChIP analysis,
p73 was immunoprecipitated (IP) from formaldehyde-crosslinked H1299 cells
transduced with adenoviral p73 or a GFP control. Associated DNA fragments
were PCR-amplified using primers flanking the p53 family response elements in
p21 and mdm2. Nonspecific binding was assayed by IP of p73 from non-
crosslinked lysates or crosslinked lysates with an isotype-matched antibody („-„
specific IP).
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Gene Title Gene Symbol
Fold Change 
by Microarray
References for 
Known Targets*
stratifin (14-3-3sigma) SFN 275
(Hermeking et al, 
1997)
IBR domain containing 2 IBRDC2 (p53RFP) 99 (Huang et al, 2006)
S100 calcium binding protein A2 S100A2 61
(Tan et al, 1999)        
(Hibi et al, 2003)
transformed 3T3 cell double minute 2 MDM2 53
(Momand et al, 
1992) (Michael et al, 
2002) (Harms & 
Chen, 2006)
carboxypeptidase M CPM 48
microtubule-associated protein 2 MAP2 41
basic helix-loop-helix domain containing BHLHB2 (DEC1) 34
(Thin et al, 2007)     
(Qian et al, 2007)
jagged 2 JAG2 34
(Candi et al, 2007) 
(Sasaki et al, 2002)
p21 CDKN1A (p21) 32
(el-deiry et al, 1993) 
(Nozell et al, 2002)
DNA-damage-inducible transcript 4 DDIT4 (REDD1) 21 (Ellisen et al, 2002)
apoptotic peptidase activating factor 1 APAF1 17
(Moroni et al, 2001) 
(Gressner et al, 
2005)
chromosome 11 open reading frame 17 C11orf17 17
pantothenate kinase 1 PANK1 17
SRY-box 7 SOX7 16
RAP2B, member of RAS oncogene family RAP2B 16
ferredoxin reductase FDXR 15
(Liu et al, 2002)   
(Hwang et al, 2001)
dystonin DST (BPAG-1) 13 (Osada et al, 2005)
angiopoietin-like 4 ANGPTL4 13
hypothetical protein MGC5370 MGC5370 12
endothelial PAS domain protein 1 EPAS1 11
Table 2: Top 20 genes identified by microarray analysis
* Genes regulated by p53, p63, and/or p73 as described in (144).
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Figure 3: Generation of a multi-tiered p73 signature. A) Schematic showing the
number of genes that increase or decrease after p73 over-expression relative to
GFP control by microarray alone, the number of genes identified by ChIPSeq
analysis alone, and the number of genes that are present in both datasets. B-C)
DNA fragments were created from ChIP, and analysis of p73 binding at genomic
regions near the indicated genes was performed by semi-quantitative PCR for
genes showing high levels of binding (B), and lower levels of binding (C). Neg.
represents a negative control region. Error bars represent standard deviation from
three experiments.
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Connectivity Map perturbagens increase p73 levels 
Multiple tiers of information were used to create a rank-ordered list of target 
genes for further analysis, including: (i) presence in microarray dataset, (ii) fold change 
in expression level with p73 over-expression, (iii) presence in ChIP dataset, (iv) presence 
of a cluster of ChIP tags at gene locus, (v) number of tags per cluster, (vi) cluster length, 
and (vii) functional annotation by a variety of methods that are described in greater detail 
below.  The microarray dataset was used to query the connectivity map because it 
contains a large number of genes analyzed in the proper format.  However, we later used 
all tiers of information to choose target genes for follow-up analysis. 
To begin our analysis, genes whose transcript levels increased or decreased two-
fold after ectopic p73 expression were analyzed using the Connectivity Map.  Because we 
were ultimately interested in connecting p73 to pathways rather than just drugs per se, we 
focused on the 'pharmaceutical' subset of 85 perturbagens, which we found to be better 
affiliated with known molecular targets and signaling pathways.  Five of the top thirty 
perturbagens predicted to induce p73 activity were either direct or indirect inhibitors of 
mTOR signaling (Table 3).  This includes sirolimus (known as rapamycin) a drug that 
binds to FKBP12 to form a complex that inhibits mTOR (101), as well as metformin, a 
drug widely used to treat diabetes mellitus type 2 activates AMPK and inhibits mTOR in 
cell culture (172).  We also identified phenformin, a drug that is in the same class as 
metformin but is no longer used therapeutically, pyrvinium, an inhibitor of the Akt kinase 
that is an upstream activator of mTOR (173), and dexamethasone, known to inhibit 
mTOR in muscle cells (174).   
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  Annotation of genes in the p73 signature by ontology (function) and pathway 
analyses generated additional evidence supporting a connection between mTOR and p73.  
Enrichment of functional categories in the p73 signature was determined by comparing 
the observed number of genes in that category to the number of genes expected by chance 
based on sample size (see Materials and Methods).  Known p73 functions were enriched 
in our datasets, including regulation of the cell cycle and cell death (Figure 4).  
Interestingly, the p73 signature also showed enrichment for novel functions such as 
cellular metabolism (Figure 4).  The Kyoto Encyclopedia of Genes and Genomes 
(KEGG), a compendium of genes annotated and organized by signaling pathway (175), 
was used to annotate p73-regulated genes by pathway.  Both the mTOR pathway and the 
insulin signaling pathway [a canonical pathway upstream of mTOR (176)] were enriched 
in the p73 signature (Figure 4).  Taken together, the data from the Connectivity Map and 
gene annotation analyses led us to hypothesize that mTOR is an upstream regulator of 
p73.  
To validate p73 modulation by the mTOR inhibitors identified through the 
Connectivity Map, we focused on two drugs that are widely used therapeutically, 
rapamycin and metformin.  MDA-MB-231 cells were treated with these drugs and mTOR 
inhibition was confirmed using phospho-4EBP1 as a marker of mTOR activity.  Both 
agents caused an elevation in p73 protein levels (Figure 5).  (Unless otherwise noted, p73 
refers to the TAp73 isoform throughout.)  To determine if the observed effects of these 
drugs on p73 levels were specific to breast cancer cell lines such as MDA-MB-231, we 
also treated the rhabdomyosarcoma cell line Rh30 with rapamycin and metformin using 
phospho-S6 as a marker of drug activity. 
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Figure 4: Enrichment of genes by function and signaling pathway in the p73
gene signature. A-B) Enrichment of major biological processes among genes
regulated by p73. Gene Ontology enrichment is shown for sets of genes that are
both present in the ChIP dataset, and increased (A) or decreased (B) 2-fold over
GFP with p73 over-expression in H1299 cells by microarray. Processes with p-
value by hypergeometric test of less than 0.01, and containing two or more genes
as annotated by WebGestalt, are graphed. C) Analysis of KEGG signaling
pathways enriched among all genes that were upregulated two-fold or more in
p73-overexpressing H1299 cells by microarray. Enrichment is shown as the
number of observed genes in the dataset, compared to the expected number of
genes as calculated using the WebGestalt software.
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Figure 5: Western analysis of perturbagen effect on p73. A) p73
levels were increased in MDA-MB-231 cells treated with rapamycin (rap)
(left panel), or metformin (met) (right panel) for 24 h. B) Rh30 cells
treated with rap (left panel), or met (right panel) for 24 h. C) MDA-MB-
468 cells treated with pyrvinium (pyr) for 36 h.
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 Unlike MDA-MB-231 cells that express one predominant p73 isoform (TAp73), 
Rh30 cells express high levels of two p73 isoforms, TAp73 and TAp73, that differ 
only in the presence or absence of a C-terminal Sterile Alpha Motif of unknown function 
(37).  Only the TAp73β isoform is elevated after treatment with rapamycin and 
metformin in Rh30 cells (Figure 5).  Pyrvinium pyruvate inhibits mTOR through the 
upstream kinase Akt (173).  In a breast cell line expressing high levels of Akt (MDA-
MB-468) (177) we also observed an increase in p73 protein levels 12 h after treatment 
with pyrvinium (Figure 5).  Thus, drugs that inhibit mTOR by multiple mechanisms were 
found to induce p73 levels. 
Serum-starvation is a model for energy depletion in cell culture, and leads to 
changes in mTOR signaling (178), and to differences in the effect of rapamycin on 
MDA-MB-231 cells (179).  When rapamycin was added to MDA-MB-231 cells in media 
lacking serum, the elevation of p73 was synergistically enhanced at later time-points 
(Figure 6).  The observed changes in p73 protein in MDA-MB-231 and Rh30 cells were 
not due to parallel changes in p73 RNA levels (Figure 7).  In addition, because mutant 
p53 is a known regulator of p73 through physical interaction (97), we assessed both 
mutant p53 levels and the potential of mutant p53 to co-associate with p73 in both cell 
lines.  The levels of mutant p53 protein did not change in response to rapamycin, nor was 
there detectable co-association between p73 and mutant p53 as assessed by co-
immunoprecipitation analysis (data not shown). 
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Figure 6: Serum-starvation enhances rapamycin-induced regulation of
p73. Left panel: MDA-MB-231 cells were treated with 20 nM rapamycin
12 h after replacement of media containing 10% serum. Right panel: MDA-
MB-231 cells were treated with 20 nM rapamycin in fresh serum-free
media. C is vehicle control. Protein lysates were analyzed by Western blot
for p73, pS6, total S6, and actin as indicated. Panels are representative of at
least three independent experiments.
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Figure 7: Changes in p73 protein levels do not correspond to changes in
p73 RNA levels. A) MDA-MB-231 cells and (B) Rh30 cells were treated
with rapamycin for 24 h in 10% serum and analyzed by Western Blot for
p73, pS6, Total S6, and actin. Total RNA was purified 24 h after treatment,
reverse transcribed, and quantitative real-time PCR performed with primers
to TAp73. The samples were normalized to GAPDH and the results are
presented as fold-change over vehicle-control. Error bars represent
standard deviation from three experiments. Densitometry was performed
on p73 western signals, followed by normalization to actin. The increase in
TAp73β protein levels over vehicle-control was 2.2-fold in (A) and 4.3-fold
in (B).
69 
 
 To determine if the rapamycin-induced elevation of p73 was an indirect 
consequence of rapamycin-induced cell cycle arrest (180), we treated MDA-MB-231 and 
Rh30 cells with the cell-cycle inhibitors hydroxyurea and mimosine.  Cells were treated 
with the inhibitors for 24 h to achieve a G1/S phase arrest; however, TAp73β levels 
remained constant (Figure 8).  These data show that p73 levels are responsive to cellular 
energy status but not general cell-cycle arrest. 
MDA-MB-231 and Rh30 cells do not express detectable levels of p63 by Western 
blot, and in both cases p53 is known to be mutant (181,182).  In contrast, experiments 
within the Connectivity Map were often performed in cell lines that express multiple 
family members.  Because both p53 and p63 can regulate overlapping sets of target genes 
with p73 (37), we addressed the possibility that rapamycin-induced changes in gene 
expression are due to modulation of p53 and/ or p63.  To assess the effect of rapamycin 
on protein levels of all three family members we used nontransformed HMECs.  Only 
p73 increased in response to rapamycin in HMECs; p53 and p63 levels both decreased 
slightly (Figure 9).  We tested additional cell lines that express functional p53 or p63 
(UM-SCC-012, UM-SCC-6, UM-SCC-17b, and MCF-7); in no case did we observe an 
increase in p53 or p63. 
 
mTOR regulates p73 signaling 
To determine if the modulation of p73 by rapamycin was mTOR-dependent and 
to control for any off-target effects induced by rapamycin and metformin, we inhibited 
mTOR using a non-pharmaceutical approach.  MDA-MB-231 cells were infected for 
three days with lentivirus expressing shRNA that targets mTOR (Figure 10).  
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Figure 9: Differential regulation of p53 family members by
rapamycin. HMECs were treated with vehicle control (C) or
rapamcyin for 12 h. Protein lysates were analyzed by Western
blot for p53, p63, p73, actin, pS6 and total S6. Representative of
three independent experiments.
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Figure 10: mTOR regulates p73 levels and activity. A) mTOR knock-down induces p73.
MDA-MB-231 cells were transduced with lentivirus engineered to express shRNA against
the FRAP1 subunit of mTOR, or with control lentivirus. Protein lysates were harvested
three days after transduction, and mTOR, p73, p4EBP1, and actin were analyzed by
Western blot to demonstrate knock-down of mTOR levels and activity and induction of p73
levels. Westerns are representative of three independent experiments. B) MDA-MB-231
cells were transduced with lentivirus engineered to express shRNA against GFP or p73.
Protein lysates were harvested five days after transduction. C) p73 activity is induced in
MDA-MB-231 cells treated with 20 nM rapamycin, with or without concurrent serum-
starvation, verified using p73 RNAi. p73 RNAi was performed by transducing cells with
lentivirus engineered to express shRNA against either GFP or p73 72 h before treatment.
Total RNA was prepared 48 h after treatment, reverse transcribed, and quantitative real-time
PCR performed with primers to the indicated genes. The samples were normalized to
GAPDH, and the results are presented as fold-change over vehicle-control for an average of
three experiments. Samples that exhibited a 30% or greater increase relative to control are
indicated in red. Twelve of seventeen genes exhibited a p73-dependent increase in RNA
levels after rapamycin treatment and serum-starvation.
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Expression of the shRNA resulted in a significant decrement in mTOR protein levels and 
activity and an increase in p73 protein levels (Figure 10). 
Since a signature of p73-regulated genes was the initial query that identified a link 
to mTOR, we hypothesized that several of these genes should be regulated by mTOR in a 
p73-dependent manner.  To test our hypothesis, MDA-MB-231 cells were infected with 
lentiviral shRNA targeting p73 (Figure 10).  RNA was harvested from these cells after 
treatment with rapamycin in the presence or absence of serum in the media.  The target 
genes selected for further analysis were genes in the p73 signature with mTOR-related 
gene ontologies (e.g. involvement in insulin signaling), as well as genes with general 
metabolic functions if they exhibited a high fold-change after p73 expression, and if one 
or more ChIP tags mapped to the gene locus.  All of the target genes that were selected 
are shown in Figure 10.  We found that twelve out of the seventeen candidate target 
genes identified using our ad hoc selection method exhibited an increase in expression 
after treatment with rapamycin that was abrogated by depletion of p73 (Figure 10). 
Three target genes further demonstrate our selection methods.  The insulin 
receptor (INSR) was identified by both microarray and ChIP, and was selected based on 
known cellular function.  Similarly, Tuberous Sclerosis 1 (TSC1) was identified by ChIP 
and is a known component of the mTOR signaling pathway (183).  Finally, xanthine 
dehydrogenase (XDH) is an example of a target gene chosen both for its ontology and for 
its presence as a cluster of tags in the ChIPSeq dataset (data not shown).  XDH regulates 
cellular metabolism and cellular response to reactive oxidative stress (184), a process that 
can by regulated by mTOR during hypoxia (118).  
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XDH, TSC1, and INSR are three examples of a larger subset of genes whose 
regulation by mTOR is p73-dependent at the transcriptional level.  An increase in 
expression from all three genes after treatment with rapamycin in the absence of serum is 
abrogated by p73 knock-down, as depicted in Figure 11.  In addition, semi-quantitative 
ChIP in Rh30 cells revealed an increase in p73 binding to promoter or intronic sequences 
in all three genes in response to rapamycin (Figure 11).  These genes, that were selected 
using multiple criteria, thus serve as readout of an mTOR-p73 signaling axis. 
Also consistent with mTOR being an upstream modifier of p73 signaling, knock-
down of p73 prevented a decrease in cell growth rate in MDA-MB-231 cells after 
treatment with rapamycin (Figure 11).  These data suggest that cellular processes 
affecting growth rate are modulated by mTOR and p73. 
To assess more specific functions of p73 that might be regulated by mTOR, we 
focused on autophagy, a form of degradative cell death in response to energy starvation 
that is induced by p73 (185).  Because our gene signature was generated using the 
TAp73 isoform, and only TAp73 is induced by rapamycin, we tested the effect of 
selective knock-down of this isoform on autophagy using two different RNAi constructs 
targeting either the N-terminal TA domain or the C-terminal  domain.  In both cases, 
knock-down abrogated baseline autophagy as measured by detection of the cleaved forms 
of MAP1LC3 (LC-I and LC-II) by Western blot. MAP1LC3-II is the only protein known 
to be associated with the completed autophagolysosome, and is considered a marker of 
autophagy (186). 
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 We next sought to identify downstream factors that might mediate this effect on 
autophagy.  p73-regulated genes were analyzed using publicly available datasets in which 
biological states involving mTOR modulation, such as nutrient deprivation and 
autophagy, were profiled using DNA microarrays (187,188).  Several known p73 target 
genes showed increased expression in response to starvation and/or starvation-induced  
autophagy (Figures 12 and 13; orange font) (85,117,187-193).  Two unknown genes in 
the p73 gene signature, Kelch-like 24 (KLHL24) and LOC153222, clustered with the 
known and functionally better-annotated target genes that were increased in these 
biological states (Figures 12 and 13; blue font).  Both KLHL24 and LOC153222 RNA 
levels increased in MDA-MB-231 cells treated with rapamycin (Figure 13).  For both 
genes, this increase was p73-dependent (Figure 13).  Thus our approach resulted in the 
identification of new p73-regulated genes associated with autophagy and metabolism.  A 
gene signature of p73 target genes, when queried using the Connectivity Map, allowed us 
to identify mTOR as a key signaling pathway upstream of p73. 
 
mTOR and p73 in triple-negative breast cancers 
 We next explored the relevance of the mTOR-p73 signaling pathway to human 
cancer, focusing on a particular subtype of breast cancer that expresses p53 family 
members, is basal-like, and is associated with a poor prognosis (57).  As described above, 
using a combination of microarray profiling and ChIPSeq, we generated a robust p73 
gene signature.  We also generated a p63 gene signature comprised of 299 genes that are 
regulated by p63 in squamous tissues, as measured by Barbieri et al. (131).   
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Figure 12: Analysis of p73-regulated genes in a profiling study of starvation. A) p73β
knock-down decreases levels of autophagy markers. MDA-MB-231 cells were transduced with
lentivirus engineered to express shRNA against TAp73 isoforms or against p73β isoforms.
Protein lysates were prepared and p73, actin, and the autophagy markers LC3-I and LC3-II were
detected by Western blot. B) Genes from the p73 signature were assessed using a publicly
available dataset in which T98G glioblastoma cells were grown asynchronously or serum-
starved for 3 d before RNA harvest and microarray analysis (187). Known p53, p63 and/or p73
target genes indicated in orange are: DDIT4 (117), DDB2 (193), DFNA5 (192), CDKN1C
(191), GADD45A (190), and JAG1 (85). Cell lines are arranged in columns, grouped by
treatment as indicated. Genes (annotated from Affymetrix probes) are in rows that are ordered
based on hierarchical clustering results (data not shown). Color range shown indicates baseline
transformed expression level on a log scale. Genes that are upregulated during serum-starvation
that were selected for additional analysis are in blue.
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Figure 13: Analysis of p73-regulated genes in a profiling study of starvation-
induced autophagy. A) Genes from the p73 signature were assessed using a
publicly available dataset in which Awells B-lymphoblastoid cells were serum
starved for 6 h or 24 h, inducing autophagy (188). A known p53, p63 and/or p73
target genes indicated in orange is SESN2 (189). Cell lines are arranged in
columns, grouped by treatment as indicated. Genes (annotated from Affymetrix
probes) are in rows that are ordered based on hierarchical clustering results (data
not shown). Color range shown indicates baseline transformed expression level on
a log scale. Genes that are upregulated during autophagy or serum-starvation that
were selected for additional analysis are in blue. B) Fold change in RNA as in
Figure 4 for KLHL24 and LOC153222 indicate increases in RNA levels after
rapamycin treatment in a p73-dependent manner in MDA-MB-231 cells.
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Because p63 expression is restricted to the triple negative, basal-like subtype of breast 
cancer, where it functions to inhibit TAp73-mediated apoptosis (37,57), we assessed the 
ability of our p63 and p73 signatures to segregate triple negative tumors into additional 
subtypes. 
 For this line of investigation we analyzed a dataset that was made available to us 
by Andrea Richardson (Brigham and Women's Pathology Department; GSE7904 in the 
Gene Expression Omnibus).  Dr. Richardson generated microarray data from a collection 
of 22 basal-like tumors.  We took this microarray data and filtered it through a p73 
signature (comprised of 333 genes that increased more than 2-fold with p73 over-
expression).  We were able to cluster the 22 basal-like tumors into two groups of 8 and 14 
tumors based on differential expression of genes from the p73 signature (Figure 14).  
These genes, when segregated by their tumor expression patterns, fell into distinct 
functional categories (Figure 14).  Further, we filtered microarray data generated from 16 
pretreatment biopsies isolated from patients enrolled on the VICC BRE9936 trial 
(concurrent neoadjuvant paclitaxel and radiation for locally advanced breast cancer 
patients (194)) through a subset of the p63 signature comprised of 44 genes repressed by 
p63.  Of the 16 tumors, 8 were from triple negative breast cancer patients.  The gene 
signature clustered 6 of 16 tumors and all 6 were triple negative (Figure 14).  These data 
suggested that, with a larger cohort of patients, biological meaningful subtypes of basal-
like tumors could be identified using p73 and/or p63 gene signatures. 
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Figure 14: p63/p73 gene signatures can subclassify basal-like tumors and locally advanced
tumors. (Left panel) Hierarchical clustering of GSE7904, microarray data from 22 basal-like
tumors using a p73 gene signature (333 genes). Of the 22 tumors, 8 were classified based on
the differential expression of genes regulated by the p63/p73 signaling axis. (Right panel)
Hierarchical clustering of microarray data generated from 16 biopsies collected from patients
with locally advanced breast cancer enrolled in VICC BRE9936 using a p63 gene signature (42
of original 299 genes in our signature). The gene signature clustered 6 of 16 tumors into one
subgroup and all 6 were triple negative. Of the 16 tumors analyzed there were 8 triple negative
tumors.
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 Given the induction of p73 by rapamycin in mammary epithelial cells, and the 
decrease in inhibitory p63 levels, we hypothesized that rapamycin would perturb the 
p63/p73 signaling axis to favor apoptosis.  We further hypothesized that mTOR inhibitors 
would synergize with other agents that induce p73 and are used as neoadjuvant therapies 
in triple-negative breast cancers such as cisplatin and paclitaxel (32) (195).  We examined 
the sensitivity of MDA-MB-231 cells as well as primary cultures of HMECs to various 
combinations of cisplatin, paclitaxel, and everolimus [RAD001, an FDA-approved 
rapamycin analog and mTOR inhibitor (Novartis)].  We found that RAD001 and cisplatin 
could elevate p73 levels when used as single agents and could decrease p63 levels in cells 
(HMECs) that expressed the protein (Figure 15).  We observed a synergistic effect of the  
three drugs in combination as evidenced by increased expression of the p73 target gene 
Puma, cleavage of PARP and caspase-3, and apoptosis (Figure 15 and data not shown).  
These data serve as preclinical evidence supporting an ongoing clinical trial studying the 
activity of cisplatin and paclitaxel ± RAD001 in patients with triple negative breast 
cancer. 
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Figure 15: Drug modulation of p63/p73 signaling axis. The indicated cell
lines were treated with RAD001 (20 nM), cisplatin (CDDP, 25 µM), or
paclitaxel (Tax, 100 nM) alone or with the indicated combinations. Protein
lysates were harvested at 24 h and Western analysis performed for p73, p63,
pS6, Puma, PARP, caspase-3, or actin. The *s indicate cleaved products of
PARP or caspase-3 found in cells undergoing apoptosis. Cell treatment and
Western analysis were performed by Maria Pino and Lucy Tang.
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Discussion 
Through whole-genome ChIP coupled with gene expression profiling, we have 
created a p73 gene signature that contains multiple tiers of expression and genome 
location information.  This signature was used to identify a novel connection between 
p73 and the upstream kinase mTOR.  Further, select genes from the p73 signature 
exhibited mTOR-mediated, p73-dependent regulation.  Our approach, using a 
downstream signature to identify upstream regulators, is based on straightforward cell 
culture methods and should be widely applicable to the study of many transcription 
factors. 
Determinants of our approach include over-expression of the protein of interest in 
a cell line that does not express high levels of the protein.  This should be easily applied 
to transcription factors that are not essential for cell cycle progression or proliferation.  In 
addition, we predict that modifications of our approach such as using a knock-down 
instead of an over-expression technique would be successful.  One of the striking findings 
from the completion of the Connectivity Map was the extent to which connections could 
be made across different cell lines and tissues (143,196).  Likewise, we did not encounter 
any problems due to the cell lines that we chose for analysis, although this might be a 
significant issue for a modified knock-down approach.  In our study, p73 was regulated 
by mTOR inhibitors in primary cells as well as multiple cancer cell lines. 
The link between mTOR and p73 sheds new light on p73 biology, further 
demonstrating that p73 can be regulated by upstream pathways outside of canonical p53 
signaling (77,78,93,197-200).  For example, Akt can regulate p73 and p73-dependent 
apoptosis (162,201).  It would be intriguing to determine the role of mTOR (and 
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additional members of the mTOR signaling pathway such as Akt) on canonical p53-
family functions such as apoptosis and cell-cycle arrest.  Because Akt directly regulates 
YAP, an activator of p73 (201), this mechanism may function in parallel with mTOR to 
affect p73-dependent transcriptional regulation. 
Other functions downstream of mTOR may also be mediated by p73.  Metformin 
induces apoptosis specifically in p53-null tumor cells (202).  Given our results that 
metformin can induce p73 levels, additional studies are ongoing to test the role of p73 in 
metformin-induced apoptosis and tumor toxicity, in the presence or absence of p53. 
It is the isoform TAp73 that is induced by rapamycin and metformin, with 
apparent coordinate downregulation of TAp73 (Figure 5).  Few proteins that 
differentially modify the alpha versus beta isoforms of p73 have been identified 
(203,204).  We identified a putative E3-ubiquitin ligase in our datasets, TRIM32.  The 
RNA levels of TRIM32 increase 142% upon serum-free treatment with rapamycin 
(Figure 10 and data not shown).  The increase is abrogated to 37% after treatment with 
concomitant p73 RNAi-mediated knockdown (Figure 10 and data not shown).  Perhaps 
TRIM32 or another regulatory protein differentially modifies TAp73 and TAp73 
isoforms in response to signaling from the mTOR pathway.  
We demonstrated that endogenous regulation of caspase-independent cell death 
known as autophagy is a specific function of the TAp73 isoform (Figure 12).  Although 
the mechanism that links p73 to autophagy is unknown (185), the p73 signature presented 
in this work contains candidate target genes, including unknown factors such as KLHL24 
and LOC153222, that are increased in autophagy by microarray profiling (Figures 12 and 
13).  KLHL24 contains a BTB/POZ domain that can function in transcriptional 
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repression, and LOC153222 contains a basic-leucine zipper domain suggesting 
transcription factor activity (205).  These factors may regulate a transcriptional program 
inhibited by mTOR but induced by p73 during autophagy. 
Our study suggests a larger role for mTOR in regulating the p53 family as a 
whole.  p53 is upstream of mTOR through regulation of PTEN, TSC2, and IGFBP3 
(116), as well as downstream of mTOR in vivo in hamartomas (119).  In general the 
mTOR signaling pathway integrates multiple inputs, and can involve alteration of and 
feedback regulation by Akt and the mTORC2 complex (111,206-208).  In later chapters 
we will explore the signaling mechanism(s) by which this pathway is connected to p73.  
Our data suggest that p73 is regulated by mTOR at the post-transcriptional level, either 
by altering protein stability or other mechanisms.  For example, p53 family transcripts 
may have internal ribosomal entry sites that would allow for cap-independent translation 
(209-211).  Cap-independent translation may play a role in mTOR regulation of the p53 
family. 
As has been suggested by Golub, Lamb and colleagues, our study demonstrates 
the potential impact of an expanded Connectivity Map as a community-wide resource 
that would include many more drugs and perturbagens than were included in the first 
build (143,196).  Here we show utility for linking the pathways represented by the 
Connectivity Map to the study of transcription factors in particular, but the power of this 
approach is dependent on the number of drugs and drug-inducible pathways that are 
testable through this resource.  In our study we chose to assess the top 30 compounds 
predicted to induce a p73 gene signature.  This was based on our pilot study using 
transcription factors with known activators.  In contrast, few compounds were identified 
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that would be predicted to repress p73 (i.e. compounds with a negative connectivity 
score), and we did not do a formal analysis of these drugs.  However, one compound with 
a negative connectivity score was estradiol (data not shown), a known activator of the 
mTOR pathway (212).  Preliminary data suggests that estradiol can decrease p73 levels 
(data not shown).  Therefore, we predict that using our approach to identify compounds 
that inhibit transcription factors could also elucidate signaling connections.  An expanded 
Connectivity Map that included more drugs that impact the same pathway at multiple 
levels would allow for more rigorous statistical testing, and thus increase an 
investigator‟s ability to look for enrichment of pathways and agents among their top hits. 
Already, genomic technologies have created a wealth of information downstream 
of transcription factors.  We propose that this information can be used not only to 
characterize downstream signaling pathways, but also to map upstream drug-inducible 
pathways.  Using a genomic-based screening procedure and cell culture-based validation 
techniques, we identified a novel link between p73 and mTOR, an important kinase in 
energy homeostasis and tumorigenesis. 
Because p73 isoforms are over-expressed in many tumors, they may provide 
effective targets for cancer treatment (161).  Recent studies suggest that p73 may be 
present in an inactive form in select head and neck squamous cell carcinomas and basal-
like breast tumors, and that activation of p73 would lead to tumor cell apoptosis (56-58).  
We explored the ability of p63 and p73 to define subtypes of triple-negative breast 
tumors.  Given the synergistic effect of mTOR inhibition on cisplatin and paclitaxel-
induced apoptosis and on p73 induction in basal-like tumors, p63 and p73 gene signatures 
may be useful for predicting patients that will respond to combination therapies that 
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include mTOR inhibitors.  Thus, our results have implications for ongoing and future 
clinical trials examining the efficacy of mTOR inhibitors in tumors expressing p73. 
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CHAPTER IV 
 
 
DIFFERENTIAL REGULATION OF THE P73 CISTROME BY MTOR 
REVEALS TRANSCRIPTIONAL PROGRAMS OF MESENCHYMAL 
DIFFERENTIATION AND TUMORIGENESIS 
 
Introduction 
It has become increasingly clear that no single target gene can explain more than a 
fraction of the tumor suppressive activity of p53.  Instead, p53 regulates the transcription 
of an extensive network of genes involved in diverse functions such as cell cycle arrest, 
apoptosis, senescence, and autophagy (213).  Genome-wide technologies such as 
chromatin immunoprecipitation (ChIP) coupled with sequencing (ChIP-Seq or ChIP-
PET) or microarray (ChIP-on-Chip) have confirmed that p53 regulates highly complex 
gene networks (15,82,86,88).  For example, a recent ChIP-PET study showed that p53, 
when activated, binds to hundreds of sites in the genome (86).   
The complexity of the p53 response, however, extends beyond its genomic 
binding profile, and is reflected by the existence of many p53-like variant proteins that 
can also bind DNA.  Alternative splicing and multiple promoter usage can generate p53 
isoforms with variable N- and C-terminal domains (35).  In addition, mammals have two 
homologs of p53: p63 and p73.  All three p53 family members share a core structural 
architecture and significant sequence identity, and, although their precise roles remain 
unknown, p63 and p73 can also act as tumor suppressors (35). 
It is clear that p63 and p73 can regulate many p53 functions.  However, 
comprehensive whole-genome analyses are needed to identify the full extent of shared 
versus unique target genes that underlie these functions, as well as biochemical 
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determinants such as sequence-specificity, use of cofactors, and epigenetic context.  
Along these lines, a recent study used ChIP-on-Chip technology to create a complete, 
unbiased resource of p63 binding sites in cervical cancer cells (13).  This work revealed 
both similarities and differences in the way that p53 and p63 regulate gene expression 
(13).  Such insights into p53 and p63 highlight the need to investigate p73 upstream of 
transcriptional networks during development, tumorigenesis, and tumor therapy. 
Herein we report the first comprehensive, whole genome analysis of p73 binding 
in human cells.  Furthermore, we re-analyzed this p73 cistrome after perturbation with an 
upstream stressor, an mTOR inhibitor that induces p73 as shown in Chapter III.  The p73 
cistrome shows significant overlap with p53 and p63-regulated target genes.  In addition, 
we identified determinants of p73 binding, activity, and function, some of which were 
modulated by mTOR.  We created an mTOR-p73 gene signature that is enriched for 
genes, micro-RNAs (miRNAs), and non-coding RNAs (ncRNAs) involved in 
mesenchymal stem cell differentiation and rhabdomyosarcoma tumorigenesis. 
 
Results 
 
mTOR modulates the p73 cistrome 
 To perform a comprehensive analysis of p73 binding sites in the genome (the p73 
cistrome), we sought a cell line that expresses abundant p73 with detectable binding to 
chromatin.  We analyzed two cell lines in which we had observed an intact mTOR-p73 
signaling pathway in Chapter III: the rhabdomyosarcoma line Rh30, and the breast cancer 
line MDA-MB-231.  We used ChIP coupled with quantitative real-time PCR (ChIP-
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qPCR) to compare the binding levels of endogenous p73 to representative target genes, 
identified in Chapter III, in these two cell lines after rapamycin treatment.  p73 exhibited 
more robust binding in Rh30 cells (Figure 16), therefore we performed subsequent 
genomic analyses in that cell line.  For genome-wide ChIP analysis and for the ChIP-
qPCR in Figure 16, we used the A300-126A antibody that only recognizes p73 proteins 
that contain a transactivation domain.  These TAp73 isoforms are considered 'active' as 
they are capable of inducing expression of target genes (214). 
p73 also exhibits C-terminal diversity, and TAp73 can be expressed as any of nine 
variants (e.g. TAp73α, TAp73β, TAp73γ…).  We detect two p73 isoforms in Rh30 cells 
at the protein level, TAp73α and TAp73β, which have the ability to form hetero-
oligomers (Figure 17) (137).  The levels of p73 are increased in rapamycin-treated Rh30 
cells, and both isoforms are present and bind DNA (Figure 17).  Therefore, protein-DNA 
complexes immunoprecipitated with the A300-126A antibody contain all of the active 
isoforms of p73 that are detectable in Rh30 cells, and this antibody was used for 
subsequent ChIP-on-Chip. 
 ChIP-on-Chip was performed in both control and rapamycin-treated samples.  
DNA recovered from ChIP was hybridized to oligonucleotide tiling arrays that cover the 
entire nonrepetitive human genome at 35 bp resolution, and p73 binding was measured as 
fold enrichment after ChIP compared to un-enriched input.  A total of 7,678 sites in 
control cells, and 8,165 sites in rapamycin-treated cells, showed greater than 2.5-fold 
enrichment after p73 ChIP.  Using the 'negative peaks' approach to estimate error, the 
false discovery rate at this cut-off is ~0.86%, giving us high confidence that these sites 
were indeed bound by p73 (215). 
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Figure 16: Assessment of p73 occupancy by qRT-PCR. ChIP-qPCR was
performed to assess p73 occupancy at genomic regions in MDM2, RRAD, and
RPS27L promoters in Rh30 or MDA-MB-231 cells treated with 40 nM
rapamycin (rap) for 24 h. To facilitate comparison across cell lines, ChIP-
qPCR was also performed in H1299 lung carcinoma cells transduced with an
adenovirus that expresses high levels of p73. Binding levels were normalized
to input, and “Control” represents a negative-control region.
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Figure 17: p73 levels and binding increase with rapamycin treatment in
Rh30 cells. A) p73 protein levels increase in chromatin-enriched fractions
from Rh30 cells treated with 40 nM rapamycin for 24 h, as analyzed by
Western blot. p73 was detected using an antibody specific for TAp73
isoforms. “C” is vehicle control. pS6 was used as a marker of mTOR
activity. B) ChIP-qPCR was performed to assess p73 occupancy at genomic
locations in MDM2 and RPS27L promoters using two unique antibodies that
preferentially recognize either p73α or p73β. Error bars indicate standard
deviation from triplicate analyses.
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  The accuracy of ChIP is highly reliant on antibody specificity.  Thus, we 
validated our ChIP-on-Chip results on thirty randomly chosen p73-binding sites by 
performing ChIP-qPCR with two different p73 antibodies.  p73 binding was observed at 
all thirty sites (Figure 18).  The two antibodies used preferentially recognize either p73α 
or p73β, suggesting that both p73 isoforms bind to the same sites, either directly or 
through hetero-dimerization with the other p73 isoform.  Previous studies suggest that 
TAp73α forms hetero-oligomers with TAp73β (De Laurenzi et al., 1998).  However, we 
cannot formally distinguish between hetero-oligomers and mixed populations of TAp73α 
and TAp73β homo-dimer-DNA complexes.  Currently, sequential ChIP that measures 
simultaneous co-occupancy of two proteins on a stretch of DNA is too technically 
challenging to pursue on a genome-wide scale (Geisberg and Struhl, 2005).  Regardless, 
each p73 binding site as measured by ChIP-on-Chip is likely to reflect genuine binding 
by both TAp73α and TAp73β.  Sites with higher enrichment as measured by ChIP-on-
Chip also exhibited higher enrichment by ChIP-qPCR. 
 To further validate our ChIP-on-Chip results, we used the phastCons score as a 
measure of evolutionary conservation at every nucleotide in the genome (148).  Sequence 
conservation is an established property of functional genomic elements.  As expected, 
p73 binding sites were conserved relative to non-bound, distant regions (Figures 19 and 
20).  Thus, our ChIP-on-Chip method identified high-confidence p73 binding sites of 
likely functional significance. 
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Figure 18: Verification of p73 binding by qRT-PCR. To confirm the ChIP-on-Chip results,
p73 occupancy was re-measured using different antibodies and methodology. Thirty loci
were chosen randomly from among all p73-bound regions. p73 binding was confirmed by
immunoprecipitating either p73α or p73β from sonicated lysates prepared from formaldehyde-
crosslinked Rh30 cells, and PCR-amplifying associated DNA fragments using primers
flanking each of the thirty sites. The gene nearest each genomic interval (“Intvl”) is indicated
when located within 10 kb.
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peak
interval
MDM2 gene track:
signal in control 
sample:
signal in rapa-
treated sample:
Figure 19: Dimensions of p73 binding. The MDM2 gene is depicted using the Integrated
Genome Browser in order to demonstrate two dimensions of p73 occupancy. The
„interval‟ is the region across which p73 binding exceeds threshold. The „peak‟ is the
location in the interval with the highest p73 binding level. These two dimensions are
related - binding sites with higher peaks generally have longer intervals.
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Figure 20: p73 binding sites are conserved. Sequence conservation was determined using
phastCons scores from the UCSC GoldenPath genome resource in both control and rapamycin-
treated samples. The conservation of broad p73-bound intervals and more sharply defined peaks
was assessed. Regions were extended to 3 kb and aligned at their centers, and an average
conservation score was calculated at each aligned nucleotide. Conservation is higher at p73-
bound regions (center of each plot), compared to genomic background (at both ends of each plot).
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 We next examined whether inhibition of mTOR results in alteration of the p73 
genomic binding profile.  A second ChIP-on-Chip analysis was performed in Rh30 cells 
treated with 40 nM rapamycin for 24 h, conditions that induced p73 in Chapter III.  We 
measured the effect of rapamycin on p73 binding relative to two different parameters.  
First, we measured the p73 cistrome by distance to nearest transcriptional start site.  As 
shown in Figure 21, rapamycin treatment did not alter p73 binding distribution when 
measured relative to the start site of human genes.  As a second measure of p73 
occupancy, ChIP enrichment levels were compared before and after rapamycin treatment.  
There was a significant increase in p73 binding level after rapamycin treatment (Figure 
21, p<0.0001, skew test).  Thus, although the overall distribution of p73 binding location 
was unaffected by inhibition of mTOR, p73 occupancy increased in magnitude. 
p73 binding did not increase uniformly at all sites in the genome.  Instead, only 
8.7% of p73 binding sites demonstrated greater than 50% increase in binding level after 
rapamycin treatment.  Eighteen sites to which p73 exhibited greater than 2.5-fold 
increased binding are shown in Figure 22.  Only nine of the eighteen sites shown are 
within 10 kb of known human genes, yet eight of the remaining nine sites have a high 
level of sequence conservation across vertebrate species (data not shown).  Thus some of 
these sites may be functional elements such as enhancers that can regulate gene 
transcription across great distances.  We hypothesize that as chromosome conformation 
capture-based technologies are developed to map long-range chromosome interactions, 
more p73-binding sites will be linked to mRNA transcripts. 
 Collectively, these data suggest that mTOR inhibition increases p73 protein 
levels, but does not significantly change the overall distribution of p73 binding sites  
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Figure 21: Rapamycin increases p73 occupancy levels. A) Histogram analysis was
performed to assess the distribution of p73 binding sites relative to transcriptional start
sites. The control sample (left half of plot) and rapamycin-treated sample (right half of
plot) were compared using the two-sample Kolmogorov-Smirnov test. The p-value was
0.6, indicating that these distributions are not significantly different. B) Histogram
analysis was performed to assess the impact of rapamycin on overall p73 binding level.
The ratio of binding levels in rapamycin-treated versus control samples was calculated
and log transformed. A skew to the right is evident in this plot, indicating higher binding
in rapamycin-treated samples. The degree of skew is 0.34, with p < 0.0001. Statistical
analysis was performed by Aixiang Jiang and Yu Shyr.
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Figure 22: Rapamycin increases p73 binding to specific regions of the genome.
p73 binding levels were plotted for 18 loci that exhibited the greatest increase in
binding after rapamycin treatment. For comparison, the average p73-binding site
exhibits only 1.1-fold higher binding after rapamycin treatment. Chromosomal
locations that are within 10 kb of known genes are indicated by an asterisk. From left
to right, these genes are: FLJ32810, ARHGEF12, ETV6, RAPGEF3 / FLJ20489,
RBMS3, SCHIP1, HNRPDL / ENOPH1, and FBXO32.
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across the genome.  Instead, the increased p73 protein is either recruited to specific sites 
in the genome, or undergoes a selective increase in affinity to specific loci.  We next 
explored determinants of p73 binding, such as sequence-specificity or association with 
cofactors, which could be responsible for selective, mTOR-induced changes in p73 
activity. 
 
Annotation and analysis of the p73 cistrome reveals multiple determinants of p73 binding 
 We hypothesized that detailed annotation of the p73 cistrome would uncover 
determinants of p73 activity, some of which would be sensitive to mTOR signaling.  
First, we mapped all p73 binding sites to within 10 kb of human genes.  A total of 4,083 
genes in the genome are bound by p73, with some genes containing multiple p73 binding 
sites (Figure 23).  Rapamycin treatment results in only an ~5% increase in p73-bound 
genes (Figure 23).  In both treated and untreated cells, p73 binds predominantly to 
enhancers, introns, and proximal promoters (Figure 23).  These findings suggest that p73 
plays a primary role in the regulation of gene expression.  p73-bound genes were 
assigned to functional and biochemical pathways using the Kyoto Encyclopedia of Genes 
and Genomes (KEGG) database (175).  p73 binds genes associated with diverse signaling 
pathways and cancer types (Figure 24).  Some of these associations, including all cancer 
pathways, had increased significance in rapamycin-treated samples (Figure 24), 
suggesting that mTOR selectively regulates p73 functions. 
 One mechanism transcription factors use to engage in selective binding is to 
recognize a specific DNA sequence, or motif.  We used a de novo motif-finding 
algorithm to identify a sequence enriched in top p73-bound loci (Figure 25A),  
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Figure 24: Enrichment of genes in the p73 cistrome by signaling pathway. KEGG signaling
pathways that are enriched among genes within 10 kb of p73-binding sites are shown for control
and rapamycin-treated samples. Significance is indicated by color, based on p-values from
hypergeometric tests. The mTOR pathway is marked with an asterisk. Cancer pathways are
marked with „+‟; also of note the p-value for pancreatic cancer changes from 1E-4 to 4E-7 with
rapamycin-treatment, and the p-value for colorectal cancer changes from 2E-5 to 2E-6 with
rapamycin treatment.
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Figure 25: p73 binds a consensus DNA sequence similar to the p53 and p63 response
elements. Motifs were identified de novo from A) the top fifty p73-bound sequences in control and
rapamycin-treated samples, and validated in B) the top 500 p73-bound sequences in groups of 50 in
control samples, and C) all p73 binding sites on chromosome 22. Arrows indicate similarities in
the motifs of p63 and p73 that differ from p53. These results suggest that, like p53 and p63, p73 is
capable of binding sequences that deviate from its consensus motif. The height of each nucleotide
indicates its relative frequency at that position in the motif. The probability of identifying an
equally well-conserved pattern in random sequences (E-value) is also indicated for each motif.
A
B
C
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and validated it against less stringently bound loci (Figures 25B and C).  We also 
validated the p73 consensus binding sequence by performing the systematic evolution of 
ligands by exponential enrichment technique (SELEX), in which the affinity of p73 for 
randomly generated oligonucleotide motifs is measured in vitro.  SELEX did identify the 
p73 consensus binding sequence from a pool of random sequences. 
 The p73 binding motif is nearly identical to the p53 response element (86).  
However, as indicated by the arrows in Figure 25, p73 also shares certain motif elements 
with p63 that may decrease p63 selectivity of binding, leading to a larger pool of 
potential p63 binding sites (47,48).  p63 and p73 share 87% sequence identity in their 
DNA binding domain, compared to only 63% for p53 and p73 (216), supporting our 
finding that p73 and p63 have highly similar DNA binding motifs.  In addition, p73 binds 
~4,000 genes, compared to ~3,000 for p63 and ~1,500 for p53 (13,82).  Thus, within the 
p53 family, strictness of DNA motif conservation does seem to correlate with total 
number of loci bound, and p63 and p73 share more similarity in this regard than either do 
to p53.  Still, the p53, p63, and p73 consensus binding sequences are highly similar, and 
all family members regulate highly overlapping sets of target genes (Figure 26).  The 
identification of this novel consensus binding sequence will be useful for the future 
identification of response elements in novel p73 target genes. 
 p73 binds less than 10% of all its motifs that exist in the genome (data not 
shown).  Thus, other determinants must specify whether or not p73 binds a particular 
motif both at baseline and during mTOR inhibition.  One such determinant may be the 
association of p73 with other transcription factors and cofactors.  
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Figure 26: Regulation of common sets of genes by p53, p63, and p73. The
observed overlap between p73-bound genes and A) p63-bound genes from Yang and
colleagues (see text) or B) p53-bound genes Wei and colleagues (see text) is compared
to the overlaps of 10,000 random groups of equivalent size. None of the random
overlaps has a larger overlap than the observed data (p < 0.0001). Bootstrap analyses
were performed by Aixiang Jiang and Yu Shyr.
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To obtain a list of DNA-binding factors associated with p73-bound loci, we used the 
TRANSFAC and JASPAR databases of eukaryotic cis-acting regulatory DNA elements 
that contain a total of ~800 nucleotide distribution matrices (148).  By searching for 
enriched motifs in p73-bound regions, 58 DNA-binding factors were found to have 
significant association with the p73 cistrome.  As shown in Table 4, many of these factors 
are involved in tissue-specific functions such as neuron lineage specification, endocrine 
organ development, hematopoietic development, and muscle development.  Interestingly, 
p73
-/-
 mice suffer from a number of tissue-specific defects such as neuron cell death, loss 
of pheromone sensing, intestinal erosion, and immune cell infiltration (28). 
 Several cofactors show selective interaction with p73-bound loci in rapamycin-
treated or untreated cells (Table 4).  For example, Neuron Restrictive Silencing Factor 
(NRSF) is a transcription factor that binds to and represses neuronal genes in non-
neuronal tissues (16).  The NRSF motif was enriched in p73-bound loci, particularly in 
rapamycin-treated samples (Table 4).  Because a comprehensive list of NRSF-bound 
genes was previously reported (16), we were able to identify genes bound by both p73 
and NRSF.  The overlap between NRSF and p73-bound loci was statistically significant 
when compared to 10,000 random groups of equivalent size (Figure 27A).  Gene 
Ontology and KEGG analyses confirmed that NRSF and p73 co-associated genes are 
involved in neuron-specific processes such as axon guidance and neuropeptide hormone 
activity (Figure 27B).  As more cistromes are identified and made publicly available, 
additional associations can be validated as we have done for NRSF and p73. 
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Table 4:  Tissue-specific factors associated with p73-bound loci
DNA-binding factors with motifs over-represented in the p73 cistrome are organized by tissue-
specific function (binomial test, p<0.0001).  Marked factors have greater than 20% increased 
enrichment in rapamycin-treated samples, or greater than 20% decreased enrichment.
Increase w/ 
rap
Decrease w/ 
rap
CNS/ Neuron lineage
MYCN
NRSF* X
TEAD2
EGR2
HEN1 X
ZIC2 X
Endocrine organ development
PAX4
PAX8 X
GCM2 X
Hematopoietic development
RUNX1
LMO2
BACH2
TAL1 X
MYB
HOXA9 X
Muscle development
MYF
MYOD
PAX3
ELK1
TEAD1 X
ZEB1
* Negative regulator of neurogenesis
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Figure 27: Tissue-specific transcription factors associate with p73-bound genomic
regions. A) The observed overlap between p73-bound genes and NRSF-bound genes
(from Johnson and colleagues, see text) is compared to the overlaps of 10,000 random
groups of equivalent size. None of the bootstrap sampling results has a larger overlap
than the observed data (p < 0.0001). B) Major nervous system processes are enriched
among genes bound by both p73 and NRSF. The number of observed genes in the
dataset is compared to the number of genes expected by chance for neuronal ontologies
with p < 0.05 by hypergeometric test.
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mTOR and p73 regulate the expression of genes, miRNAs, and ncRNAs 
 Microarray analyses were performed to determine which p73-binding sites are 
associated with transcriptional regulation by the mTOR-p73 axis.  Rh30 cells were 
treated with vehicle or rapamycin as above.  In addition, RNAi was used to deplete p73 to 
assess p73-dependence.  Two different RNAi targeting sequences were used to deplete 
p73 in independent samples.  One sequence depletes all p73 isoform mRNAs, and the 
other depletes only TAp73 mRNA.  Knock-down of both TAp73α and TAp73β protein 
using these constructs was confirmed by Western blot in Chapter III. 
 Gene expression patterns using the two p73 RNAi constructs showed a high level 
of correlation (Pearson correlation coefficient r
2
=0.996 in rapamycin-treated samples), 
and were treated as duplicates to calculate fold-change differences in expression.  In 
Chapter III, we identified 12 genes that are transcriptionally activated by p73 when 
mTOR is inhibited.  Consistent with those results, 118 transcripts in our whole-genome 
analysis were increased in a p73-dependent manner during mTOR inhibition.  However, 
we were surprised to find that these genes were only a subset of those regulated by 
mTOR and p73.  Figure 28 depicts these 118 transcripts (indicated as cluster B) 
combined with all genes that changed >50% with rapamycin treatment and/or p73 
depletion.  Clustering analysis reveals that 591 transcripts, which comprise an mTOR-
p73 gene signature, segregated into discrete groups (Figure 28, clusters A-E).  Cluster A 
contains transcripts that decreased after knockdown of p73 regardless of rapamycin 
treatment, including known targets of p73 such as Mdm2 (81).  Intriguingly, however, 
most genes in the signature increased rather than decreased after knockdown of p73, and 
thus were targets of p73-mediated repression (Figure 28, clusters C and D).   
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Figure 28: Genes regulated by mTOR and p73 display distinct patterns of regulation.
Microarray analysis was performed in duplicate to assess gene expression patterns. Rh30 cells
were transduced with lentivirus expressing shRNA targeting p73 (KD) or GFP (C) for 3 d,
cells were treated with vehicle (C) or 40 nM rapamycin (Rap) for 24 h, and total RNA was
harvested and hybridized to whole-genome oligonucleotide arrays. A total of 118 transcripts
had p73-dependent log (expression level) increases > 20% after rapamycin treatment. These
were combined with all transcripts that changed after either rapamycin treatment or p73 RNAi
to create an mTOR-p73 signature of 591 transcripts. Hierarchical clustering reveals distinct
groups of transcripts (A-E). Major gene ontologies (hypergeometric test, p<0.05) and the
percentage of genes present in the ChIP-on-Chip dataset are indicated for each cluster. Cluster
E was too small for additional statistical analysis.
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This may be due to the presence of two isoforms of p73 in Rh30 cells, and is consistent 
with reports that domains exclusive to the TAp73 isoform prevent p73 from interacting 
with transcriptional co-activators (54).  Cluster E contains transcripts regulated by mTOR 
alone, a group too small for additional statistical analysis (Figure 28).  However, gene 
ontologies were used to functionally categorize the genes in the other four clusters 
(hypergeometric test, p<0.05). 
Comparison of these p73-regulated genes to our ChIP-on-Chip database showed 
that 29% of p73-regulated genes were direct targets of p73.  Interestingly, genes that were 
transcriptionally repressed by p73 contain a disproportionate number of genes with 
rapamycin-enhanced p73 occupancy (Figure 29).  Thus, we generated a gene signature of 
the mTOR-p73 axis that has a highly modular architecture, demonstrating that p73 both 
activates and represses gene expression on a large scale.  A comprehensive list of genes 
and ncRNAs directly regulated by p73 is presented in Table 5, and contains both known 
and novel p73 targets. 
 Finally, we addressed one class of transcript that is not covered by whole-genome 
oligonucleotide arrays: short miRNAs.  p73 may regulate genes indirectly through direct 
modulation of miRNAs.  Indeed, analysis of p73 ChIP data revealed p73 binding sites 
within 10 kb of 116 miRNAs (Table 6).  Less is known about the regulatory regions of 
miRNAs than of genes.  However, miRNA promoters were recently mapped across the 
human genome (217).  We found that p73 bound within the promoters of eight of these 
miRNAs (Table 7).  These data suggest that p73 could play an extensive role in 
regulation of gene expression through direct miRNA targets. 
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Figure 29: Analysis of p73-regulated gene clusters. Microarray analysis was
performed in duplicate to assess gene expression patterns in Rh30 cells treated
with p73 RNAi and/ or rapamycin. The percentage of genes in each cluster (from
mTOR-p73 gene signature hierarchical clustering) to which p73 binding level
increases > 50% after rapamycin treatment is plotted. Genes with expression
repressed by p73 (clusters C and D) exhibit more frequent rapamycin-mediated
inductions in p73 occupancy. (For comparison, 8.6% of total p73-bound loci
exhibit increased occupancy after rapamycin treatment.)
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Table 5:  Genes and ncRNAs regulated by p73 and present in ChIP
dataset
Organized by hierarchical cluster from mTOR-p73 microarray analyses
Affymetrix
Transcript 
Cluster ID
Transcript Description or 
Gene Symbol
Affymetrix 
Transcript 
Cluster ID
Transcript Description or 
Gene Symbol
Cluster A Cluster C
7956989 MDM2 7904414 HSD3B1 /// LOC440606 
7918313 MYBPHL /// PSRC1 7904693 FLJ21272
7920128 S100A11 7930559 hCG_1776259
7951593 FLJ45803 7935776 PRO1933
7970150 C13orf28 7957835 NR1H4
7980680 FOXN3 8005446 LOC339240
7997427 CMIP 8018860 EPR1
8042346 FLJ16124 8074780 YPEL1
8050813 DNMT3A 8106516 JMY
8085393 TMEM40 8124057 LOC728380
8093997 SORCS2 8135069 SERPINE1
8121794 SMPDL3A 8154563 ASAH3L
8149953 ncRNA:snoRNA_pseudogene 8157800 mir-181a-2
7900350 ncRNA:tRNA_pseudogene 7924967 ncRNA:snRNA
8085114 ncRNA:misc_RNA 7927773 ncRNA:snRNA
8025996 ncRNA:rRNA
Cluster B 8042466 snoRNA_pseudogene
7935058 FER1L3 8052231 ncRNA:snRNA
7942332 FOLR1 8099717 ncRNA:Mt_tRNA_pseudogene
7945228 FLJ34521
7950235 STARD10 Cluster D
7952375 OR6M1 /// OR6X1 7910022 CNIH3
7957338 SYT1 7915882 KIAA0494
7958377 BTBD11 7916928 ANKRD13C
7960654 ING4 7917649 TGFBR3
7969677 MBNL2 7924207 PTPN14
7973314 OXA1L 7930593 C10orf81
7983630 FGF7 7934979 ANKRD1
8030171 FTL 7943998 NNMT
8036636 SIRT2 7946504 TMEM41B
8077503 CAV3 7956867 HMGA2
8090098 MYLK 7957759 APAF1
8095870 CCNG2 7959251 P2RX7
8099912 C4orf34 7965335 DUSP6
8100464 NMU 7970999 SPG20
8115397 C5orf4 7974870 SNAPC1
8116859 TMEM14C 7975344 SLC39A9
8132055 C7orf41 7984259 RNU5B
8140534 SEMA3C 7988467 FBN1
8146230 CHRNB3 8009243 C17orf60
8148059 DEPDC6 8024019 PTBP1
8149320 LOC157740 8032909 M6PRBP1
8152703 FBXO32 8046340 DYNC1I2
8156573 C9orf3 8047538 BMPR2
8179055 ZNRD1 8052680 RAB1A
8026292 pseudogene 8057797 SDPR
8041642 ncRNA:snRNA_pseudogene 8088979 VGLL3
8124922 ncRNA:misc_RNA 8094460 RBPJ
8147038 ncRNA:scRNA_pseudogene 8101429 PLAC8
8104234 TRIP13
8105585 RNF180
8112202 PLK2
8123744 F13A1
8124144 DEK
8132710 FLJ21075
8135218 LRRC17
8168622 KLHL4
8012854 snoRNA_pseudogene
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Table 6:  miRNAs within 10 kb of p73 binding sites
p73 binding sites were measured by ChIP-on-Chip.  miRNAs whose expression 
levels changed >50% after p73 RNAi are indicated.
miRNA * Positive Negative miRNA * Positive Negative
mir-200b mir-453
mir-200a mir-485 x
mir-429 mir-377 x
mir-9-1 mir-656 x
mir-205 mir-410 x
mir-28 mir-369 x
mir-26a-1 x mir-412
mir-569 mir-409
mir-128b x mir-541
mir-568 mir-370 x
mir-95 mir-376b
mir-887 mir-376a-1 x
mir-583 mir-300
mir-580 mir-381
mir-582 mir-654 x
mir-548a-1 mir-376a-2 x
mir-586 mir-368
mir-206 x mir-495 x
mir-133b x mir-487b x
mir-590 mir-758 x
mir-486_os mir-323 x
mir-151 mir-543 x
mir-320 x mir-494
mir-601 mir-329-2 x
mir-204 mir-329-1 x
mir-24-1 mir-380 x
mir-27b x mir-299
mir-23b mir-411 x
mir-126 mir-379 x
mir-602 mir-625 x
mir-600 mir-190 x
mir-505 mir-549_os
mir-603 mir-193b x
mir-604 mir-365-1
mir-606 mir-484
mir-107 mir-634
mir-146b mir-21
mir-125b-1 mir-744 x
let-7a-2 mir-451
mir-100 mir-144
mir-611 mir-365-2
mir-326 mir-193a x
mir-34b mir-152 x
mir-34c mir-548d-2
mir-619 mir-657 x
mir-620 mir-338 x
mir-200c mir-640
mir-141 mir-7-3 x
mir-616 x mir-638
let-7i x mir-330
mir-623 mir-150
mir-342 mir-645
mir-382 x mir-103-2 x
mir-134 mir-1-1
mir-496 mir-133a-2 x
mir-154 x mir-125b-2
let-7c x
mir-99a
mir-802
mir-648
* organized by polycistron
Regulation by p73 Regulation by p73
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Chrom #
Promoter 
Start
Promoter 
End
miRNA
p73 
binding 
level*
Nearby gene(s)+
5 59100080 59100279 miR-582 3.5 PDE4E
10 91395210 91395409 miR-107 7.6 PANK1
12 61282697 61282896 let-7i 3.7 C12orf61
12 93540063 93541288 miR-492 11.9 TMCC3
16 14309749 14312532 miR-365-1 3.7 LOC10019781
16 15643093 15645825 miR-484 18.9 KIAA0430, NDE1
17 76753312 76755359 miR-338 2.8 NM_207389, KIAA0641
17 76753312 76755359 miR-657 2.8 NM_207389, KIAA0641
Table 7:  miRNA promoters directly bound by p73
* from the ChIP-on-Chip dataset
+ within 10 kb of the miRNA
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 Interrogation of 667 miRNA expression levels after rapamycin treatment and p73 
depletion in Rh30 cells was performed using TaqMan Low-Density Arrays.  p73 knock-
down was performed with two different RNAi constructs.  A total of 142 miRNAs were 
identified whose expression levels changed more than 50% with either p73 knockdown or 
rapamycin treatment.  Unlike the p73-regulated genes in Figure 28, most of these 
miRNAs were transcriptionally activated by p73 (Figure 30A).  In addition, 14 miRNAs 
were regulated by mTOR in a p73-dependent manner (Figure 30B). 
We next mapped the 142 miRNAs that were modulated after p73 knockdown to 
p73-bound loci to identify direct miRNA targets.  A total of 41 p73-regulated miRNAs 
were in the vicinity of p73 binding sites, and thus are likely directly regulated by p73, 
though in some cases this is due to the regulation of large polycistrons of miRNAs by p73 
(Table 6).  Of those miRNAs whose promoters were bound by p73 in Table 7, four were 
not expressed at detectable levels in Rh30 cells (miR-582, miR-107, miR-492, and miR-
356-1), three were positively regulated by p73 (let-7i, miR-484 and miR-338), and one 
was negatively regulated by p73 (miR-657).  Interestingly, both miR-338 and let-7i are 
associated with tumorigenesis, and let-7i regulates tumor cell chemosensitivity (218,219) 
in a manner reminiscent of p73 (220).  As more regulatory regions of miRNAs are 
identified, additional annotation of p73 binding sites can be performed.  These are the 
first miRNA targets of p73 to be identified. 
 
p73-regulated genes classify rhabdomyosarcoma subtypes and are associated with 
differentiation of mesenchymal stem cells 
 
 Our genomic analyses gave us an unprecedented opportunity to explore p73 
function using the mTOR-p73 gene signature. 
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Figure 30: p73 regulates miRNA expression. A) Hierarchical clustering was used to
segregate 142 miRNAs whose expression levels were regulated by mTOR or p73 into
discrete groups. Mature miRNA levels were measured using TaqMan assays in Rh30 cells
treated with p73 RNAi and/ or rapamycin, and the ∆∆CT method was used to calculate
expression relative to control samples. B) A total of 14 miRNAs whose expression levels
increase after rapamycin treatment in a p73-dependent manner are shown. Those miRNAs
that are located within 10 kb of a p73 binding site are highlighted in orange text.
A B
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We were particularly intrigued by pathways enriched in p73-bound loci that are 
associated with muscle function and development (Table 8).  p53, p63, and p73 play at 
least partially redundant roles in myogenic differentiation and rhabdomyosarcoma 
formation (159).  Alteration of the p53 pathway, for example through a dominant-
negative isoform of p73, can block skeletal muscle differentiation and promote 
transformation in vitro (159,221).  The mTOR pathway, perhaps by acting upstream of 
p73, is a marker of rhabdomyosarcoma outcome (222). 
 We hypothesized that p73 leaves recognizable 'patterns' of gene expression in 
tissues in which it is active, allowing us to use our newly derived mTOR-p73 gene 
signature as a measure of p73 activity in rhabdomyosarcoma tumors.   Wachtel and 
colleagues analyzed the gene expression patterns of 29 primary rhabdomyosarcomas 
(149).  We filtered these data against the mTOR-p73 signature, and used hierarchical 
clustering to segregate tumors according to the status of the mTOR-p73 signature (Figure 
31).  The rhabdomyosarcoma patients segregated into two distinct clusters that were 
equivalent to the major rhabdomyosarcoma subtypes: alveolar and embryonal. 
 These two subtypes of rhabdomyosarcoma are associated with different outcomes, 
molecular alterations, age groups, and histologic appearances (223,224).  While alveolar 
tumors (ARMS) are more common in older children and exhibit small round cells with 
primitive myoblast differentiation, embryonal rhabdomyosarcoma (ERMS) typically 
presents at an earlier age and is histopathologically analogous to embryonic skeletal 
muscle (223,224).  We found that genes positively regulated by p73 (clusters A and B, 
Figure 28) were increased in ARMS (Figure 31).  Conversely, genes transcriptionally 
repressed by p73 (clusters C and D, Figure 28) were decreased in ARMS (Figure 31).   
119 
 
Table 8:  Muscle-related Biocarta pathways enriched among p73-bound genes
(p < 0.05+)
Enrichment 
Ratio*
Skeletal muscle hypertrophy is regulated via AKT/mTOR pathway 2.1
CUTL1
IGF1
IGF1R
PPP2R4
RPS6KB1
EIF2B4
Control of skeletal myogenesis by HDAC & calcium/calmodulin-dependent kinase (CaMK) 2.4
HDAC5
CABIN1
IGF1
IGF1R
INSR
PPP3CA
Actions of nitric oxide in the heart 2.6
CRAT
PDE3B
ACTA1
BDKRB2
TNNI2
CAV1
NFAT and hypertrophy of the heart (transcription in the broken heart) 2.0
CSNK1A1
HBEGF
GATA4
IGF1
LIF
PPP3CA
MAP2K1
ACTA1
RPS6KB1
CAMK4
Role of EGF receptor transactivation by GPCRs in cardiac hypertrophy 3.3
EGF
EGFR
FOS
RHOA
NFKB1
PRKCA
ADAM12
ALK in cardiac myocytes 2.7
GATA4
SMAD1
SMAD5
NPPB
BMP5
BMP7
BMPR2
TGFBR1
TGFBR2
TGFBR3
AXIN1
ACVR1
+ calculated by hypergeometric test
*  # observed genes in category / # genes expected by chance
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Figure 31: p73-regulated genes are differentially expressed in rhabdomyosarcoma subtypes.
The mTOR-p73 gene signature was assessed using a publicly available dataset from Wachtel and
colleagues (see text) in which 29 rhabdomyosarcoma tumors were profiled by microarray. A) All
genes that changed >20% with rapamycin or p73 RNAi were included in this initial analysis to
increase overlap across microarray platforms. Hierarchical clustering demonstrates that the mTOR-
p73 gene signature segregates tumors into two classes, corresponding to the clinical alveolar and
embryonal subtypes. B) Genes positively regulated > 50% by p73 and genes negatively regulated >
50% by p73 were analyzed in ARMS and ERMS subtypes. Box plots demonstrate opposing gene
expression trends in these two tumor subtypes.
A
B
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A similar effect was observed in an independent cohort containing 139 
rhabdomyosarcoma patients, previously reported by Davicioni and colleagues (150) 
(Figure 32).  As a control, we examined the ability of all genes (unfiltered) to segregate 
rhabdomyosarcomas and found that ARMS and ERMS were not segregated in either 
cohort as they were by p73-regulated genes.  These data suggest that p73 is actively 
engaged in transcriptional regulation in the alveolar subtype that is associated with a 
worse prognosis. 
 Clinical outcome data was available for 134 rhabdomyosarcoma patients in the 
Davicioni et al. cohort (150).  In this cohort we could identify genes in the p73 signature 
that correlated with 5-year survival after treatment for ARMS (Figure 33), but not ERMS 
(data not shown).  Several of these p73 target genes were also associated with clinical 
outcome in an independent cohort of rhabdomyosarcomas deposited in the Oncomine 
database by De Pitta and colleagues (152).  The four most significant genes, genes 
involved in muscle function, are plotted by survival outcome in Figure 34.  These data 
strongly suggest a role for p73-regulated genes in ARMS disease progression. 
 We performed additional survival analyses by using the tumor expression levels 
of 17 direct p73 target genes, selected by t-test and shown in Figure 33 (orange text), to 
create a compound score model (described in Chapter II) that could segregate 
rhabdomyosarcoma patients into subgroups.   
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Figure 32: Differential expression of the p73 signature in an independent cohort of alveolar and
embryonal rhabdomyosarcomas. The mTOR-p73 gene signature was assessed using a second
publicly available data set, from Davicioni and colleagues (see text), in which 139
rhabdomyosarcoma tumors were profiled by microarray. A) Hierarchical clustering demonstrates
that the mTOR-p73 gene signature segregates tumors into two classes, corresponding to the clinical
alveolar and embryonal subtypes. (Botryoid and spindle tumors are subtypes of embryonal tumors.)
Those p73-regulated genes that were most significantly associated with ARMS are shown. These 23
genes exhibit significant differential expression in the two subtypes (multiple testing-corrected p-
value < 0.001, Fold Change > 2). Direct p73 target genes are highlighted in orange text. B) Genes
positively regulated > 50% by p73 and genes negatively regulated > 50% by p73 were analyzed in
ARMS and ERMS subtypes, demonstrating opposing gene expression patterns in these two tumor
subtypes.
A
B
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Figure 33: p73-regulated genes associated with clinical outcome in alveolar
rhabdomyosarcoma patients. Alveolar rhabdomyosarcoma microarray data from Davicioni and
colleagues were annotated by 5-year survival outcome (see text). In this cohort we could identify
genes in our p73 signature that correlated with 5-year survival after treatment for ARMS. The
probes in the p73 signature that exhibited the most significant association with clinical outcome (by
Benjamini-Hochberg false discovery rate t-test) are shown by gene. Hierarchical clustering was
performed with these probes, leading to partial segregation of tumors from alive and deceased
outcomes. Genes present in the p73 ChIP-on-Chip dataset are indicated in orange text.
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Figure 34: p73-regulated genes associated with clinical outcome.
Additional data for a limited number of genes in our signature were available
in the Oncomine database, using a third independent rhabdomyosarcoma
cohort deposited by De and colleagues (see text). Two direct targets of p73,
CSRP1 and TNNI2, and two indirect targets of p73, C11ORF67 and FN1,
were the most significant p73-regulated genes associated with clinical
outcome from those in both the Davicioni and De cohorts. Box plots for the
four indicated genes demonstrate association with clinical outcome (p < 0.05)
in the latter cohort. These plots were derived using the Oncomine data-
mining tool.
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Alveolar tumors with a low compound score for p73 target genes were associated with a 
5-year survival rate of ~85%, whereas tumors with a high compound score were 
associated with a 5-year survival rate of ~20% (Figure 35).  In contrast, there was no 
significant difference in survival from ERMS based on these genes.  Thus, genes in the 
p73 signature influence clinical outcome, suggesting that the mTOR-p73 axis plays a role 
in ARMS pathogenesis. 
 We hypothesized that this role could be related to functions of p73 during 
myogenic differentiation (159).  Supporting this hypothesis, genes in the p73 signature 
were differentially expressed in undifferentiated rhabdomyosarcoma tumors compared to 
other subtypes (Figure 36).  We sought additional, more global data supporting a role for 
p73 as a major regulator of cellular differentiation.  We took advantage of a recent 
observation that developmental genes are marked by two histone modifications 
(H3K4me3 and H3K27me3 – a bivalent mark) in embryonic stem cells (20).  These 
findings were extended when histone methylations were mapped across the entire human 
genome (225,226).  Genes generally fall into three categories: those that are modified by 
H3K4me3 and play a role in proliferation, metabolism, or housekeeping, those that are 
bivalently marked and are developmental, and those that are not marked at all and are 
lineage-specific (225,226).  We hypothesized that if genes can be generally classified in 
this fashion, then transcription factors might be generally classified based on the genes 
that they regulate.  Indeed, we found that both p73-bound genes and genes regulated by 
p73 at the expression level were highly associated with the bivalent category, as indicated 
by p-value in Table 9.  These data supported the hypothesis that p73 plays a role in 
development through the transcriptional programs that it regulates.  
126 
 
S
u
rv
iv
a
l 
P
ro
b
a
b
il
it
y
Survival Time (years)
1.0
0.8
0.6
0.4
0.2
0
0 2 4 6 8 10 12
Group 1 (low score
for gene signature)
p = 4.8e-05 
C index = 0.7
Group 2 (high score
for gene signature)
Patients with Alveolar
Rhabdomyosarcoma (n=64)
Figure 35: A 17-gene p73 signature segregates patients by
clinical outcome. The expression levels of 17 direct p73 target
genes were used to segregate an independent cohort of 64
ARMS patients into two groups, using Cox proportional hazards
modeling and Kaplan-Meier analysis. This 17-gene p73
signature segregates patients with alveolar but not embryonal
tumors by clinical survival time (see Chapter II for additional
methodology). Statistical analysis was performed by Aixiang
Jiang and Yu Shyr.
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Figure 36: p73-regulated genes associated with undifferentiated
rhabdomyosarcoma tumors. A total of 139 rhabdomyosarcoma tumors
profiled by microarray by Davicioni and colleagues, were grouped by
histology. The p73 signature was assessed for average expression level in
each of these tumor subtypes (alveolar, mixed alveolar & embryonal, botryoid,
spindle, embryonal, and undifferentiated). From among mTOR and p73-
regulated probes, 239 probes were identified that exhibit a fold change > 5 in
undifferentiated versus other tumor subtypes and used for hierarchical
clustering.
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Table 9 : Gene categories defined by epigenetic m arks
H3 K4 me3 only Bivalent No Marks
gene # 7539 1295 3505
All ChI P-on-Chip Genes* p = 8.9 x 10
-10
p = 1.7 x 10
-10
p = 0.01
gene # 1969 317 548
All p7 3 -regulated genes* p = 1.0 p = 1.3 x 10
-9
p = 7.0 x 10
-10
gene # 110 21 59
Cluster A* p = 0.99 p = 0.080 p = 0.029
Cluster B p = 0.029 p = 0.58 p = 0.40
Cluster C p = 1.0 p = 0.83 p = 0.95
Cluster D* p = 8.1 x 10
-8
p = 0.19 p = 0.29
* significant associations are highlighted
(hypergeometric test)
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 We explored this concept further with a focus on differentiation associated with 
ARMS.  Studies of molecular translocations in ARMS provide growing evidence that 
mesenchymal stem cells (MSCs) are the cell of origin for this tumor subtype (223).  This 
is in contrast to ERMS, where committed muscle progenitor cells are thought to be the 
cell of origin (223).  Thus, we decided to analyze the fate of p73-regulated genes during 
MSC differentiation.  MSCs can be induced to differentiate along the myogenic lineage 
by treating them with 5-azacytidine (5AZA) (227,228).  We identified a group of p73 
target genes, both direct and indirect, whose expression levels changed during MSC 
differentiation (corrected p-value < .05, Figure 37A).  Interestingly, the expression of 
many direct p73 target genes changed more than 50% during myogenic differentiation, or 
during myofibroblast-like differentiation induced by tumor conditioned medium (TCM) 
(227) (Figure 37B).  This suggests that a conserved set of genes are altered during 
mesenchymal differentiation programs. 
To gain greater insight into the roles such transcriptional programs might play 
during rhabdomyosarcoma tumorigenesis, we sought a minimal set of p73 target genes 
that correlate with both differentiation status and rhabdomyosarcoma subtype.    We 
identified nine direct p73 target genes from among those regulated by 5AZA in Figure 37 
that are sufficient to segregate alveolar and embryonal rhabdomyosarcoma subtypes 
(Figure 38A).  A Support Vector Machine model derived from these nine genes was able 
to predict alveolar subtype in a cohort of rhabdomyosarcoma tumors with an accuracy of 
~82%.  These nine genes include potential tumor suppressors (FBLN1, DUSP6, KLF6, 
and CCNG2) and genes with documented expression in mesenchymal tumors (OXTR, 
FAM129A, NMI, and HMGA2) (229-236).   
130 
 
131 
 
CA
B
Figure 38: Conserved patterns of p73 target genes in mesenchymal processes. A) A core set of
nine direct p73 target genes from those regulated by 5AZA was sufficient to segregate ARMS and
ERMS by hierarchical clustering. These nine genes were identified from among those regulated
during MSC differentiation. B) Ingenuity software was used to identify literature-based
connections between the nine genes. In the Ingenuity network, these genes are colored by
expression level in TGF-treated MSCs relative to control. C) Fold changes are indicated in three
bar charts for: 5AZA-treated MSCs relative to control (left panel), ARMS relative to ERMS
(middle panel), and TGF-treated MSCs relative to control (right panel). TGFβ microarray data
was obtained from Sachetti and colleagues (see text).
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Interestingly, an Ingenuity network connects all nine p73 target genes to the transforming 
growth factor  (TGF) signaling pathway, with at most one degree of separation 
between TGF and each gene (Figure 38B). 
We analyzed these nine genes further by comparing fold changes in expression 
after MSC differentiation, and in alveolar versus embryonal tumors (Figure 38C).  We 
also examined the expression levels of these genes after treatment of MSCs with TGF, a 
known inhibitor of MSC proliferation and differentiation (237,238) (Figure 38C).  
Patterns of gene expression during these three mesenchymal processes suggest a common 
mechanism of regulation. 
Interestingly, many genes indirectly regulated by p73 were also associated with 
mesenchymal differentiation (120 genes, Figure 37A).  p73 might regulate the expression 
of these genes through direct regulation of miRNAs.  Three miRNAs with established 
roles in myogenic differentiation, miR-133b, miR-133a-2, and miR-1-1 (239), mapped to 
p73-bound loci.  These three miRNAs are upregulated in certain human sarcomas 
including ARMS (240).  miR-133b was the closest of the three to a p73 binding site (~5 
kb upstream of miR-133b transcriptional start site).  We used real-time PCR and three 
different p73 RNAi constructs to confirm that p73 regulates miR-133b expression levels 
in Rh30 cells (Figure 39).  Taken together, these data strongly suggest that p73 regulates 
transcriptional programs common to both MSC differentiation and rhabdomyosarcoma 
tumorigenesis. 
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Discussion 
 Herein we demonstrate that, like p53 and p63, p73 exhibits complex patterns of 
binding and activity across the genome.  In addition, we show that mTOR modulates p73 
occupancy in a selective, locus-specific manner.  While p73 has affinity for a particular 
20 bp DNA motif, this only loosely defines the boundaries of the p73 cistrome.  
Numerous cofactors associate with p73-bound loci, and likely serve as additional 
determinants of transcriptional specificity.  These interactions provide the potential for 
exquisite control of p73 binding, and are both regulated by mTOR, and restricted to 
specific tissues and cell lineages.  The end product of this intricate regulation is the 
expression of genes and ncRNAs, for which we demonstrate functional significance 
through analysis of MSC differentiation and rhabdomyosarcoma tumorigenesis. 
 
Generation of a p73 genomic binding profile 
 Unlike previous studies of p73 binding, we used ChIP-on-Chip to obtain a 
comprehensive view of p73 occupancy (144,155).  The advantages of this technique 
include reproducibility, and avoidance of potential biases in some sequencing-based 
technologies (14).  In addition, previous analyses of p73-bound loci relied on ectopic p73 
expression (144,155), and over-expressed transcription factors can bind inappropriately 
to DNA, titrate inhibitors, and inappropriately alter cellular signaling pathways.  Here, we 
focused on endogenous p73, using the following methods to ensure specificity: 1) use of 
an antibody that recognizes only 'active' isoforms of p73, 2) validation with two 
additional p73 antibodies, 3) analysis of a cell line with robust p73 binding, and 4) 
perturbation with a stressor that engages the p73 signaling pathway. 
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p73 regulates genes and miRNAs associated with mesenchymal phenotypes 
 We coupled our ChIP data to microarray analyses, in essence mapping regions of 
transcriptional activity to p73-bound loci.  We hypothesized that p73 leaves recognizable 
'patterns' of gene expression in tissues in which it is active.  p73 is frequently over-
expressed in human cancers (54); however, in some tumor types p73 is over-expressed 
concomitantly with a protein inhibitor that prevents it from functioning (37).  The ability 
to detect a p73 signature is thus critical for measuring p73 activity in tumors in which it is 
expressed. 
Based on this concept, we determined that p73 is functional in ARMS, using two 
independent cohorts of patients.  This disease is characterized by cells that have both 
engaged a myogenic program and experienced a differentiation block (223,224).  We 
analyzed gene expression patterns in MSCs, the likely cell of origin of ARMS.  p73 
directly regulates a set of nine target genes that are involved in both MSC differentiation 
and rhabdomyosarcoma tumorigenesis, suggesting a common role in both processes. 
 The p73 cistrome can be used to expand on previous studies of p53 family 
members in myogenic differentiation.  For example, in one study an inhibitory isoform of 
p73 was over-expressed in a mouse myogenic cell line undergoing differentiation (159).  
By microarray, this p73 isoform modulated the expression of a large number of genes; 
however, due to lack of information on the p73 cistrome the authors were unable to 
identify which of these genes were direct targets (159).  By mapping the mouse genes in 
this microarray study to human orthologs, and comparing them to the p73 cistrome, we 
were able to identify 76 target genes that are directly regulated by p73 in this system. 
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 In addition to genes, several miRNAs involved in mesenchymal differentiation 
and tumorigenesis are present in the p73 cistrome (e.g. miR-1-1, miR-133a-2, and miR-
133b), suggesting extensive regulation of the mesenchymal transcriptome by p73.  Work 
from our laboratory has shown that p63 is not only a master regulator of epithelial 
phenotype, but also inhibits genes that are normally expressed in mesenchymal tissues 
(131,241).  Our data suggest that this may occur through inhibition of p73 in mammalian 
cells.  Consistent with a role for p73 in regulating mesenchymal phenotype, we identified 
a number of genes in the p73 cistrome associated with epithelial-to-mesenchymal 
transition (Figure 40) (242).  Thus, p73 may regulate mesenchymal programs both in 
human sarcomas and in epithelial tumors that have transitioned to an invasive state. 
 
Clinical utility of p73 transcriptional programs  
 p73 can be engaged to activate p53 apoptotic pathways in tumor cells that have 
mutated p53 (161), thus there has been substantial interest both in drugs that target p73, 
and in potential prognostic markers of p73 activity (128).  We have shown that mTOR 
inhibition induces p73 and selectively alters the p73 cistrome.  Even more striking, the 
majority of transcriptional changes that followed rapamycin treatment were dependent on 
p73.  mTOR inhibitors are currently in clinical trials for a number of human cancers, and 
it will be interesting to see if these drugs activate p73, or synergize with other drugs that 
can activate p73. 
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 We have developed an mTOR-p73 gene signature, demonstrated that p73 is active 
in certain human sarcomas, and importantly, shown that p73 target genes influence 
clinical outcome.  Because p73 is not mutated in tumors, key to a p73-based treatment 
approach will be the ability to predict response based on the isoforms of p73 that are 
present, the modifying proteins that are inhibiting its activity, and the other p53 family 
members that are interacting with it in any given tumor.  The complexity of p73 in 
cancers makes it particularly amenable to using gene signatures as biomarkers of its 
activity.  Such signatures might find utility in the molecular profiling of sarcomas and 
other tumor types for therapeutic decision-making. 
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CHAPTER V 
 
METABOLIC FUNCTIONS OF P73 
 
Introduction 
One function of mTOR is to regulate the bulk degradation system, autophagy, 
which occurs through the concerted, step-wise efforts of a number of proteins that are 
conserved from yeast to man.  First, an isolation membrane forms to engulf cytoplasmic 
material and organelles into a phagophore.  This process is often initiated through 
inhibition of mTOR.  This inhibition results in dephosphorylation of the regulatory 
subunit Atg13, allowing Atg13 to associate with the kinase Atg1/ULK1 and stimulate its 
kinase activity, leading to initiation of phagophore nucleation (243).  One of the first 
steps in vesicle nucleation involves phosphorylation and activation of the class III 
phosphatidylinositol 3-kinase Vps34.  Vps34 activation depends on a multiprotein 
complex including Beclin-1 and its cofactors such as UVRAG and Bif1 (243). 
Elongation of the phagophore results in complete engulfment of the cytoplasmic 
materials into a double-membraned vesicle called the autophagosome.  This is 
accomplished by a ubiquitin-like conjugation system.  Although the enzymes in this 
system resemble E1, E2, and E3 ubiquitin ligases, they typically only have one or a 
limited number of substrates in the autophagy pathway.  First, ubiquitin-like Atg12 is 
covalently conjugated to Atg5 through the activities of the E1-like enzyme Atg7 and the 
E2-like enzyme Atg10.  In parallel, phosphatidylethanolamine is conjugated to ubiquitin-
like LC3/Atg8 after protealytic cleavage of LC3 by Atg4, through the activities of the E1-
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like Atg7, the E2-like Atg3, and the Atg12-Atg5-Atg16 complex which has E3-like 
activity (244,245). 
Of note, there are additional mammalian homologs of LC3 such as GATE-16 and 
GABARAP that may be associated with autophagosome membranes in specific contexts.  
For example, GABARAP-phospholipid conjugates are activated during myoblast 
differentiation (246).  Lipidated LC3 is inserted into the developing autophagosome 
membrane, and can be used as a marker to detect autophagy, because the lipid moiety 
causes faster electrophoretic mobility on a gel and exhibits a distinctive puncate 
distribution in cells undergoing autophagy.  The final stage of autophagy is fusion of the 
autophagosome with a lysosome to form an autophagolysosome, in which the engulfed 
components as well as the inner membrane are degraded. 
The above cascades allow rapid regulation of autophagy at the protein level.  
However, gene expression changes are also associated with autophagy (144,247,248).  
The mechanisms by which transcription is regulated during and to induce autophagy are 
largely unknown, thus there is interest in identifying transcription factors associated with 
autophagic processes. 
Discoveries linking p53 to autophagy, and to core metabolic pathways, marked a 
shift in our understanding of p53 as a tumor suppressor.  p63 and p73 likely coordinate 
with p53 during select cellular responses to environmental and developmental cues (37).  
All three p53 family members are subject to a variety of post-translations modifications 
and can exist as multiple protein isoforms, so there is the potential for substantial 
complexity in the p53 family transcriptional response (37,54,98).  Indeed, each family 
member can regulate thousands of target genes (13,82,86). 
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In Chapter III genome-wide technologies were used to identify a p73 gene 
signature.  This signature was compared to pathway-associated gene signatures in the 
Broad Institute Connectivity Map (143,144).  Using this approach, mTOR was identified 
and validated as a negative regulator of p73 (144).  Further analysis of subcomponents of 
the p73 gene signature revealed autophagy-associated genes that were regulated by 
mTOR in a p73-dependent manner (144).  In addition, a reported link between p73 and 
autophagy was confirmed, and a transactivation-competent isoform of p73 was identified 
as a positive regulator of autophagy (144,185). 
These data suggest that there are both similarities and differences between p53 
and p73 in relation to mTOR.  While our data showed that mTOR negatively regulates 
p73, in multiple contexts mTOR is a positive regulator of p53 (119,126).  Consistent with 
these observations, we observed a simultaneous increase in p73 and decrease in p53 and 
p63 protein levels in primary human mammary epithelial cells treated with rapamycin 
(144).  Of note, at least in some basal cell types, p63 is expressed as an isoform that can 
inhibit p73 (37,57).  Thus, a coordinate upregulation of p73 and downregulation of p63 
may be needed to fully activate p73 in response to metabolic stress.  Given the critical 
role of mTOR as a regulator of autophagy, we hypothesized that analysis of the mTOR-
p73 gene signature generated in Chapter IV would identify additional target genes 
involved in both autophagy and cellular metabolism. 
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Results 
 
mTOR regulates autophagy-associated genes downstream of p73 
We first explored potential mechanisms by which p53 family members engage 
metabolic stress responses such as autophagy.  p53 itself plays opposing roles (125,126).  
Cytoplasmic p53 inhibits autophagy in multiple cell types and organisms (126).  Nuclear 
p53 activates autophagy by upregulating genes such as DRAM (125).  The cytoplasmic 
function of p53 is a basal activity of p53, while the nuclear function of p53 seems to 
require activating signals such as genotoxic stress (125,126).  In addition, p53 can act 
upstream of mTOR, inhibiting mTOR by activating AMPK (96,116), and this may alter 
cellular autophagy levels as well. 
Like p53, transactivation-competent p73 isoforms can activate autophagy, 
presumably through nuclear activity (185).  However, the upstream signals that regulate 
p73 to do so, and the target genes that mediate autophagy downstream of p73 have been 
largely unknown.  Unlike p53, p73 induces autophagy in a DRAM-independent manner 
(185).  In addition, it is unknown whether p73 translocates to the cytoplasm to regulate 
autophagy as p53 does. 
 To explore the nuclear function of p73 further, we focused on p73-regulated 
genes that we had identified in the Rh30 cell line.  ChIP-on-Chip experiments 
demonstrated that p73 bound to genomic sites near genes associated with autophagy or 
with lysosomal function (Figure 41A).  Both of the p73 isoforms expressed in Rh30 cells 
bound to sites near autophagy-associated genes such as ATG5 and ATG7, and in some 
cases binding level was enhanced after treatment with rapamycin (Figure 41B).   
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Figure 41: Analysis of autophagy-associated, p73-regulated genes. A) ChIP-on-
Chip was performed in Rh30 cells, and p73 binding was detected within 10 kb of the
indicated autophagy-associated and lysosome-associated genes. B) ChIP-qPCR was
used to measure p73 binding at a negative control region, or at sites within 10 kb of the
ATG5 and ATG7 genes, using antibodies specific for either the α or β isoform of p73.
Cells were pre-treated +/- 40 nM rapamycin (Rap) in serum-free medium for 24 h before
formaldehyde cross-linking and isolation of protein-DNA complexes. C) Microarray
analysis of duplicate samples was used to assess UVRAG RNA levels in Rh30 cells
treated with vehicle or 40 nM rapamycin (Rap) for 24 h and/or lentivirus expressing p73
sh RNA. D) Location of a p73-bound p53 response element in relation to the UVRAG
transcriptional start site.
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Thus, p73 regulates a network of genes, and the cumulative effect of this network may be 
to enhance and/or fine-tune the autophagic response. 
These data suggest a role for p73 that is similar to that of nuclear p53, to activate 
target genes that regulate autophagy.  However, the role of p73 may not be entirely 
straightforward.  In the case of at least one autophagy-associated gene (UVRAG), 
microarray analysis revealed that p73 knock-down increased UVRAG expression levels 
(Figure 41C).  In addition, ChIP showed that p73 bound to a region upstream of the 
UVRAG transcriptional start site that contains a p53 family response element (Figure 
41D).  p73 may directly suppress UVRAG expression, perhaps through recruitment of 
transcriptional repressors such as histone deacetylases.  In this case, p73 would be 
expected in inhibit autophagosome nucleation and maturation (249,250).  Our recent 
studies have revealed an entire network of autophagy-associated genes that are regulated 
by p73, and suggests multiple mechanisms by which this pattern of genes may alter the 
autophagic process. 
 
p73 influences metabolic phenotypes 
 The above results suggest that p73 regulates metabolic processes such as 
autophagy in response to cellular stress.  We tested this hypothesis in cell culture, and 
treated Rh30 and MDA-MB-231 cells with 40 nM rapamycin, resulting in an increase in 
lipidated LC3 as detected by Western blot.  This was the expected result for Rh30 cells 
that are highly sensitive to rapamycin (182); however, MDA-MB-231 cells are relatively 
insensitive to the effect of rapamycin on cell proliferation (177).  Our experiments in 
Chapter III demonstrated that mTOR signaling is intact in MDA-MB-231 cells from the 
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mTOR kinase to downstream targets such as 4EBP1 and S6K and secondary targets such 
as S6.  In Chapter III, rapamycin inibited the growth of these cells but failed to cause 
complete cell cycle arrest.  However, mTOR signaling seemed to be intact and we 
observed an increase in autophagy in response to rapamycin, which suggested that the 
intrinsic resistance to cell cycle arrest may be mediated by a different downstream 
signaling pathway. 
 We next treated cells with rapamcyin after RNAi-mediated depletion of p73.  In 
Rh30 cells we observed only a slight decrease in the levels of rapamycin-induced 
autophagy in cells after p73 knockdown (data not shown).  These data suggest that p73 
signaling may be only one of many pathways through which mTOR regulates autophagy.  
This is consistent with the observation that mTOR inhibition causes both transcriptional 
and translational changes that induce autophagy (110,125). 
 We further hypothesized that p73 plays a role in the ability of cells to adapt and 
respond to metabolic stresses in general.  To test this hypothesis, we measured the growth 
of Rh30 cells incubated in serum-free media.  There was a decrease in the total number of 
viable cells after three days of incubation in serum-free media (Figure 42), likely due to 
cell death from metabolic stress arising from lack of nutrients and growth factors that are 
present in serum.   However, concurrent RNAi-mediated depletion of p73 abrogated this 
effect (Figure 42).  These data suggest that p73 is required for tumor cell death that 
occurs as a slow response to metabolic stress. 
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Figure 42: p73 mediates a cellular response to serum starvation.
Rh30 cells were grown in medium with 10% fetal bovine serum or
serum-free medium, in the presence of lentivirus that expresses shRNA
targeting GFP or p73. The change in total cell number per day after 3 d
growth in these conditions was plotted for each condition, demonstrating
a p73-dependent decrease in cell number, likely due to cell death from
metabolic stress during serum starvation.
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- - +            +      sh p73
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Metabolic networks in the p73 cistrome 
 We used Ingenuity Pathway Analysis to explore additional networks among the 
p73 target genes identified in Rh30 cells.  As described in Chapter IV, Ingenuity Analysis 
uses literature-based curations to connect genes into functional pathways.  Three key 
pathways, linked to metabolic processes, emerged from our analysis.  The first pathway 
was related to lipid metabolism (Figure 43A), and included five triacylglycerol lipases 
(DAGLI, PNPLA3, CEL, LIPC (helpatic lipase), and LIPG (endothelial lipase)).  These 
lipases were connected to lipid transport mechanisms; the LDL receptor is one of the 
genes that exhibited the greatest p73 occupancy (~20-fold enrichment over input by 
ChIP-on-Chip).  This network also consisted of enzymes that regulate the metabolism of 
fatty acids (Figure 43A). 
 The other two Ingenuity pathways are related to glucose metabolism (Figures 43B 
and C).  Several phosphatidylinositol kinases and genes related to insulin and the insulin 
receptor were bound by p73 (Figure 43B).  Other p73 target genes regulate glycolysis 
levels and are specific to muscle cells (Figure 43C).  These pathways highlight the 
potential importance of p73 not only for cellular metabolic processes such as autophagy, 
but also for metabolism on a whole-organism level.  This role would be best elucidated 
through in vivo analysis of p73 in adult tissues (see Chapter VII). 
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Discussion 
 Our observations that mTOR negatively regulates p73, and that p73 regulates 
many genes associated with autophagy, suggest both similarities and differences in the 
ways that p53 family members respond to metabolic stress and regulate autophagy.  The 
role of autophagy in the different in vivo functions of the p53 family remains to be 
determined.  p53 is one of the most frequently mutated genes in human cancer.  Whether 
p63 and p73 are also tumor suppressors has long been controversial, although a recent 
isoform-specific p73 mouse model suggests that it is indeed a bona fide tumor suppressor 
(65).  Thus, p53 family members may regulate autophagy to maintain genome integrity or 
suppress necrosis and inflammation that promotes tumorigenesis.  
 In addition, p63 and p73 play critical roles during development (37).  p63 plays an 
essential role in the development of the epidermis and mammary gland (27).  Loss of p73 
leads to hippocampal dysgenesis, gastrointestinal erosion, hemorrhage, and an increased 
propensity for neurodegenerative disease in mice (28,251), phenotypes that are associated 
with dysregulation of autophagic pathways (252-254).  Interestingly, we have identified 
p73 target genes such as GABARAP, an LC3 homolog expressed in neurons and muscle 
cells, that are important for tissue- and context-specific regulation of autophagy (246).  
Further, all three p53 family members have been associated with aging or aging-related 
pathology (251,255,256).  In fact, the effect of the p53 orthologue CEP-1 on the life-span 
of C. elegans is mediated by autophagy (257).  Thus, the discovery that p53 family 
members regulate autophagy may have implications for a wide range of human diseases. 
 Our results also provide another link between metabolic stress and tumor 
suppression.  It has been suggested that p53 is required for induction of a metabolic 
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checkpoint in response to glucose deprivation (96).  Low energy levels activate AMPK, 
but p53 can also activate AMPK by increasing the expression of sestrins that bind to 
AMPK and promote its phosphorylation (96).  Cells that have undergone p53-mediated 
cell cycle arrest can still maintain high levels of metabolic processes.  By inhibiting 
mTOR, p53 decreases the energy requirements of cells that have arrested (96,258).  
Interestingly, in Chapter III we identified sestrins as target genes of p73.  Could p73, like 
p53, play roles both downstream and upstream of mTOR?  Our data show that both p53 
and p73 regulate cellular responses to metabolic stress, and raise many intriguing 
questions about the mechanisms by which they do so. 
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CHAPTER VI 
 
MTOR-RELATED KINASES DIFFERENTIALLY PHOSPHORYLATE P53 
FAMILY MEMBERS 
 
Introduction 
 The p53 family of transcription factors contains three members, p53, p63, and 
p73, that share significant homology and evolved from a common ancestral gene.  Yet the 
divergent expression patterns of these family members, both during development and in 
human tumors, are suggestive of key differences in their upstream regulators.   p53 and 
its family members play critical roles by checking inappropriate cell growth in response 
to a wide range of stresses such as hypoxia, DNA damage, viral infection, loss of contact 
inhibition, glucose deprivation and activated oncogenes (100,259,260).  Many of these 
cellular stresses also regulate mammalian target of rapamycin (mTOR), a 
serine/threonine kinase that is a master modulator of cellular growth.  The mTOR 
pathway can be thought of as kinase-centric.  mTOR integrates multiple signals that feed 
into it through upstream kinases such as Akt (responsive to growth factors) and AMP-
activated protein kinase (AMPK, responsive to energy levels) (261).  Output is achieved 
in part through kinases such as p70S6K, which is phosphorylated by mTOR to regulate 
protein synthesis (262), and glycogen synthase kinase 3-β (GSK3β), which is inhibited by 
both Akt and p70S6K to regulate energy metabolism (263). 
 The p53 family and the mTOR pathway are connected through many signaling 
nodes (98,110).  p53 inhibits mTOR in response to genotoxic stress through target genes 
(sestrin-1 and sestrin-2) that interact with and activate AMPK (96).  p53 is also 
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downstream of mTOR, as hamartomas containing constitutively activated mTOR have 
increased levels of wild-type p53, and p53 can suppress apoptosis caused by the mTOR 
inhibitor rapamycin (119,264).  In contrast, in Chapter III we showed that p73 is inhibited 
by mTOR.  Rapamycin treatment (as well as other methods of mTOR inhibition) resulted 
in increased p73 levels and activity.  In Chapter IV we demonstrated that mTOR 
inhibition resulted in an altered p73 genomic binding profile. 
 Other kinases in the mTOR pathway can also regulate p53 family members.  
AMPK can phosphorylate p53, resulting in induction of p53 and thus an apoptotic 
response to glucose deprivation (260,265).  AMPK can bind to p73, and this is thought to 
inhibit the ability of p73 to transactivate target genes in a kinase-independent manner 
(266).  Evidence suggests that both p63 and p73 can act upstream of Akt.  In one study, 
treatment of cells with the plant lectin ConA resulted in apoptosis that was dependent on 
p73-mediated inhibition of Akt (162).  In another, p63 blocked UV-induced keratinocyte 
apoptosis by activating Akt (267).  Finally, kinases downstream of mTOR interact with 
p53 family members, such as GSK3β which phosphorylates and activates p53 after DNA 
damage (268,269). 
 The mechanisms of many of the above interactions are unknown, and in cases 
where a mechanism is known it is usually unclear if only one or multiple p53 family 
members are involved.  In previous chapters we explored the inhibition of p73 by mTOR; 
treatment of primary cells with rapamycin led to an increase in p73 but not p53 or p63 
levels.  Other agents such as cisplatin induce p73 through c-abl-mediated phosphorylation 
of Y-99 (31,32,34), and we questioned whether mTOR inhibitors induced p73 through 
similar, synergistic, or unrelated mechanisms.  In Chapter III we demonstrated increased 
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p73 levels after treatment of cells with a combination of rapamycin and cisplatin 
compared to treatment with cisplatin alone.  Understanding the mechanism by which 
mTOR regulates p73 could yield insight into potentially synergistic drug combinations, 
combinations that would be effective in tumor cells with inactivated p53. 
 To explore the mechanism by which mTOR regulates p73, and to study the inter-
connections between the p53 family and mTOR pathway in general, we performed a 
candidate kinase approach.  Key kinases in the mTOR pathway were assessed for their 
ability to phosphorylate p53 family members and isoforms.  Phosphorylation patterns 
appeared to be both member and isoform-specific.  Through this method we identified 
p73 as a substrate of mTOR, and confirmed a physical interaction between the mTOR 
kinase and p73 in cells. 
 
Results 
 
Development of a candidate kinase approach 
 In Chapter III we showed that rapamycin enhanced the induction of p73 and of 
apoptotic markers by cisplatin and taxol.  While there are as many as 35 potential p73 
protein isoforms, we observed an increase specifically in the levels of TAp73β, the 
isoform that has the strongest ability to transactivate target genes such as those involved 
in apoptosis (137).  As a single agent, rapamycin usually elicits cell cycle arrest in the G1 
phase (102), although it can induce apoptosis in some cell lines with inactivated p53 
(182).  Our data in Chapter III are consistent with reports that, when used in combination, 
rapamycin enhances the efficacy of a number of cytotoxic agents (120). 
154 
 
 We explored the role of p73 during mTOR inhibition by treating Rh30 cells with 
rapamycin, and by depleting p73 with RNAi targeting either the TA domain or a C-
terminal domain specific to p73β isoforms, as in Chapter III.  Rapamycin caused an 
increase in PARP cleavage that was dependent on TAp73β (Figure 44A).  While the 
amount of PARP cleavage that we observed seemed insufficient for robust induction of 
apoptosis, it may contribute to the ability of rapamycin to 'prime' cells for apoptosis in 
response to cytotoxic drugs. 
 We reasoned that mTOR regulates p73 by a distinct mechanism that allows for 
synergy with DNA damage pathways.  In Chapter III we showed that rapamycin 
increased p73 protein levels but not RNA levels.  Given the many kinases in the mTOR 
pathway, and the fact that some kinases in the pathway such as AMPK and GSK3β are 
known to phosphorylate p53 (260,265,268,269), we decided to test the ability of mTOR-
related kinases to phosphorylate p73.  As shown in Figure 44B, we chose three tiers of 
kinases to analyze.  mTOR exists as two complexes, mTORC1 and mTORC2, with 
mTORC2 acting upstream of mTORC1 (Tier 1) (261).  As mentioned above, Akt and 
AMPK transmit growth factor and nutrient signals to mTORC1 (Tier 2), and p70S6K and 
GSK3β are downstream of these kinases (Tier 3). 
 We tested the ability of these kinases to phosphorylate not only p73, but also p53 
and p63, in order to gain insight into common versus distinct methods of regulation of 
these family members.  We chose to test the ∆Np63α isoform, because this is the 
predominant isoform expressed in human tissues (270).  We also assessed three different 
isoforms of p73: TAp73α, TAp73β, and TAp73γ.   
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Figure 44: Rationale for a candidate kinase approach. A) Rapamycin
induces PARP cleavage in Rh30 cells in a p73-dependent manner. Rh30
cells were treated with 40 nM rapamycin (rap) or vehicle control for 24 h in
serum-free media, and treated with lentivirus expressing shRNA targeting
GFP, TAp73, or p73β for 3 d. Western blot analysis was performed for
PARP and actin; the blots shown are representative of three independent
experiments. B) The mTOR pathway is depicted as three tiers of kinases
(mTOR exists as two complexes, mTORC1 and mTORC2) that were chosen
for assessment in a candidate kinase approach.
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Theoretically, phosphorylation of one isoform but not another would help define a region 
of the protein required for phosphorylation.  This region could have domains needed for 
interaction with kinase(s) and/or contain the actual phophorylates site(s).  We generated 
recombinant proteins for each of these family members in E. coli; these proteins were 
GST fusion proteins containing a protease cleavage site for removal of the GST tag, if 
needed (Figure 45). 
 
Kinases in the mTOR signaling pathway phosphorylate p53 family members 
 p53 is a known substrate of GSK3β and we observed phosphorylation of both p53 
and p63 by GSK3β in vitro (Figure 46A).  By comparison GSK3β did not phosphorylate 
any of the three p73 isoforms analyzed (Figure 46A).  In contrast, in vitro kinase assays 
using p70S6K resulted in phosphorylation of all p53 family members (Figure 46B).  
Although we observed modulation only of p73 and not p53 or p63 by rapamycin, we 
considered that p70S6K might specifically target p73 due to selective mechanisms that 
exist in cells.  Therefore, we used RNAi to deplete p70S6K levels and measured p73 
protein by Western blot.  We did not observe regulation of p73 levels by p70S6K in Rh30 
cells, BPH prostate cells, or MDA-MB-231 breast cells (Figure 47).  Thus, p70S6K-
mediated signaling does not appear to be the mechanism by which mTOR regulates p73. 
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Figure 45: Substrates for in vitro kinase assays. Recombinant
glutathione S transferase (GST) fusion proteins were generated in
bacteria as described in Chapter II (Materials & Methods) with the
assisstance of Peter Knowlton. p53, p63, and three different p73
isoforms were generated as GST fusion proteins, separated by SDS-
PAGE and stained with Coomassie blue by Lucy Tang.
*
*
* * *
*
*
158 
 
159 
 
Figure 47: Depletion of p70S6K does not alter p73 levels. Rh30, BPH,
and MDA-MB-231 cells were transfected with siRNA targeting p70S6K
and harvested 3 d later. Cell lysates were prepared and analyzed by
Western blot for p70S6K, p73, phospho-S6 (pS6), and actin levels.
Rh30 BPH MDA-MB-231
C       KD            C    KD             C     KD
p70S6K
p73
actin
pS6
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 We next assessed whether p53 family members can be substrates for AMPK and 
Akt.  AMPK phosphorylated p53, p63, TAp73α, and TAp73β but not TAp73γ in an 
AMP-dependent manner (Figure 48A).  Interestingly, there is a potential AMPK 
consensus sequence (NxxNxxxNxxBNxBxxS/TxxBN where N is a hydrophobic residue, 
B is a basic residue, and x is any residue (271)) within the residues that are present in 
TAp73α and TAp73β but not TAp73γ.  In contrast, Akt showed very weak activity 
against p53 family members (Figure 48B).  We measured the phosphorylation status of 
Akt and of AMPK in Rh30 cells treated with rapamycin to induce p73 (Figure 49).  
We used phosphorylated Thr-172 AMPKα as a marker of active AMPK.  The activity of 
AMPK did not change with rapamycin treatment, suggesting that AMPK-mediated 
signaling is not the mechanism by which mTOR regulates p73.  However, the levels of 
Akt phosphorylated on Ser-473 did increase after rapamycin treatment. 
 Ser-473 is one of two residues on which Akt needs to be phosphorylated for 
maximal activity, though for many years the kinase responsible remained elusive.  
mTORC2 is the long-sought kinase that phosphorylates Ser-473 on Akt (261).  We found 
that multiple p53 family members are substrates of mTOR in vitro (Figure 50A).  Given 
our results that rapamycin modulates both mTORC1 and mTORC2 activity, we next 
determined if a physical interaction exists between mTOR and p73 in cells.  Co-
immunoprecipitation experiments demonstrated that mTOR forms a complex with p73 in 
Rh30 cells, as well as with rictor and raptor (Figure 50B).  These data suggest that p73 is 
a substrate of mTOR.  In Chapter III we found that knock-down of mTOR increased p73 
levels (Figure 10A); overall our data suggest that mTOR mediates rapamycin-induced 
changes in p73 levels by phosphorylating p73. 
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Discussion 
 Based on our finding that p73 is a substrate of mTOR, we propose future 
experiments to determine if mTOR phosphorylates p73 in cells and if this event is 
causally linked to the observed modulation of p73 protein levels after inhibition of 
mTOR by chemical inhibition or RNA knockdown.  For example, we can determine if 
p73 exhibits a differential mobility shift by 1D and 2D electrophoresis after rapamycin 
treatment.  A positive result, with a change after phosphatase treatment, would be 
consistent with phosphorylation and would lead to additional avenues of exploration.  
Identification of the phosphorylation site on p73 would allow us to make p73 mutants and 
generate phospho-specific antibodies.  These tools, in combination with protein stability 
studies, would confirm and more precisely define the regulation of p73 by mTOR.  A key 
goal of such studies would be to determine whether p73 phosphorylation is required for 
rapamycin-induced PARP cleavage in cells with inactivated p53.  It would also be 
interesting to over-express catalytically active versus kinase dead mutants of mTOR, to 
assess whether high levels of mTOR activity are capable of suppressing p73 levels (the 
reverse of our rapamycin experiments), and whether such changes are dependent on 
mTOR kinase activity. 
 We found that rapamcyin treatment not only altered mTORC1, but also 
mTORC2, as evidenced by increased phosphorylation of Akt on Ser-473.  It is important 
to consider whether or not cellular levels of Ser-473 phospho-Akt accurately reflect 
levels of mTORC2 activity.  While mTORC2 is the primary kinase responsible for 
phosphorylation of Akt on this site, it has been suggested that increased phospho-Akt 
may be due instead to negative feedback loops that increase PI3K activity and therefore 
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increase recruitment of Akt to cell membranes (261).  However, our results are consistent 
with studies that show increased Akt Ser-473 phosphorylation after mTORC1 inhibition 
in multiple cell lines (272).  These studies confirmed that rictor is required for the 
increased phosphorylation of Akt on this residue, thus it is likely that mTORC2 activity 
correlates with p73 levels in our assays.  Interestingly, although rapamycin treatment can 
modulate (perhaps variably) the ability of mTORC2 to phosphorylate its substrates, there 
does not appear to be any relationship between the resulting phospho-Akt  and the 
phosphorylation of Akt substrates (272). 
 Thus, to identify whether p73 is in a complex with mTORC1, mTORC2, or 
FRAP1 alone, it will be important to perform additional co-immunoprecipitation 
experiments with rictor and raptor.  If p73 does not associate with either of these proteins, 
it may be part of a previously unidentified mTOR complex.  However, we consider it 
more likely that p73 interacts with mTORC1 and/or mTORC2, because of preliminary 
data suggesting that RNAi-mediated depletion of raptor and rictor alters p73 levels in 
cells.  Identification of mTOR complex components associated with FRAP1 and p73 will 
be critical for understanding this signaling axis. 
 Another remaining question is: In what subcellular compartment does mTOR 
phosphorylate p73?  p73 contains nuclear export and nuclear localization signals that 
allow it to shuttle between the nucleus and cytoplasm (50).  When in the cytoplasm, p73 
can interact with the tumor suppressor WWOX (273), but the functional consequences of 
cytoplasmic p73 remain unknown.  mTOR has primarily been studied in the cytoplasm 
where it phosphorylates targets such as p70S6K and 4EBP1, however some studies found 
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that mTOR can shuttle between the nucleus and cytoplasm (274,275), thus it could 
potentially phosphorylate p73 in either compartment. 
 mTOR contains a nuclear localization signal (274).  Furthermore, when cells are 
treated with leptomycin B, a specific inhibitor of the export receptor Crm1, mTOR 
accumulated in the nucleus (276).  In some cell lines, including Rh30 cells, Houghton 
and colleagues have found that mTOR is predominantly nuclear (275).  In addition, Rag 
proteins have been proposed to localize mTOR to perinuclear vesicles after amino acid 
stimulation (277).  p73 has also been detected in a perinuclear extranuclear compartment 
(278,279), but it is unclear if this is the same compartment as mTOR or a side-effect of 
apoptotic nuclear blebbing.  Localization studies will shed significant light on the 
regulation of mTOR-p73 complexes. 
 Finally, we took a general approach and tested the ability of mTOR-related 
kinases to phosphorylate p53 and p63 in addition to p73.  Our results highlight previous 
findings about p53, p63, or p73 that might be extended to the other family members.  For 
example, GSK3β phosphorylates p53 following DNA damage and activates it (269).  
However, we found that GSK3β can phosphorylate both p53 and p63; thus the role of 
p63 in this pathway should be examined.  Similarly, we identified specific isoforms of 
p73 that can be substrates for AMPK.  A previous report showed that AMPK inhibits p73 
transactivation activity, but suggested that this occurred in a kinase-independent manner 
(266).  Our data show that reassessment of this model is warranted, and should include 
comparison to p53 and p63.  All three family members are substrates of mTOR and 
p70S6K, adding to the multiple layers of inter-connection that seem to exist between the 
p53 family and mTOR signaling pathway. 
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CHAPTER VII 
 
GENERATION OF A CONDITIONAL P73 NULL MOUSE 
 
Introduction 
 Although p63- and p73-deficient mouse models have been extremely informative 
for assessing the in vivo role of these proteins, the profound developmental defects, the 
perinatal lethality of the p63
-/-
 mice and the early death of the p73
-/-
 mice limit the utility 
of these models for examining the function of these proteins at later stages in the adult or 
during tumorigenesis.   Engineered mice that allow conditional knockout of either p63 or 
p73 are needed to circumvent the limitations of the 'globally' deficient animals.   Mice 
expressing a conditional p63 allele (p63
flox
) have been generated (280).  With the goal of 
generating a conditional p73 null mouse model, as part of this dissertation research we 
created a targeting vector and screened gene-targeted embryonic stem cells for generation 
of a mouse line expressing a conditional allele of p73. 
 Previous p63 and p73 mouse models informed our strategy for inactivation of 
p73.  Two groups have generated p63 knockout mouse lines using different embryonic 
stem cell-ablation technologies.  The p63
-/-
 mice generated by McKeon and colleagues 
contained a neomycin resistance (Neo) cassette instead of exons 6, 7, and 8, which 
encode part of the p63 DNA-binding domain that is common to all p63 isoforms (27).  
p63
Brdm2
 were generated by Bradley and colleagues using a gap-repair methodology to 
insert a cassette into and disrupt the p63 allele (281).  The p63 gene in the p63
Brdm2
 mice 
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is disrupted after exon 10 by an inserted region that includes a puro resistance cassette 
and a duplication of the region of homology (exons 5 through 10). 
 The p63
-/-
 and p63
Brdm2
 mice yielded similar developmental defects (complete lack 
of epidermal structures) with some key differences (retention versus lack of basal skin 
cell patches) and highly divergent tumor phenotypes (increased tumor susceptibility in 
the p63
-/-
  but not p63
Brdm2
  mice).  The majority of subsequent studies by a number of 
laboratories used the p63
Brdm2
 mice, and major conclusions were drawn under the 
assumption that these mice were p63 null.  However, additional in-depth analysis of the 
p63
Brdm2
 mice showed that, instead of being a global knock-out line, these mice retained 
expression of a p63 isoform similar to p63γ that lacks the C-terminal SAM domain (68). 
 In contrast, only one group has generated a mouse model deficient for all isoforms 
of p73.  (As discussed in the Introduction, a second mouse line that lacks TAp73 but 
retains ∆Np73 isoforms has been generated.  However, direct comparison is complicated 
as it remains unclear if ∆Np73 can compensate for TAp73 loss in some contexts.)  The 
p73
-/-
 mice were generated by replacing two exons in the DNA-binding domain with a 
Neo cassette.  As discussed in Chapter I, homozygotes exhibited severe developmental 
defects and heterozygotes had an increased frequency of spontaneous tumor formation.  
The complex alternative splicing of the p73 gene, and the retention of the Neo cassette in 
the p73
-/-
 line warranted generation of a second p73-deficient mouse model using 
alternative methodology.  Thus, our aim is to generate a conditional p73 null mouse for 
comparison to the existing p73
-/-
 mice, and for analysis of p73 function in adult tissues 
and during tumorigenesis. 
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Results 
 
Strategy and bacterial artificial chromosome screening 
 Our strategy for creation of a mouse model with a conditional p73 allele included 
targeting exons 7, 8, and 9 (p73
floxE7-9
).  Removal of these three exons ensured disruption 
of two key functional domains of the p73 protein that are common to all isoforms, both 
the 3' end of the DNA-binding domain (DBD), as well as the oligomerization domain 
(OD).  Previous p63 and p73 mouse models demonstrated the feasibility of removing the 
DBD.  We chose to remove the OD to prevent alternative expression of any truncated p73 
proteins that could oligomerize with and affect other p53 family members.  This is 
relevant given that generation of small protein fragments containing the p73 OD cannot 
be ruled out in the previously generated p73 knockout mouse model (28). 
 The entire p73 targeting region is 1.5 kb, and removal of this region was designed 
so that the 3' sequence was no longer in the p73 open reading frame.  The RPCl-22 
Mouse 129S6/SvEv Taconic BAC library was hybridized to filters and screened for p73 
genomic sequences using a probe in exon 8 (5‟-
gtcctgggccgccggtctttcgagggtcgcatctgtgcct).  Two bacterial artificial chromosome (BAC) 
clones were obtained that contained this region of the p73 gene.  These two BACs were 
screened by PCR to identify the extent of p73 genomic sequence present, and one BAC 
was chosen (176-B7) because it contained sequence > 10 kb upstream and downstream of 
exon 8.  The primers used to generate the BAC probes and to screen by PCR are listed in 
Table 10.   
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Table 10:  Primers used for generation of conditional p73 null mouse
Primer Name Primer Sequence (5’ -> 3’) Notes
DNp73-F GTCCTGGGCCGCCGGTCTTTCGAG BAC probe primer
DNp73-R AGGCACAGATGCGACCCTCGAAAG BAC probe primer
TAp73.P1 ACAGCTACAGTGTACTTATGT for screening BAC by PCR
TAp73.P2 CTTCCTGTGTGTCTGTGAGAT for screening BAC by PCR
TAp73.P3 TGCATCTTCTCATGTAGAGTG for screening BAC by PCR
TAp73.P4 TGAGGAATCATAATATGCCTG for screening BAC by PCR
TAp73.P5 AGCTGGAGCATCATACAGCAA for screening BAC by PCR
TAp73.P6 ACATAATGAAGTGTCTGTACA for screening BAC by PCR
TAp73.P7 ACTGATGAGGTACAGGTGTGT for screening BAC by PCR
TAp73.P8 AGGCTACATAGACTCCAGTGT for screening BAC by PCR
TAp73.P9 AGCCGTTCTCAGAGACGGAAC for screening BAC by PCR
TAp73.P10 AGCCTCGTGCGAAATACCT for screening BAC by PCR
TAp73.P11 TCATGTGTAACAGCAGCTGTG for screening BAC by PCR
TAp73.P12 TAGCCTCAGAGCATAGACA for screening BAC by PCR
FragA.top agtcgcggccgcTCAGAGATCAGAAACTCTCACA PCR fragment A from BAC
FragA.bottom agtcaagcttCGCCACAGTCCAAGATGGGCC PCR fragment A from BAC
FragB.top atgcaagcttCTAGAGTCTAACACCTGCAT PCR fragment B from BAC
FragB.bottom agtcactagtCTGCAAGAGCGATGGGCAC PCR fragment B from BAC
FragC.top: AGTCggtaccGACTGGGGTTTATGGCGTTTG PCR fragment C from BAC
FragC.bottom: agtcgaattcCCCACTCACTTGCCGGTC PCR fragment C from BAC 
FragD.top: agtcggatccGTAGGTGGATACGTGGGTGTG PCR fragment D from BAC
FragD.bottom: agtcccgcggGAATGCCCACCGAGGAGAGC PCR fragment D from BAC
FragE.top: agtcctcgagCCTTCCAGCCTAGGTTTG PCR fragment E from BAC
FragE.bottom: agtcgtcgacAGGCTGAACCCTATAGGATC PCR fragment E from BAC
FragF.top: agtcggatccGTGTTTAAATCCATGGTCC PCR fragment F from BAC
FragF.bottom: agtcccgcggCTATAGGACCATGGATTTAAAC PCR fragment F from BAC
FragCOut2: CAAACTCTGTACCTCCCCTA used to sequence final construct
New3: GGGAAGGGCTTAGTATCAGT used to sequence final construct
New7: GACTCACAGGCAAGGAAATA used to sequence final construct
SeqE1:  GGTACCAACGTGAAGAAGAG used to sequence final construct
452RevOut: CACGAGACTAGTGAGACGTG used to sequence final construct
451Out2:  GATTGGGAAGACAATAGCAG used to sequence final construct
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These screens were performed in collaboration with the laboratory of Dr. Mark 
Magnuson, Professor of Molecular Physiology and Biophysics, Professor of Medicine, 
and Director of the Transgenic Mouse and ES Cell Core at Vanderbilt.  The 176-B7 BAC 
was used to generate a targeting vector in the pL253 backbone as described below. 
 
Construction of a p73 targeting vector 
 The p73 targeting vector was generated using a highly efficient recombineering-
based method generated by Copeland and colleagues.  Recombineering is a form of 
chromosome engineering based on homologous recombination in Escherichia coli that 
takes advantage of proteins encoded in the λ phage (282).  In the EL350 E. coli strain, the 
λ phage genes that mediate homologous recombination are under the control of a 
temperature-sensitive repressor.  Thus, a brief heat induction causes expression of a 5'-3' 
exonuclease (Exo), a pairing / annealing protein (Beta), and an inhibitor of the RecBCD 
exonuclease (Gam), to promote gap repair of linear dsDNA into DNA cloned on 
plasmids.  EL350 cells also express Cre under the control of an arabinose-inducible 
promoter. 
 In the first recombineering step, a 14.1 kb fragment of the p73 gene locus was 
transferred from the BAC described above to the high-copy plasmid vector pL253.  This 
backbone was used because the alternative strategy, introducing loxP sites into the BAC, 
would necessitate both the removal of loxP sites already present in the BAC and the time-
consuming confirmation of BAC integrity after every modification.  The 14.1 kb p73 
segment contained the 1.5 kb targeted region, as well as 7.3 kb of upstream DNA (long 
arm) and 4.3 kb of downstream DNA (short arm).  The long arm included exons 5 and 6, 
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and the short arm included exons 10, 11, 12, and 13.  Two 500 bp sequences (Fragment A 
and Fragment B generated using primers in Table 10) that flank the 14.1 kb segment were 
subcloned into the pL253 backbone.  The resulting vector was electroporated into EL350 
cells along with the p73 BAC, and recombineering was induced (Step 1, Figure 51). 
 The next step was to introduce a loxP site 5' of p73 exon 7 (Figure 51).  
Homologous recombination was used to introduce a floxed Neo cassette (pL452) using 
Fragments C and D (500 bp each, see Table 10 for primers) that flank the appropriate 
region as in Figure 51.  Then, arabinose was used to induce Cre expression in the EL350 
cells, resulting in removal of the Neo gene leaving only a single loxP site upstream of 
exon 7.  The second loxP site was introduced 3' of exon 9, along with an upstream 
selection cassette that contains Neo floxed by two Frt sites and a bacterial EM7 promoter 
in between the PGK promoter and the coding sequence of Neo to allow for selection in 
both bacterial and murine ES cells with either kanamycin or G418 (Figure 51).  (The Frt 
sites that surround the Neo cassette allow removal of the selection cassette once the 
conditional allele is introduced into the mouse germ line, by breeding the mice with a 
strain that expresses Flpe recombinase in the germ line.  This is important because the 
Neo cassette can have untoward effects on expression from nearby genomic loci.)  Of 
note, the pL253 vector already contained an MC1-TK negative selection marker. 
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 These recombineering steps generated a vector, pJLJDH6, as depicted in Figure 
52, that was sequenced across every junction in both directions to verify its integrity 
using the primers listed in Table 10.  The vector contains a long arm of 7.3 kb 
homologous to p73, a loxP site, the targeted region (exons 7, 8, and 9), the pgk-EM7-Neo 
cassette flanked by Frt sites, a second loxP site, a short arm of 4.3 kb homologous 
sequence, and a negative selection MC1-TK cassette. 
 
Southern and PCR-based screening and generation of chimeric mice 
 There was approximately 13 kb total of p73 sequence contained in the targeting 
vector.  The vector was linearized using a unique NotI site and electroporated into the 
129S6 TL1 XL ES cell line (isogenic to the BAC clone we used to generate the vector).  
G418 and gancyclovir-resistant ES cell colonies were picked, expanded, and 
confirmation of targeting confirmed by Southern hybridization (probes shown in Figure 
53).  Two ES clones containing the targeted allele were chosen (see representative 
Southern blot in Figure 54) for microinjection into 129S6 blastocysts. 
 After successful germline transmission of our engineered p73 allele (p73
floxE7-9
) 
using the mouse with the highest degree of chimerism, the resulting animals will be bred 
to a global FlpE 'deleter' mouse line, B6;SJL-Tg(ACTFLPe)9205Dym/J.  FlpE is under 
the control of the actin promoter and these mice have been used routinely for the purpose 
of selectable marker deletion after germline transmission is achieved 
(http://jaxmice.jax.org/strain/003800.html).  Efficient deletion of genomic material 
between frt sites, in our case the Neo gene, is typically observed.   
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pJLJDH6
20,345 bp
Figure 52: Vector map of p73 targeting construct. LoxP sites flank exons 7, 8,
and 9 of p73. The positive selection cassette Neo and negative selection cassette
TK are indicated. A unique NotI restriction site was used to linearize the vector
prior to electroporation into ES cells.
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Figure 53: Targeting strategy for disruption of murine p73 gene. The p73 locus and
targeting vector (pL253) are shown. The 129S6 TL1 ES cells were targeted to have deletion
of exons 7, 8, and 9 of p73. Also shown are the predicted lengths of the restriction fragments
of the targeted allele that we observed by Southern analysis. The location of the hybridizing
probes used for Southern are indicated by red boxes labeled a and b. NeoR, neomycin-
resistance; TK, thymidine kinase. The yellow box is the long arm, and the green box is the
short arm.
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3 kb
6 kb
12 kb
Figure 54: Southern blot analysis to screen for recombinant clones. Five
representative murine embryonic stem cell clones are shown as an example of
our Southern screening procedures. Genomic DNA was isolated, digested with
HindIII, and fragments separated by gel electrophoresis. Southern blotting was
performed using a probe located in exon 14 of p73. As indicated by differential
digest patterns, all five clones have both a wild-type (~14 kb) and a floxed (~8
kb) genomic allele. Probe preparation, DNA digestion, and Southern blot
analysis were performed by Deborah J. Mays.
178 
 
In a few subsequent breedings, we will segregate out the FlpE gene and have a resulting 
mouse line that carries the p73
floxE7-9
. 
 
Discussion 
 Here I will discuss our plans for analysis of these conditional p73 null mice.  This 
includes both analysis of mice with global knockout of p73 and tissue-specific, 
conditional targeting of p63 and p73 in the mammary gland.  Global knockout of p73 will 
be achieved by crossing the p73
floxE7-9
 strain to the 'global deleter' mouse line B6.FVB-
Tg(Ella-cre)C5379Lmgd/J that have been used extensively 
(http://jaxmice.jax.org/strain/003724.html).  Male +/p73
delE7-9
 mice will be established 
and crossed to 129s6 females and their progeny genotyped by Southern analysis.  We will 
determine that p73
floxE7-9
 is an efficient substrate for Cre if all possible forms of this allele 
are recovered in these crosses.  +/p73
delE7-9
 mice will be intercrossed to generate 
p73
delE7-9
/p73
delE7-9
 progeny.  Given the previously published mouse model, we predict 
that breeding +/p73
delE7-9
 mice will show Mendelian distribution consistent with p73, like 
p53, not being required for embryogenesis (28).  RNA from mouse embryonic fibroblasts 
(MEFs) will be analyzed by RT-PCR as well as by sequencing to confirm disruption of 
the p73 gene.  The simple mouse genotypes of p73
+/+
, p73
+/-
, and p73
-/-
 will then be used 
for analysis of p73 function. 
 In order to analyze mice with global knockout of p73, ten males and ten females 
from p73
+/+
, p73
+/-
 and p73
-/-
 mice will be sacrificed at birth, 1, 3, and 5 months and 
analyzed for gene expression, histopathology, and phenotypes.  A complete metabolic 
profiling of blood and select tissues will be performed by the Mouse Metabolic 
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Phenotyping Center at Vanderbilt.  Analyses will involve various metabolic 
pathophysiology assays including determination of blood glucose levels, glucose 
utilization, and insulin secretion in these mice.  This is particularly relevant given our 
findings that p73 regulates genes associated with insulin, glucose and lipid metabolism 
(as described in Chapter V).  Interestingly, mTORC1/Akt is a well-known regulator of 
insulin signaling, and mTORC2 has been shown to regulate fat deposition and lipid 
metabolism in C. elegans (114).  In addition to those mice analyzed at 1, 3, and 5 months, 
we will carry out necropsies on ten additional mice at 7, 10, 12, and 15+ months 
(depending on life span) to determine if there is any tendency to develop spontaneous 
tumors or if there are other gross tissue defects. 
 Based on the previous mouse model we predict the p73 null pups will show a 
runting phenotype and high rates of mortality.  We will examine the gastrointestinal tract 
and central nervous system for hemorrhages.  A striking phenotype of the previously 
described p73 null mice was severe rhinitis and purulent otitis media due to neutrophil 
infiltrates that persisted throughout adulthood.  Lymphoid and granulocyte populations 
will be examined during the blood analysis.  The most highly noted phenotypes of the 
previous p73 null mouse was neurologic defects including hippocampal dysgenesis, 
hydrocephalus, and abnormalities in the pheromone sensing pathways (28).  All 
neurological tissue will be examined with focus on choroid plexus, lateral ventricles, 
hippocampus, pyramidal cell layer, the dentate gyrus, and the vomeronasal organ.  
Confirmation of the phenotypes originally reported will underscore the requirement for 
p73 in the processes of pheromone detection and neurogenesis.  We are most interested in 
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the overlap of genes and signaling pathways that are involved in metabolic processes (see 
Chapter V) to any noted phenotypes, whether similar to the previously described or not. 
 In addition to global knockdown of p73, and given our analyses of p73 activity in 
triple-negative breast cancers (as described in Chapter III), we will focus on p73 
depletion that is specific to the mammary gland.  A previous study demonstrated an 
increased incidence of mammary adenocarcinomas in p63
+/-
;p73
+/-
 mice (66).  In human 
breast tumors, p73 exhibits significant over-expression (158).  In the basal-like subtype of 
breast cancer, p63 is variably expressed and in those tumors it functions as an inhibitor of 
pro-apoptotic p73 function (37).  Mouse models that analyzed p63 and p73 in breast 
tumors did not use histopathological analysis to define type.  In addition, previous p63 
and p73 mouse models had confounding variables such as a deficiency in gene 
expression from embryogenesis onward and potential compensatory roles of the other 
family members.  Thus, crossing our floxed p73 allele with those expressing Cre driven 
by the MMTV LTR promoter will allow us to address many of these unresolved issues.  
The MMTV promoter responds to estrogen, so when the mice reach puberty Cre mRNA 
will be expressed in the estrogen-sensitive tissues such as the mammary gland. 
 In addition, we have received p63 conditional null mice, in which the p63 DNA-
binding domain is flanked by loxP sites (280).  As mentioned above, mice in which p63 
has been globally deleted do not form mammary glands and die shortly after birth (27).  
We will be able to determine the effect of loss of p63 or p73 or both family members 
after development of the rudimentary mammary gland.  For example, we hypothesize that 
Cre-mediated excision of both p63 alleles at 5-7 weeks in the mammary gland will lead 
to loss of the basal, myoepithelial cells and the entire architecture of the mammary gland 
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will be disrupted.  Whether or not such loss would depend on or be modulated by p73 
(∆Np63, the predominant isoform expressed during development, is an inhibitor of p73) 
could also be determined.  Loss of myoepithelial cells could either confound tumor 
studies or it could provide a growth advantage for the luminal cells given reports about 
the 'natural' tumor suppressor properties of this basal cell population (283,284).  Finally, 
we can perform a detailed histopathologic analysis to classify the subtype of breast 
cancer.  We can examine the effect of complete loss of either p63 or p73 to maintenance 
and function of the adult mammary gland under control and stress-induced conditions. 
 The studies outlined above highlight the import that a conditional p73 null mouse 
model would have on our understanding of the tissue- and temporal-specific roles of p73.  
In combination with p63 and p53 conditional null mice that have previously been 
generated, these mice would allow analysis of the coordinated and complementary 
functions of p53 family members. 
182 
 
CHAPTER VIII 
 
SUMMARY & SIGNIFICANCE 
 
p53 family isoforms inhibit p73 in tumors 
 p53 family members exhibit differential tumor expression patterns.  Whereas p53 
is frequently mutated in human cancers, reflecting its well-characterized role as a tumor 
suppressor, p63 is over-expressed or amplified in a subset of carcinomas derived from 
stratified tissues (tissues with both basal and luminal / squamous layers) (285).  The 
predominant p63 isoform that is expressed in these carcinomas is the „inhibitory‟ 
∆Np63α isoform; this isoform is critical for the development, growth and maintenance of 
stratified tissues (285).  Thus the opposing statuses of p53 and p63 in tumors matches 
their respective suppressive and oncogenic functions.  In contrast, multiple isoforms of 
p73 are over-expressed in tumors despite the fact that many of these isoforms act as 
tumor suppressors in vitro (35,54). 
 Part of the above discrepancy may be explained by the concurrent expression of 
p73 inhibitors in tumors that express p73.  The specific inhibitor or set of inhibitors that 
are engaged may be context-dependent.  In select tumor types (HNSCC and basal-like 
carcinoma), ∆Np63α has been proposed to bind to TAp73β and sequester it from 
apoptotic promoters (56-58).  Because p63:p73 hetero-dimerization is weaker than 
p73:p73 homo-dimerization (286), sequestration is likely limited to tumors in which the 
number of p63 molecules significantly outweighs the number of p73 molecules.  Thus, 
we would hypothesize that this phenomenon is limited to carcinomas derived from basal 
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epithelium or that have developed squamous-like characteristics.  Of note, our analyses 
suggest that a p63 antibody commonly used for IHC work, 4A4, can cross-react with p73 
(Appendix).  Therefore, we suggest that future analyses of p63 and p73 co-expression in 
tumors be validated with additional p63 antibodies. 
 Several studies suggest that ∆Np73 also plays a role as an inhibitor of TAp73.  
The balance of p73 isoforms expressed in any given tumor may thus dictate p73 function 
(54).  Our understanding of ∆Np73 function is hampered by a general over-reliance on 
RNA analysis to detect p73 isoforms in tumors.  In the Appendix, we evaluated 
commercially available p73 antibodies, identified a need for ∆Np73-specific antibodies, 
and generated new antibodies specific for ∆Np73.  These antibodies can be used to assess 
∆Np73 protein levels in human tumors.  If ∆Np73 is the predominant inhibitor of TAp73 
function, then its expression should be tightly correlated with TAp73 levels. 
 Finally, a few select mutations in p53 (specific hot-spot mutations that occur 
frequently in cancers) give p53 the ability to bind to p73 through weak interactions in the 
DNA-binding domain (59).  Molecules have been developed that disrupt the mutant p53-
p73 complex, freeing p73 to elicit tumor cell death or increase chemosensitivity 
(287,288).  Overall, the above studies suggest that all three family members have the 
ability to inhibit p73.  Whether they do so in vivo, the contexts under which p73 
inhibition takes place, and whether these methods of inhibition are redundant remains 
unknown. 
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mTOR signaling inhibits p73 
 We were intrigued by several cancer cell lines in which TAp73 was robustly 
expressed in the absence of detectable p63 or ∆Np73, or detectable interaction between 
TAp73 and mutant p53.  We hypothesized that either apoptotic pathways downstream of 
TAp73 were disabled, or unknown p73 inhibitors were engaged.  In Chapter III, we 
sought to identify signaling pathways upstream of TAp73 in these cell lines.  An example 
of the type of pathway we were searching for is the Rb pathway.  Rb is an inhibitor of 
E2F, and E2F can bind to the p73 promoter and activate p73 transcription (a mechanism 
that may prevent p73 from being engaged in quiescent cells) (289).  Rb can also inhibit c-
abl, a kinase that mediates cisplatin-induced p73 stabilization (290,291).  Thus, one 
hypothesis is that Rb prevents p73 from engaging tumor suppressor pathways in cancer 
cells (289).  In Chapter III, we devised a gene-signature based approach to identify 
similar pathways upstream of p73, using pattern-matching algorithms to identify 
pharmacologic agents that induce gene expression signatures similar to the p73 signature 
(144). 
 Our approach took advantage of the Broad Institute Connectivity Map resource of 
drug signatures (143).  First, we generated a p73 signature based on gene expression 
changes induced by ectopic p73 in H1299 lung carcinoma cells.  By comparing the p73 
signature to those in the Connectivity Map, we identified five drugs that target the mTOR 
pathway and induce a p73 gene signature.  We validated mTOR as an inhibitor of 
TAp73β through both pharmacologic treatment of cell lines with mTOR inhibitors, and 
RNAi-mediated depletion of mTOR.  The connection between p73 and mTOR was not 
due to general cell cycle inhibition, because treatment of the same cell lines with 
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mimosine or hydroxyurea did not result in p73 elevation.  Finally, we demonstrated that 
p73 target genes are involved in mTOR-regulated processes such as autophagy (292). 
 mTOR is a master regulator of cellular growth across tissue types.  As such, it is 
frequently activated in cancers through deregulation of upstream regulators like PTEN 
and PI3K.  Thus, mTOR may serve as an inhibitor of p73 in tumor cells, preventing p73 
from inhibiting cell growth or activating cell death pathways.  Interestingly, in some cell 
lines such as MDA-MB-468 basal-like breast cancer cells, we detect both TAp73 and 
high levels of phospho-Akt, but not Np63 or Np73.  Immunohistochemistry 
experiments are ongoing to determine whether phospho-Akt or phospho-S6, markers of 
mTORC2 or mTORC1 activation, correlate with p73 expression in human tumors. 
 In Chapter III, we further hypothesized that the mTOR-p73 signaling axis could 
be used as a therapeutic target.  As shown in Chapter VI, rapamycin induced an increase 
in PARP cleavage that was dependent on TAp73.  We hypothesized that TAp73 may 
be 'priming' cells for apoptosis.  This 'priming' effect could explain the synergy of 
rapamycin with other genotoxic agents that increase p73 levels.  The kinase c-abl, which 
phosphorylates p73 on Y-99 in response to genotoxic stress (31,32,34), may tip the 
balance and lead to more robust induction of cell death. 
 We explored this hypothesis in triple-negative breast cancers, which are sensitive 
to cisplatin but lack targeted therapeutic options.  As shown in Chapter III, the 
combination of cisplatin, paclitaxel, and everolimus (RAD001, a rapamycin analog) 
induced the levels of p73 and several apoptotic markers in basal-like breast cells.  These 
preclinical results suggest that adding RAD001 to cisplatin and paclitaxel combination 
treatment regimens may increase clinical efficacy, and a phase II clinical trial has been 
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initiated at the Vanderbilt-Ingram Cancer Center to evaluate this hypothesis.  We also 
found that our p73 gene signature could segregate triple-negative tumors into additional 
subgroups, and we posit that signatures of p73 activity could be used as tools to predict 
responsiveness of tumors to RAD001.  This is particularly relevant because previous 
clinical trials involving rapamycin analogs, while not effective on a large scale, did result 
in tumor regression in select patients (102,293).  Using gene signatures to predict clinical 
responders may be the key to an mTOR-based anti-cancer strategy. 
 
A selective model for p73 binding and activity 
 In Chapter III we demonstrated that mTOR modulated p73 activity at 14 target 
genes involved in cellular metabolism and autophagy.  However, our genomic analyses 
identified hundreds of p73 target genes, suggesting that our more traditional analysis 
provided too limited a window to p73 activity.  Therefore, we asked whether mTOR 
altered p73 activity at all or only a subset of the target genes in its cistrome.  In Chapter 
IV, we used comprehensive ChIP-on-Chip technology to answer this question, and to 
further examine the effect of mTOR inhibition on p73 binding and function at gene 
regulatory regions. 
 Our results generated a model for the regulation of p73 binding in response to 
cellular stresses.  In total, we found that p73 bound constitutively to the regulatory 
regions of almost 4,000 genes.  While mTOR inhibition resulted in an increase in p73 
levels, the distribution of p73 binding sites did not change.  Instead, p73 occupancy 
increased at ~9% of all p73-bound loci. 
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 Our analyses of p73 binding suggested both similarities and differences with other 
p53 family members.  p53 activates different subsets of its target genes depending on the 
specific cellular context and stressor.  For example, nutlin-3 induces p53-dependent cell-
cycle arrest, apoptosis or senescence in different cell types (294,295).  In addition, the 
same colon carcinoma cell line undergoes arrest in response to doxorubicin, and 
apoptosis in response to 5-FU (296).  For p73, we similarly found that rapamycin induced 
only a subset of its target genes, and this subset did not include several target genes 
known to be induced in response to other agents such as cisplatin (90). 
 Two models have been proposed to explain the selectivity of target gene 
activation by p53 (297).  In the 'Selective Binding Model' p53 exhibits different affinities 
for different DNA sequences or response elements, resulting in differential binding to 
target genes.  This model is supported by detailed kinetics analyses performed in our 
laboratory, that showed that p53 has different affinities for the response elements in 
different promoters (138).  Furthermore, ChIP-on-Chip analyses in primary cells 
demonstrated that p53 binds the majority of its target genes only after genotoxic stress 
(87).  In contrast, the 'Selective Context Model' posits that p53 binds to all of its target 
genes, but resultant activity is modulated by differential histone modifications, 
coactivator availabilities, and RNA Pol II loading.  ChIP-on-Chip analyses in established 
cell lines demonstrated that p53 bound to target genes both before and after genotoxic 
stress, and the level of p53 binding correlated only with the amount of p53 in the cell 
(87).  Analyses of p63 binding performed in our laboratory similarly showed constitutive 
p63 binding to many of its target promoters (145). 
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 By defining a comprehensive p73 binding profile we set the stage for further 
evaluation of these models.  Rapamycin resulted in an increase in p73 occupancy at 
specific loci.  Interestingly these loci were enriched for genes that were transcriptionally 
repressed by p73.  Could this be due to changes in p73 binding affinity?  We defined a 
p73 consensus binding motif from among all p73-bound loci.  This motif was very 
similar to the p53 and p63 response elements.  The p53 family motif is notably long (20 
bp) compared to other transcription factors, suggesting the potential for a high degree of 
regulatory diversity (297).  Differences in the motifs bound by p73 at baseline and after 
rapamycin treatment were very subtle (the binding site is slightly more conserved after 
rapamycin treatment at positions 9-12), and while we consider it unlikely that such 
differences mediate selectivity of binding we cannot rule that out.  Future studies that 
measure p73 binding after additional p73-inducing agents, or mere overexpression of 
p73, would yield significant insight.  If all agents that increase p73 levels result in 
increased occupancy at the same sites, then this would suggest that the affinity of p73 for 
different DNA sequences is the primary determinant of its transcriptional activity. 
 In contrast, many of the p73 target genes that we identified in Chapter IV 
exhibited p73-dependent changes in expression without any change in p73 binding level.  
These data are strong support for a Selective Context Model for p73 function; factors 
outside of p73 binding must be regulating its activity.  It is important to note that these 
types of studies are hampered by a frequent inability to link a binding site to its cognate 
target gene.  The best one can do is annotate a binding site by its closest gene in terms of 
two-dimensional proximity.  Many p73 binding sites may be regulating genes >10kb 
away but close in three-dimensional space.  Nonetheless, our results suggest that 
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contextual cues influence p73 activity.  Along these lines, we identified several tissue-
specific factors that were associated with p73-bound loci in control and/or rapamycin-
treated cells. 
 Integration of various facets of the p73 cistrome leads us to suggest the following 
model for p73 binding.  Like p53 and p63, p73 exhibits extensive binding at baseline in 
cancer cells, and all three family members share a highly similar consensus binding 
sequence.  However, p73 and p63 share additional similarities in their response elements 
that impart an ability to bind to a larger potential pool of target genes than p53.  Certain 
types of cellular stress increase p73 occupancy at selective binding sites, and this may be 
driven in part by subtle differences in the response elements at these sites.  Of greater 
impact, stress-induced changes in gene expression are modulated by the relative levels of 
the other p53 family members and by the availability of a variety of tissue-specific 
cofactors. 
 
p73 regulates mesenchymal target genes 
 Our investigation of the p73 cistrome in Chapter IV revealed a significant number 
of target genes associated with muscle development and function.  This led us to 
investigate the role of p73 in the pathogenesis of rhabdomyosarcoma, a disorder of 
skeletal muscle differentiation and growth.  p53, p63, and p73 play redundant roles 
during myogenic differentiation by activating Rb (159).  Moreover, inhibition of all three 
family members (by mutation of p53 and expression of dominant-negative ∆Np73) is 
required during rhabdomyosarcoma pathogenesis to block terminal differentiation (159).  
Interestingly, however, there are two types of rhabdomyosarcoma, ARMS and ERMS, 
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with different cells of origin and pathologies.  The impact of p53 family members on 
these tumor subtypes is of interest given their distinct properties and pathways of 
formation. 
 ARMS are associated with gene translocations; ~70% of ARMS tumors harbor a 
gene fusion product that combines the PAX3 or PAX7 DNA-binding domain with the 
FKHR (or FOXO1) transactivation domain (223).  Similar translocations have not been 
identified in ERMS, which are associated with a better prognosis.  ARMS and ERMS 
occur in different age populations, likely due to differences in the number of second hits 
required for tumorigenesis, or in the available pool of target cells. 
 In Chapter IV, we generated an mTOR-p73 gene signature by performing gene 
expression profiling in Rh30 cells treated with rapamycin and/or RNAi targeting p73.  
We explored the status of this signature in two independent cohorts of 
rhabdomyosarcomas, and in both cases identified the signature only in the alveolar 
subtype.  In addition, subsets of the p73 signature could predict clinical outcome for 64 
patients with ARMS, but were unable to predict clinical outcome for patients with 
ERMS.  Thus, p73 is functionally engaged in transcriptional activity in the alveolar 
subtype.  Our analysis of p73 target genes revealed many involved in muscle 
differentiation / function and cell cycle progression that are potentially relevant to ARMS 
tumorigenesis. 
 We present two potential models to explain these data.  First, a block in a 
signaling pathway downstream of or parallel to p73 may occur in ARMS resulting in 
retention of p73 activity in these tumors.  Under such circumstances, p73 would not be a 
good therapeutic target in ARMS tumors.  However, in this same scenario p73 may be 
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repressed in ERMS, and reactivation of p73 might lead to terminal differentiation and 
cell-cycle arrest of ERMS cells.  In the second hypothesis, specific patterns of p73 
isoforms may be expressed in ARMS tumors, and contextual cues may be present, that 
result in p73 activity at muscle-specific but not apoptotic gene promoters.  As a result, 
treating ARMS tumors with molecules that activate p73, such as genotoxic agents and 
mTOR inhibitors, would alter p73 isoform ratios leading to induction of p73-mediated 
apoptosis.  Along these lines, Rh30 xenografts treated with a rapamycin analog displayed 
a profound growth reduction (222).  Comparison of p73-inducing treatment regiments in 
ARMS and ERMS cell lines would yield insight into the role of p73 in these two sarcoma 
subtypes. 
 Studies of ARMS pathogenesis and the role of p53 provide a framework for 
understanding the role of p73 (298, 299).  Mesenchymal stem cells (MSCs) are thought to 
be the cell of origin for ARMS, as opposed to more committed muscle satellite cells that 
are thought to be the cell of origin for ERMS (223).  It is clear that gene translocation 
products play an important role in the genesis of ARMS; however, mouse models that 
stably overexpress these fusion products have been difficult to establish.  For most cell 
types, these oncogenic fusion products are lethal.  It is only in more 'permissive' cells 
such as MSCs that their expression can be tolerated.  Interestingly, attempts to establish 
xenografts from MSCs harboring ectopic expression of PAX3-FKHR were not successful 
without concurrent loss of p53 or ARF (298).  Transgenic mouse models gave similar 
results.  Conditional expression of PAX3-FKHR generated only 1 ARMS tumor out of 
228 mice, but simultaneous loss of either p53 or ARF lead to accelerated tumorigenesis 
and increased incidence (299).  It is thought that embryonal tumors, derived from more 
192 
 
committed cells, can only tolerate weaker oncogenes such as activated RAS (223).  In 
both tumor subtypes second hits, such as those in the ARF-p53 pathway, are likely 
required for cells to tolerate oncogenic activation. 
 In Chapter IV, we used our gene signature to explore p73 activity in MSCs.  
Interestingly, gene patterns in the p73 signature were altered during differentiation of 
MSCs into the myogenic lineage.  One key target gene that was present in the ChIP 
dataset and was regulated by p73 was myogenin.  Myogenin plays a critical role during 
muscle differentiation - it is part of a cascade of transcription factors that converts 
myoblasts to myotubes to terminally differentiated muscle cells (300).  Interestingly, 
unlike other core factors such as MyoD and Myf5, Myogenin is non-redundant and 
transgenic mice lacking it do not develop any skeletal muscles (301), suggesting that 
multiple potentially compensatory signals converge on myogenin during development.  
Myogenin plays a role in later parts of the differentiation cascade (300), thus if p73 
regulates myogenin it may play a role during terminal differentiation that is altered 
during tumorigenesis.  We demonstrated that p73 activates myogenin expression in a 
rhabdomyosarcoma cell line.  These data suggest that mTOR inhibition could be used to 
terminally differentiate cancer cells by activating p73.  Future examination of additional 
target genes in the p73 cistrome may yield additional insight to the role of p73 in MSCs, 
cells that are the origin of multiple tumor types. 
 We also identified many p73 target genes and miRNAs that are known to regulate 
epithelial-to-mesenchymal transition (EMT) suggesting a role for p73 that extends 
beyond human sarcomas.  Furthermore, components of the p73 signature were altered in 
MCF10A breast cells induced to undergo EMT following different treatments (302,303).  
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Work by Piccolo and colleagues has shown that a complex containing mutant p53, p63 
and Smad proteins inhibits p63, resulting in expression of genes such as cyclin G2 that 
promote tumor metastasis (304).  Given that mutant p53 and p73 can interact (305), that 
p73 expression correlates with stage and invasion in some human tumors (76,306), and 
that we have identified cyclin G2 and other TGFβ-related genes as targets of p73, future 
studies on the contribution of p73 to EMT are warranted. 
 Thus, we propose that p73 plays a larger role in regulating a mesenchymal 
phenotype.  Whether the p73 transcriptional program is the same in human sarcomas and 
in epithelial cells that have transitioned to a mesenchymal state remains to be determined.  
Interestingly, our analysis of p73-regulated genes in basal-like breast cancers in Chapter 
III may be related to this phenomenon, because basal-like breast carcinomas have 
increased expression of mesenchymal markers and a greater proclivity for EMT as 
compared to other breast cancer sub-types (307). 
 We performed additional functional analysis in Chapter III, demonstrating that 
p73 regulates cellular autophagy, a catabolic process that can provide nutrients for cells 
or accompany cell death.  In Chapter V we analyzed the p73 cistrome further and 
identified networks of target genes related to lipogenesis and glucose utilization.  
We validated p73 binding at key target genes in each of these networks using ChIP-
qPCR.  Interestingly, a meta-analysis of several rhabdomyosarcoma microarray and 
SAGE studies found that a key defining phenotype of rhabdomyosarcomas was general 
down-regulation of energy production pathways (308).  It is interesting to speculate that 
p73 regulates such metabolic pathways in rhabdomyosarcomas and other tumor types. 
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Mechanistic analysis of the mTOR-p73 axis 
 In Chapter III we demonstrated that mTOR inhibition increased p73 protein 
levels, but not p73 mRNA levels.  In Chapter VI, we further explored the mechanism by 
which mTOR regulates p73 by assessing kinases in the mTOR pathway for their ability to 
phosphorylate p73.  Because there are likely many inter-connections between the mTOR 
and p53 family pathways, as described in Chapter I, we generated recombinant p53, p63, 
and p73 for use as substrates.  Our results showed that GSK3β, p70S6K, Akt, AMPK, 
mTOR and RSK1 differentially phosphorylate p53 family members in vitro.  In some 
cases we can identify regions of the protein that are phosphorylated or required for 
phosphorylation.  For example, AMPK phosphorylated p73α and p73β but not p73γ, 
therefore we hypothesize that AMPK phosphorylates a motif that is present in the short 
amino acid stretch that is absent in p73γ.  We combined our kinase assay results with 
analyses of activation of kinases in cell lysates after various pharmacological treatments 
to narrow down the mechanism by which mTOR regulates p73.  Our results suggested 
that mTOR phosphorylates p73 directly, and co-immunoprecipitation analyses suggest a 
physical interaction between the mTOR kinase and p73 in cells. 
 Several questions remain about the interaction between mTOR and p73.  It is 
unknown whether p73 binds to components of the mTORC1 complex or mTORC2 
complex.  Rapamycin has traditionally been categorized as an inhibitor of mTORC1 
based on its mechanism of action.  However, other laboratories have disputed this 
finding, suggesting that rapamycin does inhibit mTORC2 after prolonged treatment in 
select cell lines, or that rapamycin induces mTORC2 activity due to mass action effect 
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(206,309).  A key substrate of mTORC2 is Akt, which is phosphorylated on Ser-473.  
We analyzed phospho-Akt in multiple cell lines after treatment with rapamycin and found 
that mTORC2 activity increased concomitant with increasing p73 levels.  We propose 
two models that explain rapamycin-mediated induction of p73: 1)  mTORC1 
phosphorylates p73 leading to its degradation, or  2) mTORC2 phosphorylates p73 
leading to its accumulation.  The experimental testing of these hypotheses in relation to 
the different p73 isoforms using co-immunoprecipitation- and RNAi-based metholdogy is 
ongoing in the laboratory. 
 In what subcellular compartment might mTOR phosphorylate p73?  Most studies 
of mTOR and its substrates have focused on cytoplasmic activity.  However, multiple 
reports have observed mTOR nuclear localization including in Rh30 cells (274,275).  The 
major known substrates of mTOR are restricted to the cytoplasm, and the identity of 
potential nuclear targets of mTOR remain unknown (275).  Work by Sabatini and 
colleagues showed that mTOR can localize to perinuclear vesicles upon activation (277).  
As described in Chapter I, p73 contains a NLS and a NES and has been detected in the 
cytoplasm where it interacts with the tumor suppressor WWOX (273).  Interestingly, p73 
has also been detected in a cytoplasmic perinuclear compartment (278,279).  We have 
observed gene expression changes implying nuclear localization of p73 after rapamycin 
treatment.  Thus, we hypothesize that mTOR phosphorylates p73 in the cytoplasm or 
perinuclear region, regulating shuttling of p73 to the nucleus, protein stability, and/or 
transcriptional activity.  Alternatively, in some cell types p73 may be a substrate for 
nuclear mTOR. 
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 p73 associates with distinct subnuclear compartments (278).  For example, c-abl 
phosphorylates p73 resulting in increased association with a nuclear matrix (or insoluble 
fraction) (278,279).  p73 is also associated with PML Organizing Bodies (PODs), regions 
of the nucleus where transcription factors can interact with cofactors and modifying 
proteins (278).  We have observed p73 in the insoluble nuclear fraction of cell lysates.  It 
would be of interest to determine whether rapamycin alters p73 cytoplasmic:nuclear 
distribution and p73 sub-nuclear distribution, and whether these distributions (or the mere 
phosphorylation of p73) results in changes in p73 protein stability. 
 Although we have detected phosphorylation of p73 by mTOR in vitro, and 
association of p73 with mTOR kinase in cells, there may be additional mechanisms by 
which mTOR regulates p73 levels and activity.  Most notably, mTOR may cause 
differential initiation of p73 protein translation.  The global regulation of cap-dependent 
translation is mediated by the mTORC1 signaling cascade (310).  IRES-dependent 
translation has been shown to be involved in numerous cellular events, including 
proliferation, differentiation, and stress responses, such as heat shock, DNA damage and 
starvation, apoptosis, and cell cycle regulation (311,312) - all events to which p53 family 
members have been linked.  Recent studies suggest that p53 family transcripts may have 
IRESs that would allow for cap-independent translation (209,211). Melino and colleagues 
have identified a motif that is implicated in IRES-dependent translation in the second 
exon of the p73 transcript, unique for p73 but not in p53 or p63 (211).  Furthermore, the 
fifth methionine in TAp73 contains a strong Kozak sequence that may be used for 
translation.  Therefore, cap-independent translation may play a role in the regulation of 
p73 by mTOR.  Finally, it is possible that mTOR alters the association between p73 and 
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other modifying enzymes or cofactors.  Our identification of an interaction between 
mTOR and p73, and our analyses of other mTOR-related kinases and p53 family 
members, lay the foundation for more detailed studies of the inter-connections between 
the mTOR and p53 family pathways. 
 The in vivo status of p73 was evaluated in 20 primary rhabdomyosarcomas at the 
RNA level (159).  Two tumors expressed TAp73 without detectable ∆Np73, whereas two 
tumors expressed ∆Np73 without detectable TAp73.  One tumor did not express p73, and 
fifteen tumors expressed both TAp73 and ∆Np73.  A variety of C-terminal isoforms were 
evident that were not identified in the study.  While it is clear that multiple isoforms of 
p73 RNA are being expressed in rhabdomyosarcomas, our analysis of the mTOR-p73 
signaling axis in rhabdomyosarcoma cell lines highlights the need for detection of p73 
protein in vivo.  In the Appendix, we generated new p73 antibodies and thoroughly 
evaluated commercial p73 antibodies for use in immunohistochemistry.  Correlative 
studies of p73 protein levels with phospho-S6 and phospho-Akt levels would help 
identify contexts in which the mTOR-p73 signaling axis is active.  In Chapter VII, we 
described the generation of a conditional p73 null mouse that could be used for follow-up 
analyses of p73 function downstream of mTOR signaling. 
 
Implications for cancer therapies and transcription factor signaling 
 We consider p73 to be particularly amenable for gene signature-based analysis.  
Although it is a p53 homolog with high expression levels in multiple tumor types, 
analysis of p73 in vivo is hampered by the large number of potential protein isoforms, 
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and the cross-reactivity and poor performance of many commercial antibodies.  p73 gene 
signatures are thus attractive alternative methods for assessment of p73 status in tumors.   
 Furthermore, a model is emerging whereby p73 is expressed with at least one of 
many potential inhibitors or modifiers that may prevent it from engaging apoptotic 
pathways.  Gene signatures can be thought of as collections of gene expression patterns 
or modules.  Each p73 inhibitor may selectively change p73 activity, resulting in an 
altered p73 'status'.  It may be possible to distinguish between relative levels of p73 
activity or 'status' in a tumor based on its resultant gene signature.  As a demonstration of 
this process, we identified four categories of p73 target genes in Chapter IV: genes 
transcriptionally activated by p73, genes transcriptionally repressed by p73, genes 
transcriptionally repressed by mTOR in a p73-dependent manner, and genes that are only 
expressed during concurrent mTOR inhibition and p73-depletion.  Then we detected 
these gene signature modules in multiple tumor cohorts.  By defining the p73 cistrome 
and creating a comprehensive resource of p73-bound genes and miRNAs, our work 
facilitates future analysis of p73 transcriptional programs. 
 Transcription factors can determine therapeutic outcome and thus can be viable 
predictors of clinical response as well as targets for cancer drug development.  In order to 
understand how transcription factor signaling predicts patient response or can be 
modified to benefit the patient, it will be necessary to understand the mechanisms by 
which cellular stresses modify transcriptional responses.  We have presented a model in 
which upstream signals converge on a transcription factor, causing increased occupancy 
at selective binding sites.  This model highlights the multiple layers of regulation that 
ultimately allow for exquisite control of gene expression. 
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 Many strategies to identify chemotherapy targets have focused on a 'druggable' 
part of the genome that is amenable to conventional small-molecule screening but does 
not include transcription factors.  We have developed an approach to identify 'druggable' 
signaling pathways upstream of transcription factors, identifying and studying mTOR 
inhibitors such as rapamycin and metformin that modulate p73 (144).  Other agents 
identified in our gene signature-based screen are also potent activators of p73, such as 
cyclooxygenase that has subsequently been validated as a p73 inhibitor by Irwin and 
colleagues (313).  The advantage to using a gene signature as a readout of a complex 
cellular change lies not only in the ability to connect pathways, but also in the detection 
of signaling modules that can stratify tumors into clinically relevant subtypes.  From this 
prospect transcription factors are no longer intractable therapeutic targets, but instead are 
utilized for their high degree of 'connectivity'. 
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APPENDIX A 
 
GENERATION AND CHARACTERIZATION OF P73 ANTIBODIES 
 
 p73 exists as an array of protein isoforms due to alternative splicing and the 
presence of a cryptic promoter.  These isoforms are a manifestation of its role as a node 
in a signaling network, a node that can connect multiple inputs into multiple outputs and 
thus requires a high degree of structural complexity.  However, analysis of p73 isoforms, 
and indeed of p73 in general, is made difficult by a lack of robust and isoform-specific 
p73 antibodies.  Most p73 isoforms have only been detected at the RNA level in vivo, 
thus their functional significance is unknown. 
 We provided insight to this issue by asking three questions:  1) Are commercially 
available p73 antibodies specific or do they cross-react with p53 or p63?  2) Are there 
adequate antibodies to differentiate the various p73 isoforms, in particular those 
containing the N-terminal transactivation domain?  3) Can p73 antibodies be used for in 
vivo detection of p73 protein?  As described below, we developed a rigorous system for 
testing commercial p73 antibodies, and generated new ∆N-specific p73 antibodies that 
are more robust than their commercial counterparts.  We also found that the commonly 
used p63 antibody, 4A4, can cross-react with p73, which has implications for many 
studies in the p63 field. 
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N- and C-terminal p73 antibodies 
 We assessed antibody specificity by ectopic expression of p63 and p73 isoforms 
in H1299 lung carcinoma cells that do not express detectable levels of endogenous p53 
family proteins.  p73 cDNAs were subcloned into the pcDNA3 vector and expressed as 
hemagluttinin (HA)-tagged TAp73α, TAp73β, TAp73γ, TAp73δ, TAp73ε, ∆Np73α, or 
∆Np73β.  p63 cDNAs were subcloned into the pCEP4 vector and expressed as untagged 
TAp63γ or ∆Np63α.  We generated protein lysates containing abundant levels of each of 
these protein isoforms, and immobilized them on Western blots.  We fixed parallel 
cultures of engineered H1299 cells with formalin, and created paraffin-embedded cell 
pellets that we used to make a cell/tissue microarray (p73 C/TMA).  This C/TMA 
contains punches from H1299:p73 cell blocks, in addition to formalin-fixed, paraffin-
embedded cancer cell lines and punches from human tumors (see Figure A1 for C/TMA 
map).  Our parallel approaches allowed us to screen p73 antibodies by Western, 
immunohistochemistry (IHC), and immunofluorescence (IF).  The assessment of p73 
antibodies by Western is exemplified by Figure A2; the p73 antibody Ab4 was highly 
specific for the α and β C-terminal isoforms of p73. 
 Several p73 RNA isoforms are expressed at low levels in normal cell types 
(137,314,315).  Our over-expression approach allowed us to obtain information about the 
specificity and sensitivity of antibodies for these isoforms.  We first tested the TA and 
∆N classes of p73 proteins.   
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Figure A1: Map of C/TMA used for antibody screening. H1299 lysates expressing the indicated
p63 or p73 isoforms, cell lines (M = treated with methanol vehicle, R = treated with 40 nM
rapamycin for 24 h), and a tongue squamous cell carcinoma are represented on the block in triplicate.
Subsequent versions of the p73 C/TMA (similar to the above) were constructed by Tracy Triplett and
Kimberly Johnson.
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Figure A2: Western blot analysis of Ab4 reactivity against p63 and p73 isoforms.
Lysates from H1299 cells transiently transfected with the indicated vectors (control or
expressing p63 or p73 isoforms) were analyzed by Western blot. An antibody targeting C-
terminal domains was assessed. This antibody, Ab4, is a cocktail of three monoclonal
antibodies that recognize domains specific to  or  C-terminal domains. The blue bars
indicate the molecular weight marker (82 kDa = top, 64 kDa = cross, 49 kDa = bottom
mark). Western blot analysis was performed by Tracy Triplett.
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In Chapters III-V we focused our studies on the TAp73 isoforms, because these isoforms 
were shown to have potent transactivation capability (137).  Based on our results, future 
studies on the impact of the mTOR pathway on ∆Np73 are warranted.  We therefore 
tested the ability of commercial antibodies, raised against N-terminal epitopes, to 
distinguish between TAp73 and ∆Np73. 
 As shown in Figure A3, two commercial antibodies were specific for TAp73 by 
Western blot: A300-126A (Bethyl) and IMG-246 (Imgenex).  IMG-246 generated no 
detectable signal when tested by IHC, however there were other commercially available 
antibodies that were specific for TAp73 by IHC (Bethyl-IHC and H-79).  As the 
experiments described in this Appendix were underway, there was only one 
commercially available antibody against the ∆Np73-specific epitope (clone 38C674; 
available through either Calbiochem or Imgenex).  This antibody was specific but only 
weakly detected ∆Np73α and ∆Np73β (Figure A3).  Detection was significantly 
hampered by the presence of a non-specific cross-reacting protein that migrates slightly 
slower than ∆Np73α (Figure A3). 
 Because of the apparent deficiency in ∆Np73-specific antibodies, we contracted 
with two groups to generate new antibodies in both mice (the Vanderbilt Monoclonal 
Antibody Core) and rabbits (Bethyl Laboratories).  Animals were immunized with a 
peptide containing unique residues at the N-terminus of ∆Np73 (MLYVGDPARHLA).  
We used our over-expression screening system to test polyclonal sera and monoclonal 
supernatants during the production process by both Western blot and IHC.   
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Figure A3: Western blot analysis of A300, 38C674, and IMG-246
reactivity against p63 and p73 isoforms. Lysates from H1299 cells
transiently transfected with the indicated vectors (control or
expressing p63 or p73 isoforms) were analyzed by Western blot.
Three antibodies targeting N-terminal domains were assessed: A300
(top panel, anti-TAp73), 38C674 (middle panel, anti-Np73), and
IMG-246 (bottom panel, anti-TAp73). The red arrowheads show the
locations of ∆Np73α and ∆Np73β. Additional Westerns were
performed to confirm lack of reactivity of A300 and IMG-246 with
TAp63. Western blot analysis was performed by Tracy Triplett.
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Polyclonal mouse and rabbit antibodies were highly specific for ∆Np73 protein isoforms 
by Western blot (Figure A4).  While polyclonal mouse antibodies were also specific and 
robust by IHC, polyclonal rabbit antibody did not give any signal by IHC. 
 We repeatedly attempted to generate monoclonal mouse antibodies but were 
unsuccessful, only polyclonal antibodies were able to detect ∆Np73 protein.  Therefore, 
we terminally bled the remaining mice to collect ~2 mls of antibody from each mouse, 
representing a limited supply of antibody that could be used at 1:1000 for Western 
blotting.  TAp73-specific polyclonal mouse antibodies were similarly generated for 
comparison studies of the two isoforms (data not shown).  The polyclonal antibodies that 
were collected are listed in Table A1. 
 
Cross-reactivity of pan-p63 and p73 antibodies 
 As shown in Figures A2 and A3, N- and C-terminal p73 antibodies are highly 
specific for the appropriate isoforms of p73, and do not cross-react with p63.  However, 
p63 and p73 only share 30% sequence identity at the N-terminus (Table 1).  In contrast, 
p63/p73 homology is 87% in the DNA-binding domain (Table 1).  Therefore we assessed 
the reactivity of pan-p63 and pan-p73 antibodies, raised against DNA-binding domain 
epitopes, with p63 and p73 proteins.  Interestingly, the pan-p73 antibody (IMG-259) 
detected p63 isoforms, and the pan-p63 antibody (4A4) detected p73 isoforms (Figure 
A5). 
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Figure A4: Assessment of custom polyclonal antibodies by Western blot.
Antibodies were generated against a peptide specific to the N-terminus of
Np73 isoforms only. Both rabbit (top panel) and mouse (bottom panel)
polyclonal antibodies were used to probe Western blots. Westerns blotting
was used to analyze lysates from H1299 cells transiently transfected with
vectors, either control or expressing p63 or p73 isoforms as indicated.
Western analysis with mouse polyclonal antibodies was performed by Tracy
Triplett.
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Figure A5: Western blot analysis of 4A4 and IMG-259 reactivity against p63 and
p73 isoforms. Lysates from H1299 cells transiently transfected with vectors
(expressing the indicated p63 or p73 isoforms) were analyzed by Western blot. Two
antibodies recognizing epitopes in the DNA-binding domains were assessed: 4A4
(top panel, anti-p63) and IMG-259 (bottom panel, anti-p73). Blue bars indicate
molecular weight markers (cross = 64 kDa). Western analysis was perfomed by
Tracy Triplett.
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 These results are particularly notable for the p63 antibody, 4A4, as this antibody 
has been widely used to study p63.  Many studies were performed when there were fewer 
commercially available alternatives for detection of p63 protein, due in part to the 
robustness of 4A4.  The cross-reactivity of 4A4 with p73 thus has potential wide-ranging 
implications, particularly for studies of p63 and p73 correlative expression in human 
tumors.  Of note, we tested 4A4 by IHC, and again saw cross-reactivity with p73 protein. 
 
Immunofluorescence analyses 
 We assessed the ability of commercially available antibodies to detect p73 by IF, 
using paraffin-embedded cell blocks as above.  TAp73-specific antibodies (Bethyl-IHC 
and IMG-246), a ∆Np73-specific antibody (38C674), and a pan-p73 antibody (IMG-259) 
all detected only the appropriate p73 isoforms and did not cross-react with p63 (Figure 
A6A).  C-terminal p73 antibodies that preferentially recognize α or β isoforms 
(components of the Ab4 monoclonal antibody cocktail) were also relatively specific for 
either p73α or p73β respectively (Figure A6B).  We assessed endogenous p73 in BPH 
prostate cells grown on glass coverslips and fixed with paraformaldehyde.  The IMG-259 
antibody was positive by IF in BPH nuclei, and the signal both increased after rapamycin 
treatment and correlated with expression of a p73 cofactor, YAP (Figure A7). 
 Thus, the results presented above have significant implications for a variety of 
techniques and methods that analyze members of the large collection of p53 family 
proteins.  We propose re-evaluation of studies that relied on 4A4 or IMG-259, 
particularly IHC and IF studies.  p63 and p73 antibodies, particularly those that recognize 
the DNA-binding domain, should be carefully evaluated for cross-reactivity.  
211 
 
212 
 
213 
 
REFERENCES 
 
1. Babu, M. M., Luscombe, N. M., Aravind, L., Gerstein, M., and Teichmann, S. A. 
(2004) Current opinion in structural biology 14(3), 283-291 
2. Wilson, D., Charoensawan, V., Kummerfeld, S. K., and Teichmann, S. A. (2008) 
Nucleic acids research 36(Database issue), D88-92 
3. Mees, C., Nemunaitis, J., and Senzer, N. (2009) Cancer gene therapy 16(2), 103-
112 
4. Krueger, C., and Osborne, C. S. (2006) Trends Genet 22(12), 637-639 
5. Fullwood, M. J., and Ruan, Y. (2009) Journal of cellular biochemistry 107(1), 30-
39 
6. Xu, M., and Cook, P. R. (2008) The Journal of cell biology 181(4), 615-623 
7. Xu, M., and Cook, P. R. (2008) Biochimica et biophysica acta 1783(11), 2155-
2160 
8. Odom, D. T., Dowell, R. D., Jacobsen, E. S., Gordon, W., Danford, T. W., 
MacIsaac, K. D., Rolfe, P. A., Conboy, C. M., Gifford, D. K., and Fraenkel, E. 
(2007) Nature genetics 39(6), 730-732 
9. Wilson, M. D., Barbosa-Morais, N. L., Schmidt, D., Conboy, C. M., Vanes, L., 
Tybulewicz, V. L., Fisher, E. M., Tavare, S., and Odom, D. T. (2008) Science 
322(5900), 434-438 
10. Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., and 
Yamanaka, S. (2007) Cell 131(5), 861-872 
11. Kocaefe, Y. C., Israeli, D., Ozguc, M., Danos, O., and Garcia, L. (2005) 
Experimental cell research 308(2), 300-308 
12. Cretekos, C. J., Wang, Y., Green, E. D., Martin, J. F., Rasweiler, J. J. t., and 
Behringer, R. R. (2008) Genes & development 22(2), 141-151 
13. Yang, A., Zhu, Z., Kapranov, P., McKeon, F., Church, G. M., Gingeras, T. R., 
and Struhl, K. (2006) Molecular cell 24(4), 593-602 
14. Johnson, D. S., Li, W., Gordon, D. B., Bhattacharjee, A., Curry, B., Ghosh, J., 
Brizuela, L., Carroll, J. S., Brown, M., Flicek, P., Koch, C. M., Dunham, I., 
Bieda, M., Xu, X., Farnham, P. J., Kapranov, P., Nix, D. A., Gingeras, T. R., 
Zhang, X., Holster, H., Jiang, N., Green, R. D., Song, J. S., McCuine, S. A., 
Anton, E., Nguyen, L., Trinklein, N. D., Ye, Z., Ching, K., Hawkins, D., Ren, B., 
214 
 
Scacheri, P. C., Rozowsky, J., Karpikov, A., Euskirchen, G., Weissman, S., 
Gerstein, M., Snyder, M., Yang, A., Moqtaderi, Z., Hirsch, H., Shulha, H. P., Fu, 
Y., Weng, Z., Struhl, K., Myers, R. M., Lieb, J. D., and Liu, X. S. (2008) Genome 
research 18(3), 393-403 
15. Cawley, S., Bekiranov, S., Ng, H. H., Kapranov, P., Sekinger, E. A., Kampa, D., 
Piccolboni, A., Sementchenko, V., Cheng, J., Williams, A. J., Wheeler, R., Wong, 
B., Drenkow, J., Yamanaka, M., Patel, S., Brubaker, S., Tammana, H., Helt, G., 
Struhl, K., and Gingeras, T. R. (2004) Cell 116(4), 499-509 
16. Johnson, D. S., Mortazavi, A., Myers, R. M., and Wold, B. (2007) Science 
316(5830), 1497-1502 
17. Wingender, E., Dietze, P., Karas, H., and Knuppel, R. (1996) Nucleic acids 
research 24(1), 238-241 
18. Robertson, A. G., Bilenky, M., Tam, A., Zhao, Y., Zeng, T., Thiessen, N., Cezard, 
T., Fejes, A. P., Wederell, E. D., Cullum, R., Euskirchen, G., Krzywinski, M., 
Birol, I., Snyder, M., Hoodless, P. A., Hirst, M., Marra, M. A., and Jones, S. J. 
(2008) Genome research 18(12), 1906-1917 
19. Schones, D. E., and Zhao, K. (2008) Nat Rev Genet 9(3), 179-191 
20. Bernstein, B. E., Mikkelsen, T. S., Xie, X., Kamal, M., Huebert, D. J., Cuff, J., 
Fry, B., Meissner, A., Wernig, M., Plath, K., Jaenisch, R., Wagschal, A., Feil, R., 
Schreiber, S. L., and Lander, E. S. (2006) Cell 125(2), 315-326 
21. Lupien, M., Eeckhoute, J., Meyer, C. A., Wang, Q., Zhang, Y., Li, W., Carroll, J. 
S., Liu, X. S., and Brown, M. (2008) Cell 132(6), 958-970 
22. Blandino, G., and Dobbelstein, M. (2004) Cell cycle (Georgetown, Tex 3(7), 886-
894 
23. Moll, U. M., and Slade, N. (2004) Mol Cancer Res 2(7), 371-386 
24. Bjorkqvist, A. M., Husgafvel-Pursiainen, K., Anttila, S., Karjalainen, A., 
Tammilehto, L., Mattson, K., Vainio, H., and Knuutila, S. (1998) Genes, 
chromosomes & cancer 22(1), 79-82 
25. Hibi, K., Trink, B., Patturajan, M., Westra, W. H., Caballero, O. L., Hill, D. E., 
Ratovitski, E. A., Jen, J., and Sidransky, D. (2000) Proc Natl Acad Sci U S A 
97(10), 5462-5467 
26. Massion, P. P., Taflan, P. M., Jamshedur Rahman, S. M., Yildiz, P., Shyr, Y., 
Edgerton, M. E., Westfall, M. D., Roberts, J. R., Pietenpol, J. A., Carbone, D. P., 
and Gonzalez, A. L. (2003) Cancer Res 63(21), 7113-7121 
215 
 
27. Yang, A., Schweitzer, R., Sun, D., Kaghad, M., Walker, N., Bronson, R. T., 
Tabin, C., Sharpe, A., Caput, D., Crum, C., and McKeon, F. (1999) Nature 
398(6729), 714-718 
28. Yang, A., Walker, N., Bronson, R., Kaghad, M., Oosterwegel, M., Bonnin, J., 
Vagner, C., Bonnet, H., Dikkes, P., Sharpe, A., McKeon, F., and Caput, D. (2000) 
Nature 404(6773), 99-103 
29. Yang, A., Kaghad, M., Wang, Y., Gillett, E., Fleming, M. D., Dotsch, V., 
Andrews, N. C., Caput, D., and McKeon, F. (1998) Molecular cell 2(3), 305-316 
30. Stiewe, T., and Putzer, B. M. (2000) Nature genetics 26(4), 464-469 
31. Agami, R., Blandino, G., Oren, M., and Shaul, Y. (1999) Nature 399(6738), 809-
813 
32. Gong, J. G., Costanzo, A., Yang, H. Q., Melino, G., Kaelin, W. G., Jr., Levrero, 
M., and Wang, J. Y. (1999) Nature 399(6738), 806-809 
33. Jost, C. A., Marin, M. C., and Kaelin, W. G., Jr. (1997) Nature 389(6647), 191-
194 
34. Yuan, Z. M., Shioya, H., Ishiko, T., Sun, X., Gu, J., Huang, Y. Y., Lu, H., 
Kharbanda, S., Weichselbaum, R., and Kufe, D. (1999) Nature 399(6738), 814-
817 
35. Murray-Zmijewski, F., Lane, D. P., and Bourdon, J. C. (2006) Cell Death Differ 
13(6), 962-972 
36. Bourdon, J. C., Fernandes, K., Murray-Zmijewski, F., Liu, G., Diot, A., 
Xirodimas, D. P., Saville, M. K., and Lane, D. P. (2005) Genes & development 
19(18), 2122-2137 
37. Deyoung, M. P., and Ellisen, L. W. (2007) Oncogene 26(36), 5169-5183 
38. Harms, K. L., and Chen, X. (2006) Cell Death Differ 13(6), 890-897 
39. Scoumanne, A., Harms, K. L., and Chen, X. (2005) Cancer biology & therapy 
4(11), 1178-1185 
40. Ghosh, A., Stewart, D., and Matlashewski, G. (2004) Mol Cell Biol 24(18), 7987-
7997 
41. Harms, K., Nozell, S., and Chen, X. (2004) Cell Mol Life Sci 61(7-8), 822-842 
42. Liu, G., Nozell, S., Xiao, H., and Chen, X. (2004) Mol Cell Biol 24(2), 487-501 
43. Oswald, C., and Stiewe, T. (2008) Cell cycle (Georgetown, Tex 7(12), 1726-1731 
216 
 
44. Brunner, H. G., Hamel, B. C., and Van Bokhoven, H. (2002) Journal of medical 
genetics 39(6), 377-381 
45. el-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., and Vogelstein, B. 
(1992) Nature genetics 1(1), 45-49 
46. Jordan, J. J., Menendez, D., Inga, A., Nourredine, M., Bell, D., and Resnick, M. 
A. (2008) PLoS genetics 4(6), e1000104 
47. Osada, M., Park, H. L., Nagakawa, Y., Yamashita, K., Fomenkov, A., Kim, M. S., 
Wu, G., Nomoto, S., Trink, B., and Sidransky, D. (2005) Mol Cell Biol 25(14), 
6077-6089 
48. Perez, C. A., Ott, J., Mays, D. J., and Pietenpol, J. A. (2007) Oncogene  
49. Liang, S. H., and Clarke, M. F. (1999) Oncogene 18(12), 2163-2166 
50. Inoue, T., Stuart, J., Leno, R., and Maki, C. G. (2002) J Biol Chem 277(17), 
15053-15060 
51. Chene, P. (2001) Oncogene 20(21), 2611-2617 
52. Qiao, F., and Bowie, J. U. (2005) Sci STKE 2005(286), re7 
53. Barrera, F. N., Poveda, J. A., Gonzalez-Ros, J. M., and Neira, J. L. (2003) J Biol 
Chem 278(47), 46878-46885 
54. Vilgelm, A., El-Rifai, W., and Zaika, A. (2008) Drug Resist Updat 11(4-5), 152-
163 
55. Zaika, A. I., Slade, N., Erster, S. H., Sansome, C., Joseph, T. W., Pearl, M., 
Chalas, E., and Moll, U. M. (2002) J Exp Med 196(6), 765-780 
56. Rocco, J. W., Leong, C. O., Kuperwasser, N., DeYoung, M. P., and Ellisen, L. W. 
(2006) Cancer Cell 9(1), 45-56 
57. Leong, C. O., Vidnovic, N., DeYoung, M. P., Sgroi, D., and Ellisen, L. W. (2007) 
The Journal of clinical investigation 117(5), 1370-1380 
58. Deyoung, M. P., Johannessen, C. M., Leong, C. O., Faquin, W., Rocco, J. W., and 
Ellisen, L. W. (2006) Cancer Res 66(19), 9362-9368 
59. Di Como, C. J., Gaiddon, C., and Prives, C. (1999) Mol Cell Biol 19(2), 1438-
1449 
60. Anensen, N., Oyan, A. M., Bourdon, J. C., Kalland, K. H., Bruserud, O., and 
Gjertsen, B. T. (2006) Clin Cancer Res 12(13), 3985-3992 
217 
 
61. Boldrup, L., Bourdon, J. C., Coates, P. J., Sjostrom, B., and Nylander, K. (2007) 
Eur J Cancer 43(3), 617-623 
62. Ebrahimi, M., Boldrup, L., Coates, P. J., Wahlin, Y. B., Bourdon, J. C., and 
Nylander, K. (2008) Oral oncology 44(2), 156-161 
63. McKeon, F., and Melino, G. (2007) Cell cycle (Georgetown, Tex 6(3), 229-232 
64. Mills, A. A. (2006) Curr Opin Genet Dev 16(1), 38-44 
65. Tomasini, R., Tsuchihara, K., Wilhelm, M., Fujitani, M., Rufini, A., Cheung, C. 
C., Khan, F., Itie-Youten, A., Wakeham, A., Tsao, M. S., Iovanna, J. L., Squire, 
J., Jurisica, I., Kaplan, D., Melino, G., Jurisicova, A., and Mak, T. W. (2008) 
Genes & development 22(19), 2677-2691 
66. Flores, E. R., Sengupta, S., Miller, J. B., Newman, J. J., Bronson, R., Crowley, D., 
Yang, A., McKeon, F., and Jacks, T. (2005) Cancer Cell 7(4), 363-373 
67. Keyes, W. M., Vogel, H., Koster, M. I., Guo, X., Qi, Y., Petherbridge, K. M., 
Roop, D. R., Bradley, A., and Mills, A. A. (2006) Proc Natl Acad Sci U S A 
103(22), 8435-8440 
68. Wolff, S., Talos, F., Palacios, G., Beyer, U., Dobbelstein, M., and Moll, U. M. 
(2009) Cell Death Differ  
69. Flores, E. R., Tsai, K. Y., Crowley, D., Sengupta, S., Yang, A., McKeon, F., and 
Jacks, T. (2002) Nature 416(6880), 560-564 
70. Senoo, M., Manis, J. P., Alt, F. W., and McKeon, F. (2004) Cancer Cell 6(1), 85-
89 
71. Jacobs, W. B., Kaplan, D. R., and Miller, F. D. (2006) Journal of neurochemistry 
97(6), 1571-1584 
72. Suh, E. K., Yang, A., Kettenbach, A., Bamberger, C., Michaelis, A. H., Zhu, Z., 
Elvin, J. A., Bronson, R. T., Crum, C. P., and McKeon, F. (2006) Nature 
444(7119), 624-628 
73. Bagchi, A., Papazoglu, C., Wu, Y., Capurso, D., Brodt, M., Francis, D., Bredel, 
M., Vogel, H., and Mills, A. A. (2007) Cell 128(3), 459-475 
74. Pluta, A., Nyman, U., Joseph, B., Robak, T., Zhivotovsky, B., and Smolewski, P. 
(2006) Leukemia 20(5), 757-766 
75. Zaika, A. I., and El-Rifai, W. (2006) Cell Death Differ 13(6), 935-940 
218 
 
76. Dominguez, G., Garcia, J. M., Pena, C., Silva, J., Garcia, V., Martinez, L., 
Maximiano, C., Gomez, M. E., Rivera, J. A., Garcia-Andrade, C., and Bonilla, F. 
(2006) J Clin Oncol 24(5), 805-815 
77. Irwin, M., Marin, M. C., Phillips, A. C., Seelan, R. S., Smith, D. I., Liu, W., 
Flores, E. R., Tsai, K. Y., Jacks, T., Vousden, K. H., and Kaelin, W. G., Jr. (2000) 
Nature 407(6804), 645-648 
78. Lissy, N. A., Davis, P. K., Irwin, M., Kaelin, W. G., and Dowdy, S. F. (2000) 
Nature 407(6804), 642-645 
79. Muller, M., Schleithoff, E. S., Stremmel, W., Melino, G., Krammer, P. H., and 
Schilling, T. (2006) Drug Resist Updat 9(6), 288-306 
80. Liu, S. S., Chan, K. Y., Cheung, A. N., Liao, X. Y., Leung, T. W., and Ngan, H. 
Y. (2006) Clin Cancer Res 12(13), 3922-3927 
81. Zhu, J., Jiang, J., Zhou, W., and Chen, X. (1998) Cancer Res 58(22), 5061-5065 
82. Smeenk, L., van Heeringen, S. J., Koeppel, M., van Driel, M. A., Bartels, S. J., 
Akkers, R. C., Denissov, S., Stunnenberg, H. G., and Lohrum, M. (2008) Nucleic 
acids research 36(11), 3639-3654 
83. Cui, R., Nguyen, T. T., Taube, J. H., Stratton, S. A., Feuerman, M. H., and 
Barton, M. C. (2005) J Biol Chem 280(47), 39152-39160 
84. Zheng, X., and Chen, X. (2001) FEBS Lett 489(1), 4-7 
85. Sasaki, Y., Ishida, S., Morimoto, I., Yamashita, T., Kojima, T., Kihara, C., 
Tanaka, T., Imai, K., Nakamura, Y., and Tokino, T. (2002) J Biol Chem 277(1), 
719-724 
86. Wei, C. L., Wu, Q., Vega, V. B., Chiu, K. P., Ng, P., Zhang, T., Shahab, A., 
Yong, H. C., Fu, Y., Weng, Z., Liu, J., Zhao, X. D., Chew, J. L., Lee, Y. L., 
Kuznetsov, V. A., Sung, W. K., Miller, L. D., Lim, B., Liu, E. T., Yu, Q., Ng, H. 
H., and Ruan, Y. (2006) Cell 124(1), 207-219 
87. Shaked, H., Shiff, I., Kott-Gutkowski, M., Siegfried, Z., Haupt, Y., and Simon, I. 
(2008) Cancer Res 68(23), 9671-9677 
88. Hearnes, J. M., Mays, D. J., Schavolt, K. L., Tang, L., Jiang, X., and Pietenpol, J. 
A. (2005) Mol Cell Biol 25(22), 10148-10158 
89. Zeng, X., Chen, L., Jost, C. A., Maya, R., Keller, D., Wang, X., Kaelin, W. G., 
Jr., Oren, M., Chen, J., and Lu, H. (1999) Mol Cell Biol 19(5), 3257-3266 
219 
 
90. Strano, S., Monti, O., Pediconi, N., Baccarini, A., Fontemaggi, G., Lapi, E., 
Mantovani, F., Damalas, A., Citro, G., Sacchi, A., Del Sal, G., Levrero, M., and 
Blandino, G. (2005) Molecular cell 18(4), 447-459 
91. Levy, D., Adamovich, Y., Reuven, N., and Shaul, Y. (2007) Cell Death Differ 
14(4), 743-751 
92. Strano, S., Munarriz, E., Rossi, M., Castagnoli, L., Shaul, Y., Sacchi, A., Oren, 
M., Sudol, M., Cesareni, G., and Blandino, G. (2001) J Biol Chem 276(18), 
15164-15173 
93. Urist, M., Tanaka, T., Poyurovsky, M. V., and Prives, C. (2004) Genes & 
development 18(24), 3041-3054 
94. Talos, F., Nemajerova, A., Flores, E. R., Petrenko, O., and Moll, U. M. (2007) 
Molecular cell 27(4), 647-659 
95. Shimodaira, H., Yoshioka-Yamashita, A., Kolodner, R. D., and Wang, J. Y. 
(2003) Proc Natl Acad Sci U S A 100(5), 2420-2425 
96. Budanov, A. V., and Karin, M. (2008) Cell 134(3), 451-460 
97. Irwin, M. S., Kondo, K., Marin, M. C., Cheng, L. S., Hahn, W. C., and Kaelin, W. 
G., Jr. (2003) Cancer Cell 3(4), 403-410 
98. Rosenbluth, J. M., and Pietenpol, J. A. (2008) Genes & development 22(19), 
2591-2595 
99. Bourdon, J. C. (2007) British journal of cancer 97(3), 277-282 
100. Beitzinger, M., Hofmann, L., Oswald, C., Beinoraviciute-Kellner, R., Sauer, M., 
Griesmann, H., Bretz, A. C., Burek, C., Rosenwald, A., and Stiewe, T. (2008) The 
EMBO journal 27(5), 792-803 
101. Guertin, D. A., and Sabatini, D. M. (2007) Cancer Cell 12(1), 9-22 
102. Mita, M. M., Mita, A., and Rowinsky, E. K. (2003) Clinical breast cancer 4(2), 
126-137 
103. Kim, D. H., Sarbassov, D. D., Ali, S. M., Latek, R. R., Guntur, K. V., Erdjument-
Bromage, H., Tempst, P., and Sabatini, D. M. (2003) Molecular cell 11(4), 895-
904 
104. Loewith, R., Jacinto, E., Wullschleger, S., Lorberg, A., Crespo, J. L., Bonenfant, 
D., Oppliger, W., Jenoe, P., and Hall, M. N. (2002) Molecular cell 10(3), 457-468 
220 
 
105. Pearce, L. R., Huang, X., Boudeau, J., Pawlowski, R., Wullschleger, S., Deak, M., 
Ibrahim, A. F., Gourlay, R., Magnuson, M. A., and Alessi, D. R. (2007) The 
Biochemical journal 405(3), 513-522 
106. Sarbassov, D. D., Ali, S. M., Kim, D. H., Guertin, D. A., Latek, R. R., Erdjument-
Bromage, H., Tempst, P., and Sabatini, D. M. (2004) Curr Biol 14(14), 1296-
1302 
107. Jung, C. H., Jun, C. B., Ro, S. H., Kim, Y. M., Otto, N. M., Cao, J., Kundu, M., 
and Kim, D. H. (2009) Molecular biology of the cell 20(7), 1992-2003 
108. Hosokawa, N., Hara, T., Kaizuka, T., Kishi, C., Takamura, A., Miura, Y., Iemura, 
S., Natsume, T., Takehana, K., Yamada, N., Guan, J. L., Oshiro, N., and 
Mizushima, N. (2009) Molecular biology of the cell 20(7), 1981-1991 
109. Garcia-Martinez, J. M., and Alessi, D. R. (2008) The Biochemical journal 416(3), 
375-385 
110. Levine, A. J., Feng, Z., Mak, T. W., You, H., and Jin, S. (2006) Genes & 
development 20(3), 267-275 
111. Sarbassov, D. D., Guertin, D. A., Ali, S. M., and Sabatini, D. M. (2005) Science 
307(5712), 1098-1101 
112. Shaw, R. J., Bardeesy, N., Manning, B. D., Lopez, L., Kosmatka, M., DePinho, R. 
A., and Cantley, L. C. (2004) Cancer Cell 6(1), 91-99 
113. Jones, K. T., Greer, E. R., Pearce, D., and Ashrafi, K. (2009) PLoS biology 7(3), 
e60 
114. Soukas, A. A., Kane, E. A., Carr, C. E., Melo, J. A., and Ruvkun, G. (2009) 
Genes & development 23(4), 496-511 
115. Guertin, D. A., Stevens, D. M., Saitoh, M., Kinkel, S., Crosby, K., Sheen, J. H., 
Mullholland, D. J., Magnuson, M. A., Wu, H., and Sabatini, D. M. (2009) Cancer 
Cell 15(2), 148-159 
116. Feng, Z., Hu, W., de Stanchina, E., Teresky, A. K., Jin, S., Lowe, S., and Levine, 
A. J. (2007) Cancer Res 67(7), 3043-3053 
117. Ellisen, L. W., Ramsayer, K. D., Johannessen, C. M., Yang, A., Beppu, H., 
Minda, K., Oliner, J. D., McKeon, F., and Haber, D. A. (2002) Molecular cell 
10(5), 995-1005 
118. Deyoung, M. P., Horak, P., Sofer, A., Sgroi, D., and Ellisen, L. W. (2008) Genes 
& development 22(2), 239-251 
221 
 
119. Lee, C. H., Inoki, K., Karbowniczek, M., Petroulakis, E., Sonenberg, N., Henske, 
E. P., and Guan, K. L. (2007) The EMBO journal 26(23), 4812-4823 
120. Mondesire, W. H., Jian, W., Zhang, H., Ensor, J., Hung, M. C., Mills, G. B., and 
Meric-Bernstam, F. (2004) Clin Cancer Res 10(20), 7031-7042 
121. Calabro, A., Tai, J., Allen, S. L., and Budman, D. R. (2008) Anti-cancer drugs 
19(7), 705-712 
122. Tam, K. H., Yang, Z. F., Lau, C. K., Lam, C. T., Pang, R. W., and Poon, R. T. 
(2009) Cancer letters 273(2), 201-209 
123. Shi, Y., Frankel, A., Radvanyi, L. G., Penn, L. Z., Miller, R. G., and Mills, G. B. 
(1995) Cancer Res 55(9), 1982-1988 
124. Mizushima, N., Levine, B., Cuervo, A. M., and Klionsky, D. J. (2008) Nature 
451(7182), 1069-1075 
125. Crighton, D., Wilkinson, S., O'Prey, J., Syed, N., Smith, P., Harrison, P. R., 
Gasco, M., Garrone, O., Crook, T., and Ryan, K. M. (2006) Cell 126(1), 121-134 
126. Tasdemir, E., Maiuri, M. C., Galluzzi, L., Vitale, I., Djavaheri-Mergny, M., 
D'Amelio, M., Criollo, A., Morselli, E., Zhu, C., Harper, F., Nannmark, U., 
Samara, C., Pinton, P., Vicencio, J. M., Carnuccio, R., Moll, U. M., Madeo, F., 
Paterlini-Brechot, P., Rizzuto, R., Szabadkai, G., Pierron, G., Blomgren, K., 
Tavernarakis, N., Codogno, P., Cecconi, F., and Kroemer, G. (2008) Nature cell 
biology 10(6), 676-687 
127. Wang, W., Kim, S. H., and El-Deiry, W. S. (2006) Proc Natl Acad Sci U S A 
103(29), 11003-11008 
128. Bell, H. S., Dufes, C., O'Prey, J., Crighton, D., Bergamaschi, D., Lu, X., 
Schatzlein, A. G., Vousden, K. H., and Ryan, K. M. (2007) The Journal of 
clinical investigation 117(4), 1008-1018 
129. Das, S., Nama, S., Antony, S., and Somasundaram, K. (2005) Cancer gene 
therapy 12(4), 417-426 
130. Oshima, Y., Sasaki, Y., Negishi, H., Idogawa, M., Toyota, M., Yamashita, T., 
Wada, T., Nagoya, S., Kawaguchi, S., Yamashita, T., and Tokino, T. (2007) 
Cancer biology & therapy 6(7), 1058-1066 
131. Barbieri, C. E., Tang, L. J., Brown, K. A., and Pietenpol, J. A. (2006) Cancer Res 
66(15), 7589-7597 
132. Boukamp, P., Petrussevska, R. T., Breitkreutz, D., Hornung, J., Markham, A., and 
Fusenig, N. E. (1988) The Journal of cell biology 106(3), 761-771 
222 
 
133. Chang, S. B., Miron, P., Miron, A., and Iglehart, J. D. (2007) The Journal of 
surgical research 138(1), 37-44 
134. Ventura, A., Meissner, A., Dillon, C. P., McManus, M., Sharp, P. A., Van Parijs, 
L., Jaenisch, R., and Jacks, T. (2004) Proc Natl Acad Sci U S A 101(28), 10380-
10385 
135. He, T. C., Zhou, S., da Costa, L. T., Yu, J., Kinzler, K. W., and Vogelstein, B. 
(1998) Proc Natl Acad Sci U S A 95(5), 2509-2514 
136. Niemantsverdriet, M., Vermeij, W. P., and Backendorf, C. (2005) Leukemia 
19(9), 1685-1686 
137. De Laurenzi, V., Costanzo, A., Barcaroli, D., Terrinoni, A., Falco, M., 
Annicchiarico-Petruzzelli, M., Levrero, M., and Melino, G. (1998) J Exp Med 
188(9), 1763-1768 
138. Szak, S. T., Mays, D., and Pietenpol, J. A. (2001) Mol Cell Biol 21(10), 3375-
3386 
139. Thedieck, K., Polak, P., Kim, M. L., Molle, K. D., Cohen, A., Jeno, P., 
Arrieumerlou, C., and Hall, M. N. (2007) PLoS ONE 2(11), e1217 
140. Spandidos, A., Wang, X., Wang, H., Dragnev, S., Thurber, T., and Seed, B. 
(2008) BMC genomics 9, 633 
141. Wang, X., and Seed, B. (2003) Nucleic acids research 31(24), e154 
142. Zhang, B., Kirov, S., and Snoddy, J. (2005) Nucleic acids research 33(Web 
Server issue), W741-748 
143. Lamb, J., Crawford, E. D., Peck, D., Modell, J. W., Blat, I. C., Wrobel, M. J., 
Lerner, J., Brunet, J. P., Subramanian, A., Ross, K. N., Reich, M., Hieronymus, 
H., Wei, G., Armstrong, S. A., Haggarty, S. J., Clemons, P. A., Wei, R., Carr, S. 
A., Lander, E. S., and Golub, T. R. (2006) Science 313(5795), 1929-1935 
144. Rosenbluth, J. M., Mays, D. J., Pino, M. F., Tang, L. J., and Pietenpol, J. A. 
(2008) Mol Cell Biol 28(19), 5951-5964 
145. Schavolt, K. L., and Pietenpol, J. A. (2007) Oncogene 26(42), 6125-6132 
146. Hoh, J., Jin, S., Parrado, T., Edington, J., Levine, A. J., and Ott, J. (2002) Proc 
Natl Acad Sci U S A 99(13), 8467-8472 
147. Bailey, T. L., and Elkan, C. (1995) Proceedings / ... International Conference on 
Intelligent Systems for Molecular Biology ; ISMB 3, 21-29 
223 
 
148. Ji, X., Li, W., Song, J., Wei, L., and Liu, X. S. (2006) Nucleic acids research 
34(Web Server issue), W551-554 
149. Wachtel, M., Dettling, M., Koscielniak, E., Stegmaier, S., Treuner, J., Simon-
Klingenstein, K., Buhlmann, P., Niggli, F. K., and Schafer, B. W. (2004) Cancer 
Res 64(16), 5539-5545 
150. Davicioni, E., Finckenstein, F. G., Shahbazian, V., Buckley, J. D., Triche, T. J., 
and Anderson, M. J. (2006) Cancer Res 66(14), 6936-6946 
151. Rhodes, D. R., Yu, J., Shanker, K., Deshpande, N., Varambally, R., Ghosh, D., 
Barrette, T., Pandey, A., and Chinnaiyan, A. M. (2004) Neoplasia (New York, N.Y 
6(1), 1-6 
152. De Pitta, C., Tombolan, L., Albiero, G., Sartori, F., Romualdi, C., Jurman, G., 
Carli, M., Furlanello, C., Lanfranchi, G., and Rosolen, A. (2006) Int J Cancer 
118(11), 2772-2781 
153. Davicioni, E., Anderson, M. J., Finckenstein, F. G., Lynch, J. C., Qualman, S. J., 
Shimada, H., Schofield, D. E., Buckley, J. D., Meyer, W. H., Sorensen, P. H., and 
Triche, T. J. (2009) The American journal of pathology 174(2), 550-564 
154. Hawkins, R. D., and Ren, B. (2006) Human molecular genetics 15 Spec No 1, 
R1-7 
155. Fontemaggi, G., Kela, I., Amariglio, N., Rechavi, G., Krishnamurthy, J., Strano, 
S., Sacchi, A., Givol, D., and Blandino, G. (2002) J Biol Chem 277(45), 43359-
43368 
156. Osada, M., Park, H. L., Nagakawa, Y., Begum, S., Yamashita, K., Wu, G., Kim, 
M. S., Trink, B., and Sidransky, D. (2006) Biochem Biophys Res Commun 339(4), 
1120-1128 
157. Vigano, M. A., Lamartine, J., Testoni, B., Merico, D., Alotto, D., Castagnoli, C., 
Robert, A., Candi, E., Melino, G., Gidrol, X., and Mantovani, R. (2006) The 
EMBO journal 25(21), 5105-5116 
158. Zaika, A. I., Kovalev, S., Marchenko, N. D., and Moll, U. M. (1999) Cancer Res 
59(13), 3257-3263 
159. Cam, H., Griesmann, H., Beitzinger, M., Hofmann, L., Beinoraviciute-Kellner, 
R., Sauer, M., Huttinger-Kirchhof, N., Oswald, C., Friedl, P., Gattenlohner, S., 
Burek, C., Rosenwald, A., and Stiewe, T. (2006) Cancer Cell 10(4), 281-293 
160. Dominguez, G., Silva, J. M., Silva, J., Garcia, J. M., Sanchez, A., Navarro, A., 
Gallego, I., Provencio, M., Espana, P., and Bonilla, F. (2001) Breast cancer 
research and treatment 66(3), 183-190 
224 
 
161. Bell, H. S., and Ryan, K. M. (2007) Cell cycle (Georgetown, Tex 6(16), 1995-
2000 
162. Amin, A. R., Paul, R. K., Thakur, V. S., and Agarwal, M. L. (2007) Cancer Res 
67(12), 5617-5621 
163. Melino, G., Bernassola, F., Ranalli, M., Yee, K., Zong, W. X., Corazzari, M., 
Knight, R. A., Green, D. R., Thompson, C., and Vousden, K. H. (2004) J Biol 
Chem 279(9), 8076-8083 
164. Hieronymus, H., Lamb, J., Ross, K. N., Peng, X. P., Clement, C., Rodina, A., 
Nieto, M., Du, J., Stegmaier, K., Raj, S. M., Maloney, K. N., Clardy, J., Hahn, W. 
C., Chiosis, G., and Golub, T. R. (2006) Cancer Cell 10(4), 321-330 
165. Wei, G., Twomey, D., Lamb, J., Schlis, K., Agarwal, J., Stam, R. W., Opferman, 
J. T., Sallan, S. E., den Boer, M. L., Pieters, R., Golub, T. R., and Armstrong, S. 
A. (2006) Cancer Cell 10(4), 331-342 
166. Zhao, R., Gish, K., Murphy, M., Yin, Y., Notterman, D., Hoffman, W. H., Tom, 
E., Mack, D. H., and Levine, A. J. (2000) Genes & development 14(8), 981-993 
167. Akerblad, P., Mansson, R., Lagergren, A., Westerlund, S., Basta, B., Lind, U., 
Thelin, A., Gisler, R., Liberg, D., Nelander, S., Bamberg, K., and Sigvardsson, M. 
(2005) Physiological genomics 23(2), 206-216 
168. De Brabander, M., De May, J., Joniau, M., and Geuens, G. (1977) Cell biology 
international reports 1(2), 177-183 
169. Tishler, R. B., Lamppu, D. M., Park, S., and Price, B. D. (1995) Cancer Res 
55(24), 6021-6025 
170. Zeng, X., Yan, T., Schupp, J. E., Seo, Y., and Kinsella, T. J. (2007) Clin Cancer 
Res 13(4), 1315-1321 
171. Liu, G., and Chen, X. (2002) Oncogene 21(47), 7195-7204 
172. Zakikhani, M., Dowling, R., Fantus, I. G., Sonenberg, N., and Pollak, M. (2006) 
Cancer Res 66(21), 10269-10273 
173. Esumi, H., Lu, J., Kurashima, Y., and Hanaoka, T. (2004) Cancer Sci 95(8), 685-
690 
174. Wang, H., Kubica, N., Ellisen, L. W., Jefferson, L. S., and Kimball, S. R. (2006) J 
Biol Chem 281(51), 39128-39134 
175. Ogata, H., Goto, S., Fujibuchi, W., and Kanehisa, M. (1998) Bio Systems 47(1-2), 
119-128 
225 
 
176. Avruch, J., Lin, Y., Long, X., Murthy, S., and Ortiz-Vega, S. (2005) Current 
opinion in clinical nutrition and metabolic care 8(1), 67-72 
177. Yu, K., Toral-Barza, L., Discafani, C., Zhang, W. G., Skotnicki, J., Frost, P., and 
Gibbons, J. J. (2001) Endocrine-related cancer 8(3), 249-258 
178. Vander Haar, E., Lee, S. I., Bandhakavi, S., Griffin, T. J., and Kim, D. H. (2007) 
Nature cell biology 9(3), 316-323 
179. Gadir, N., Jackson, D. N., Lee, E., and Foster, D. A. (2007) Oncogene  
180. Heitman, J., Movva, N. R., and Hall, M. N. (1991) Science 253(5022), 905-909 
181. Runnebaum, I. B., Nagarajan, M., Bowman, M., Soto, D., and Sukumar, S. (1991) 
Proc Natl Acad Sci U S A 88(23), 10657-10661 
182. Hosoi, H., Dilling, M. B., Shikata, T., Liu, L. N., Shu, L., Ashmun, R. A., 
Germain, G. S., Abraham, R. T., and Houghton, P. J. (1999) Cancer Res 59(4), 
886-894 
183. Feng, Z., Zhang, H., Levine, A. J., and Jin, S. (2005) Proc Natl Acad Sci U S A 
102(23), 8204-8209 
184. Anderson, R. F., Patel, K. B., Reghebi, K., and Hill, S. A. (1989) British journal 
of cancer 60(2), 193-197 
185. Crighton, D., O'Prey, J., Bell, H. S., and Ryan, K. M. (2007) Cell Death Differ  
186. Rubinsztein, D. C., Gestwicki, J. E., Murphy, L. O., and Klionsky, D. J. (2007) 
Nat Rev Drug Discov 6(4), 304-312 
187. Cam, H., Balciunaite, E., Blais, A., Spektor, A., Scarpulla, R. C., Young, R., 
Kluger, Y., and Dynlacht, B. D. (2004) Molecular cell 16(3), 399-411 
188. Dengjel, J., Schoor, O., Fischer, R., Reich, M., Kraus, M., Muller, M., 
Kreymborg, K., Altenberend, F., Brandenburg, J., Kalbacher, H., Brock, R., 
Driessen, C., Rammensee, H. G., and Stevanovic, S. (2005) Proc Natl Acad Sci U 
S A 102(22), 7922-7927 
189. Budanov, A. V., Sablina, A. A., Feinstein, E., Koonin, E. V., and Chumakov, P. 
M. (2004) Science 304(5670), 596-600 
190. Hollander, M. C., Sheikh, M. S., Bulavin, D. V., Lundgren, K., Augeri-
Henmueller, L., Shehee, R., Molinaro, T. A., Kim, K. E., Tolosa, E., Ashwell, J. 
D., Rosenberg, M. P., Zhan, Q., Fernandez-Salguero, P. M., Morgan, W. F., 
Deng, C. X., and Fornace, A. J., Jr. (1999) Nature genetics 23(2), 176-184 
226 
 
191. Blint, E., Phillips, A. C., Kozlov, S., Stewart, C. L., and Vousden, K. H. (2002) 
Proc Natl Acad Sci U S A 99(6), 3529-3534 
192. Masuda, Y., Futamura, M., Kamino, H., Nakamura, Y., Kitamura, N., Ohnishi, S., 
Miyamoto, Y., Ichikawa, H., Ohta, T., Ohki, M., Kiyono, T., Egami, H., Baba, H., 
and Arakawa, H. (2006) Journal of human genetics 51(8), 652-664 
193. Hwang, B. J., Ford, J. M., Hanawalt, P. C., and Chu, G. (1999) Proc Natl Acad 
Sci U S A 96(2), 424-428 
194. Chakravarthy, A., Nicholson, B., Kelley, M., Beauchamp, D., Johnson, D., 
Frexes-Steed, M., Simpson, J., Shyr, Y., and Pietenpol, J. (2000) Clinical breast 
cancer 1(1), 68-71 
195. Lin, K. W., Nam, S. Y., Toh, W. H., Dulloo, I., and Sabapathy, K. (2004) 
Neoplasia (New York, N.Y 6(5), 546-557 
196. Lamb, J. (2007) Nature reviews 7(1), 54-60 
197. Jones, E. V., Dickman, M. J., and Whitmarsh, A. J. (2007) The Biochemical 
journal 405(3), 617-623 
198. Sanchez-Prieto, R., Sanchez-Arevalo, V. J., Servitja, J. M., and Gutkind, J. S. 
(2002) Oncogene 21(6), 974-979 
199. Toh, W. H., Siddique, M. M., Boominathan, L., Lin, K. W., and Sabapathy, K. 
(2004) J Biol Chem 279(43), 44713-44722 
200. Wan, Y. Y., and DeGregori, J. (2003) Immunity 18(3), 331-342 
201. Basu, S., Totty, N. F., Irwin, M. S., Sudol, M., and Downward, J. (2003) 
Molecular cell 11(1), 11-23 
202. Buzzai, M., Jones, R. G., Amaravadi, R. K., Lum, J. J., DeBerardinis, R. J., Zhao, 
F., Viollet, B., and Thompson, C. B. (2007) Cancer Res 67(14), 6745-6752 
203. Hosoda, M., Ozaki, T., Miyazaki, K., Hayashi, S., Furuya, K., Watanabe, K., 
Nakagawa, T., Hanamoto, T., Todo, S., and Nakagawara, A. (2005) Oncogene 
24(48), 7156-7169 
204. Munarriz, E., Barcaroli, D., Stephanou, A., Townsend, P. A., Maisse, C., 
Terrinoni, A., Neale, M. H., Martin, S. J., Latchman, D. S., Knight, R. A., Melino, 
G., and De Laurenzi, V. (2004) Mol Cell Biol 24(24), 10593-10610 
205. Apweiler, R., Attwood, T. K., Bairoch, A., Bateman, A., Birney, E., Biswas, M., 
Bucher, P., Cerutti, L., Corpet, F., Croning, M. D., Durbin, R., Falquet, L., 
Fleischmann, W., Gouzy, J., Hermjakob, H., Hulo, N., Jonassen, I., Kahn, D., 
Kanapin, A., Karavidopoulou, Y., Lopez, R., Marx, B., Mulder, N. J., Oinn, T. 
227 
 
M., Pagni, M., Servant, F., Sigrist, C. J., and Zdobnov, E. M. (2000) 
Bioinformatics (Oxford, England) 16(12), 1145-1150 
206. Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J. H., Hsu, P. P., Bagley, A. F., 
Markhard, A. L., and Sabatini, D. M. (2006) Molecular cell 22(2), 159-168 
207. Wan, X., Harkavy, B., Shen, N., Grohar, P., and Helman, L. J. (2007) Oncogene 
26(13), 1932-1940 
208. Sun, S. Y., Rosenberg, L. M., Wang, X., Zhou, Z., Yue, P., Fu, H., and Khuri, F. 
R. (2005) Cancer Res 65(16), 7052-7058 
209. Ray, P. S., Grover, R., and Das, S. (2006) EMBO reports 7(4), 404-410 
210. Yang, D. Q., Halaby, M. J., and Zhang, Y. (2006) Oncogene 25(33), 4613-4619 
211. Sayan, A. E., Roperch, J. P., Sayan, B. S., Rossi, M., Pinkoski, M. J., Knight, R. 
A., Willis, A. E., and Melino, G. (2007) Annals of the New York Academy of 
Sciences 1095, 315-324 
212. Yu, J., and Henske, E. P. (2006) Cancer Res 66(19), 9461-9466 
213. Murray-Zmijewski, F., Slee, E. A., and Lu, X. (2008) Nat Rev Mol Cell Biol 9(9), 
702-712 
214. Ozaki, T., and Nakagawara, A. (2005) Cancer Sci 96(11), 729-737 
215. Johnson, W. E., Li, W., Meyer, C. A., Gottardo, R., Carroll, J. S., Brown, M., and 
Liu, X. S. (2006) Proc Natl Acad Sci U S A 103(33), 12457-12462 
216. Marin, M. C., and Kaelin, W. G., Jr. (2000) Biochimica et biophysica acta 
1470(3), M93-M100 
217. Marson, A., Levine, S. S., Cole, M. F., Frampton, G. M., Brambrink, T., 
Johnstone, S., Guenther, M. G., Johnston, W. K., Wernig, M., Newman, J., 
Calabrese, J. M., Dennis, L. M., Volkert, T. L., Gupta, S., Love, J., Hannett, N., 
Sharp, P. A., Bartel, D. P., Jaenisch, R., and Young, R. A. (2008) Cell 134(3), 
521-533 
218. Roehle, A., Hoefig, K. P., Repsilber, D., Thorns, C., Ziepert, M., Wesche, K. O., 
Thiere, M., Loeffler, M., Klapper, W., Pfreundschuh, M., Matolcsy, A., Bernd, H. 
W., Reiniger, L., Merz, H., and Feller, A. C. (2008) British journal of 
haematology 142(5), 732-744 
219. Blower, P. E., Chung, J. H., Verducci, J. S., Lin, S., Park, J. K., Dai, Z., Liu, C. 
G., Schmittgen, T. D., Reinhold, W. C., Croce, C. M., Weinstein, J. N., and 
Sadee, W. (2008) Molecular cancer therapeutics 7(1), 1-9 
228 
 
220. Concin, N., Hofstetter, G., Berger, A., Gehmacher, A., Reimer, D., Watrowski, 
R., Tong, D., Schuster, E., Hefler, L., Heim, K., Mueller-Holzner, E., Marth, C., 
Moll, U. M., Zeimet, A. G., and Zeillinger, R. (2005) Clin Cancer Res 11(23), 
8372-8383 
221. Molchadsky, A., Shats, I., Goldfinger, N., Pevsner-Fischer, M., Olson, M., Rinon, 
A., Tzahor, E., Lozano, G., Zipori, D., Sarig, R., and Rotter, V. (2008) PLoS ONE 
3(11), e3707 
222. Petricoin, E. F., 3rd, Espina, V., Araujo, R. P., Midura, B., Yeung, C., Wan, X., 
Eichler, G. S., Johann, D. J., Jr., Qualman, S., Tsokos, M., Krishnan, K., Helman, 
L. J., and Liotta, L. A. (2007) Cancer Res 67(7), 3431-3440 
223. Charytonowicz, E., Cordon-Cardo, C., Matushansky, I., and Ziman, M. (2008) 
Cancer letters  
224. Parham, D. M. (2001) Mod Pathol 14(5), 506-514 
225. Zhao, X. D., Han, X., Chew, J. L., Liu, J., Chiu, K. P., Choo, A., Orlov, Y. L., 
Sung, W. K., Shahab, A., Kuznetsov, V. A., Bourque, G., Oh, S., Ruan, Y., Ng, 
H. H., and Wei, C. L. (2007) Cell stem cell 1(3), 286-298 
226. Pan, G., Tian, S., Nie, J., Yang, C., Ruotti, V., Wei, H., Jonsdottir, G. A., Stewart, 
R., and Thomson, J. A. (2007) Cell stem cell 1(3), 299-312 
227. Mishra, P. J., Mishra, P. J., Humeniuk, R., Medina, D. J., Alexe, G., Mesirov, J. 
P., Ganesan, S., Glod, J. W., and Banerjee, D. (2008) Cancer Res 68(11), 4331-
4339 
228. Wakitani, S., Saito, T., and Caplan, A. I. (1995) Muscle & nerve 18(12), 1417-
1426 
229. Difeo, A., Martignetti, J. A., and Narla, G. (2008) Drug Resist Updat  
230. Furukawa, T., Sunamura, M., Motoi, F., Matsuno, S., and Horii, A. (2003) The 
American journal of pathology 162(6), 1807-1815 
231. Arachchige Don, A. S., Dallapiazza, R. F., Bennin, D. A., Brake, T., Cowan, C. 
E., and Horne, M. C. (2006) Experimental cell research 312(20), 4181-4204 
232. Cheng, Y. Y., Jin, H., Liu, X., Siu, J. M., Wong, Y. P., Ng, E. K., Yu, J., Leung, 
W. K., Sung, J. J., and Chan, F. K. (2008) British journal of cancer 99(12), 2083-
2087 
233. Sendemir, A., Sendemir, E., Kosmehl, H., and Jirikowski, G. F. (2008) Gynecol 
Endocrinol 24(2), 105-112 
229 
 
234. Kannangai, R., Diehl, A. M., Sicklick, J., Rojkind, M., Thomas, D., and 
Torbenson, M. (2005) Human pathology 36(4), 341-347 
235. Bao, J., and Zervos, A. S. (1996) Oncogene 12(10), 2171-2176 
236. Italiano, A., Bianchini, L., Keslair, F., Bonnafous, S., Cardot-Leccia, N., Coindre, 
J. M., Dumollard, J. M., Hofman, P., Leroux, A., Mainguene, C., Peyrottes, I., 
Ranchere-Vince, D., Terrier, P., Tran, A., Gual, P., and Pedeutour, F. (2008) Int J 
Cancer 122(10), 2233-2241 
237. Yamaguchi, A. (1995) Seminars in cell biology 6(3), 165-173 
238. Sacchetti, B., Funari, A., Michienzi, S., Di Cesare, S., Piersanti, S., Saggio, I., 
Tagliafico, E., Ferrari, S., Robey, P. G., Riminucci, M., and Bianco, P. (2007) 
Cell 131(2), 324-336 
239. Chen, J. F., Mandel, E. M., Thomson, J. M., Wu, Q., Callis, T. E., Hammond, S. 
M., Conlon, F. L., and Wang, D. Z. (2006) Nature genetics 38(2), 228-233 
240. Subramanian, S., Lui, W. O., Lee, C. H., Espinosa, I., Nielsen, T. O., Heinrich, M. 
C., Corless, C. L., Fire, A. Z., and van de Rijn, M. (2008) Oncogene 27(14), 
2015-2026 
241. Barton, C. E., Tahinci, E., Barbieri, C. E., Johnson, K. N., Hanson, A. J., Jernigan, 
K. K., Chen, T. W., Lee, E., and Pietenpol, J. A. (2009) Developmental biology, 
In press. 
242. Sabbah, M., Emami, S., Redeuilh, G., Julien, S., Prevost, G., Zimber, A., Ouelaa, 
R., Bracke, M., De Wever, O., and Gespach, C. (2008) Drug Resist Updat 11(4-
5), 123-151 
243. Maiuri, M. C., Zalckvar, E., Kimchi, A., and Kroemer, G. (2007) Nat Rev Mol 
Cell Biol 8(9), 741-752 
244. Geng, J., and Klionsky, D. J. (2008) EMBO reports 9(9), 859-864 
245. Hanada, T., Noda, N. N., Satomi, Y., Ichimura, Y., Fujioka, Y., Takao, T., 
Inagaki, F., and Ohsumi, Y. (2007) J Biol Chem 282(52), 37298-37302 
246. Tanida, I., Wakabayashi, M., Kanematsu, T., Minematsu-Ikeguchi, N., Sou, Y. S., 
Hirata, M., Ueno, T., and Kominami, E. (2006) Autophagy 2(4), 264-271 
247. Young, A. R., Narita, M., Ferreira, M., Kirschner, K., Sadaie, M., Darot, J. F., 
Tavare, S., Arakawa, S., Shimizu, S., Watt, F. M., and Narita, M. (2009) Genes & 
development 23(7), 798-803 
248. Chiacchiera, F., and Simone, C. (2009) Methods in enzymology 453, 305-324 
230 
 
249. Liang, C., Lee, J. S., Inn, K. S., Gack, M. U., Li, Q., Roberts, E. A., Vergne, I., 
Deretic, V., Feng, P., Akazawa, C., and Jung, J. U. (2008) Nature cell biology 
10(7), 776-787 
250. Liang, C., Feng, P., Ku, B., Dotan, I., Canaani, D., Oh, B. H., and Jung, J. U. 
(2006) Nature cell biology 8(7), 688-699 
251. Wetzel, M. K., Naska, S., Laliberte, C. L., Rymar, V. V., Fujitani, M., Biernaskie, 
J. A., Cole, C. J., Lerch, J. P., Spring, S., Wang, S. H., Frankland, P. W., 
Henkelman, R. M., Josselyn, S. A., Sadikot, A. F., Miller, F. D., and Kaplan, D. 
R. (2008) Neuron 59(5), 708-721 
252. Yu, S. W., Baek, S. H., Brennan, R. T., Bradley, C. J., Park, S. K., Lee, Y. S., Jun, 
E. J., Lookingland, K. J., Kim, E. K., Lee, H., Goudreau, J. L., and Kim, S. W. 
(2008) Stem cells (Dayton, Ohio) 26(10), 2602-2610 
253. Kuballa, P., Huett, A., Rioux, J. D., Daly, M. J., and Xavier, R. J. (2008) PLoS 
ONE 3(10), e3391 
254. Ling, D., and Salvaterra, P. M. (2009) Autophagy 5(5) 
255. Matheu, A., Maraver, A., and Serrano, M. (2008) Cancer Res 68(15), 6031-6034 
256. Keyes, W. M., Wu, Y., Vogel, H., Guo, X., Lowe, S. W., and Mills, A. A. (2005) 
Genes & development 19(17), 1986-1999 
257. Tavernarakis, N., Pasparaki, A., Tasdemir, E., Maiuri, M. C., and Kroemer, G. 
(2008) Autophagy 4(7), 870-873 
258. Hay, N. (2008) Cell metabolism 8(3), 184-185 
259. Gomez-Lazaro, M., Fernandez-Gomez, F. J., and Jordan, J. (2004) J Physiol 
Biochem 60(4), 287-307 
260. Jones, R. G., Plas, D. R., Kubek, S., Buzzai, M., Mu, J., Xu, Y., Birnbaum, M. J., 
and Thompson, C. B. (2005) Molecular cell 18(3), 283-293 
261. Huang, J., and Manning, B. D. (2009) Biochemical Society transactions 37(Pt 1), 
217-222 
262. Zanchi, N. E., and Lancha, A. H., Jr. (2008) European journal of applied 
physiology 102(3), 253-263 
263. Cross, D. A., Alessi, D. R., Cohen, P., Andjelkovich, M., and Hemmings, B. A. 
(1995) Nature 378(6559), 785-789 
264. Huang, S., Shu, L., Dilling, M. B., Easton, J., Harwood, F. C., Ichijo, H., and 
Houghton, P. J. (2003) Molecular cell 11(6), 1491-1501 
231 
 
265. Okoshi, R., Ozaki, T., Yamamoto, H., Ando, K., Koida, N., Ono, S., Koda, T., 
Kamijo, T., Nakagawara, A., and Kizaki, H. (2008) J Biol Chem 283(7), 3979-
3987 
266. Lee, Y. G., Lee, S. W., Sin, H. S., Kim, E. J., and Um, S. J. (2009) Oncogene 
28(7), 1040-1052 
267. Ogawa, E., Okuyama, R., Ikawa, S., Nagoshi, H., Egawa, T., Kurihara, A., 
Yabuki, M., Tagami, H., Obinata, M., and Aiba, S. (2008) Oncogene 27(6), 848-
856 
268. Watcharasit, P., Bijur, G. N., Zmijewski, J. W., Song, L., Zmijewska, A., Chen, 
X., Johnson, G. V., and Jope, R. S. (2002) Proc Natl Acad Sci U S A 99(12), 
7951-7955 
269. Turenne, G. A., and Price, B. D. (2001) BMC cell biology 2, 12 
270. Barbieri, C. E., and Pietenpol, J. A. (2005) Cancer biology & therapy 4(4), 419-
420 
271. Greer, E. L., Oskoui, P. R., Banko, M. R., Maniar, J. M., Gygi, M. P., Gygi, S. P., 
and Brunet, A. (2007) J Biol Chem 282(41), 30107-30119 
272. Breuleux, M., Klopfenstein, M., Stephan, C., Doughty, C. A., Barys, L., Maira, S. 
M., Kwiatkowski, D., and Lane, H. A. (2009) Molecular cancer therapeutics 8(4), 
742-753 
273. Aqeilan, R. I., Pekarsky, Y., Herrero, J. J., Palamarchuk, A., Letofsky, J., Druck, 
T., Trapasso, F., Han, S. Y., Melino, G., Huebner, K., and Croce, C. M. (2004) 
Proc Natl Acad Sci U S A 101(13), 4401-4406 
274. Bachmann, R. A., Kim, J. H., Wu, A. L., Park, I. H., and Chen, J. (2006) J Biol 
Chem 281(11), 7357-7363 
275. Zhang, X., Shu, L., Hosoi, H., Murti, K. G., and Houghton, P. J. (2002) J Biol 
Chem 277(31), 28127-28134 
276. Kim, J. E., and Chen, J. (2000) Proc Natl Acad Sci U S A 97(26), 14340-14345 
277. Sancak, Y., and Sabatini, D. M. (2009) Biochemical Society transactions 37(Pt 1), 
289-290 
278. Dobbelstein, M., Strano, S., Roth, J., and Blandino, G. (2005) Biochem Biophys 
Res Commun 331(3), 688-693 
279. Ben-Yehoyada, M., Ben-Dor, I., and Shaul, Y. (2003) J Biol Chem 278(36), 
34475-34482 
232 
 
280. Mills, A. A., Qi, Y., and Bradley, A. (2002) Genesis 32(2), 138-141 
281. Mills, A. A., Zheng, B., Wang, X. J., Vogel, H., Roop, D. R., and Bradley, A. 
(1999) Nature 398(6729), 708-713 
282. Liu, P., Jenkins, N. A., and Copeland, N. G. (2003) Genome research 13(3), 476-
484 
283. Deugnier, M. A., Teuliere, J., Faraldo, M. M., Thiery, J. P., and Glukhova, M. A. 
(2002) Breast Cancer Res 4(6), 224-230 
284. Lakhani, S. R., and O'Hare, M. J. (2001) Breast Cancer Res 3(1), 1-4 
285. Barbieri, C. E., and Pietenpol, J. A. (2006) Experimental cell research  
286. Davison, T. S., Vagner, C., Kaghad, M., Ayed, A., Caput, D., and Arrowsmith, C. 
H. (1999) J Biol Chem 274(26), 18709-18714 
287. Kravchenko, J. E., Ilyinskaya, G. V., Komarov, P. G., Agapova, L. S., Kochetkov, 
D. V., Strom, E., Frolova, E. I., Kovriga, I., Gudkov, A. V., Feinstein, E., and 
Chumakov, P. M. (2008) Proc Natl Acad Sci U S A 105(17), 6302-6307 
288. Di Agostino, S., Cortese, G., Monti, O., Dell'Orso, S., Sacchi, A., Eisenstein, M., 
Citro, G., Strano, S., and Blandino, G. (2008) Cell cycle (Georgetown, Tex 7(21), 
3440-3447 
289. Wang, J. Y., and Ki, S. W. (2001) Biochemical Society transactions 29(Pt 6), 
666-673 
290. Welch, P. J., and Wang, J. Y. (1993) Cell 75(4), 779-790 
291. Welch, P. J., and Wang, J. Y. (1995) Mol Cell Biol 15(10), 5542-5551 
292. Rosenbluth, J. M., and Pietenpol, J. A. (2009) Autophagy 5(1) 
293. Cloughesy, T. F., Yoshimoto, K., Nghiemphu, P., Brown, K., Dang, J., Zhu, S., 
Hsueh, T., Chen, Y., Wang, W., Youngkin, D., Liau, L., Martin, N., Becker, D., 
Bergsneider, M., Lai, A., Green, R., Oglesby, T., Koleto, M., Trent, J., Horvath, 
S., Mischel, P. S., Mellinghoff, I. K., and Sawyers, C. L. (2008) PLoS medicine 
5(1), e8 
294. Efeyan, A., Ortega-Molina, A., Velasco-Miguel, S., Herranz, D., Vassilev, L. T., 
and Serrano, M. (2007) Cancer Res 67(15), 7350-7357 
295. Tovar, C., Rosinski, J., Filipovic, Z., Higgins, B., Kolinsky, K., Hilton, H., Zhao, 
X., Vu, B. T., Qing, W., Packman, K., Myklebost, O., Heimbrook, D. C., and 
Vassilev, L. T. (2006) Proc Natl Acad Sci U S A 103(6), 1888-1893 
233 
 
296. Bunz, F., Hwang, P. M., Torrance, C., Waldman, T., Zhang, Y., Dillehay, L., 
Williams, J., Lengauer, C., Kinzler, K. W., and Vogelstein, B. (1999) The Journal 
of clinical investigation 104(3), 263-269 
297. Espinosa, J. M. (2008) Oncogene 27(29), 4013-4023 
298. Ren, Y. X., Finckenstein, F. G., Abdueva, D. A., Shahbazian, V., Chung, B., 
Weinberg, K. I., Triche, T. J., Shimada, H., and Anderson, M. J. (2008) Cancer 
Res 68(16), 6587-6597 
299. Keller, C., Arenkiel, B. R., Coffin, C. M., El-Bardeesy, N., DePinho, R. A., and 
Capecchi, M. R. (2004) Genes & development 18(21), 2614-2626 
300. Blais, A., Tsikitis, M., Acosta-Alvear, D., Sharan, R., Kluger, Y., and Dynlacht, 
B. D. (2005) Genes & development 19(5), 553-569 
301. Hasty, P., Bradley, A., Morris, J. H., Edmondson, D. G., Venuti, J. M., Olson, E. 
N., and Klein, W. H. (1993) Nature 364(6437), 501-506 
302. Andarawewa, K. L., Erickson, A. C., Chou, W. S., Costes, S. V., Gascard, P., 
Mott, J. D., Bissell, M. J., and Barcellos-Hoff, M. H. (2007) Cancer Res 67(18), 
8662-8670 
303. Zhang, J., Smolen, G. A., and Haber, D. A. (2008) Cancer Res 68(8), 2789-2794 
304. Adorno, M., Cordenonsi, M., Montagner, M., Dupont, S., Wong, C., Hann, B., 
Solari, A., Bobisse, S., Rondina, M. B., Guzzardo, V., Parenti, A. R., Rosato, A., 
Bicciato, S., Balmain, A., and Piccolo, S. (2009) Cell 137(1), 87-98 
305. Li, Y., and Prives, C. (2007) Oncogene 26(15), 2220-2225 
306. Masuda, N., Kato, H., Nakajima, T., Sano, T., Kashiwabara, K., Oyama, T., and 
Kuwano, H. (2003) Cancer Sci 94(7), 612-617 
307. Sarrio, D., Rodriguez-Pinilla, S. M., Hardisson, D., Cano, A., Moreno-Bueno, G., 
and Palacios, J. (2008) Cancer Res 68(4), 989-997 
308. Romualdi, C., De Pitta, C., Tombolan, L., Bortoluzzi, S., Sartori, F., Rosolen, A., 
and Lanfranchi, G. (2006) BMC genomics 7, 287 
309. Garcia, J. A., and Danielpour, D. (2008) Molecular cancer therapeutics 7(6), 
1347-1354 
310. Bjornsti, M. A., and Houghton, P. J. (2004) Cancer Cell 5(6), 519-523 
311. Kozak, M. (2003) Gene 318, 1-23 
312. Stoneley, M., and Willis, A. E. (2004) Oncogene 23(18), 3200-3207 
234 
 
313. Lau, L. M., Wolter, J. K., Lau, J. T., Cheng, L. S., Smith, K. M., Hansford, L. M., 
Zhang, L., Baruchel, S., Robinson, F., and Irwin, M. S. (2009) Oncogene  
314. Kovalev, S., Marchenko, N., Swendeman, S., LaQuaglia, M., and Moll, U. M. 
(1998) Cell Growth Differ 9(11), 897-903 
315. Ueda, Y., Hijikata, M., Takagi, S., Chiba, T., and Shimotohno, K. (1999) 
Oncogene 18(35), 4993-4998 
 
 
